Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity.

Abstract

The invention relates to cell stimulatory fusion proteins and DNA sequences, vectors comprising at least two agonists of TNF/TNFR super family, immunoglobulin super family, cytokine family proteins and optional antigen combination. Instructions for use of these proteins and DNA constructs as immune adjuvants and vaccines for treatment of various chronic diseases such as viral infection are also provided. Additionally, the use of these protein and DNA constructs as immune suppressant for treatment of various chronic diseases, such as autoimmunity and organ transplant rejection, is also illustrated.

Description

CROSS-REFERENCE TO RELATED APPLICATION

[0001] This application is a continuation of application Ser. No. 12/483,876, filed Jun. 12, 2009, which claims priority to U.S. Provisional Patent Application No. 61/073,010, filed Jun. 16, 2008.

REFERENCE CITED [REFERENCE BY]

U.S. Patent Documents



[0002] U.S. Pat. No. 6,410,711 Jun. 25, 2002 Armitage, et al.

[0003] U.S. Pat. No. 6,838,262 Oct. 13, 2000 Anderson, et al.

[0004] U.S. Pat. No. 6,046,310 Apr. 4, 2000 Queen, et al

[0005] U.S. Pat. No. 5,962,406 Oct. 5, 1999 Armitage, et al.

[0006] U.S. Pat. No. 5,942,607 Aug. 24, 1999 Freeman, et al.

[0007] U.S. Pat. No. 5,457,035 Jul. 23, 1993 Baum, et al.

Foreign Patent Documents

[0008] WO/2007/103048 Feb. 28, 2007

[0009] WO/2007/022273 Aug. 15, 2006

[0010] WO/2006/050949 Nov. 10, 2005

[0011] WO/2003/063899 Jan. 28, 2003

[0012] WO/1997/033617 Nov. 3, 1997

[0013] WO/1995/013293 May 18, 1995

Other References

[0014] Alderson, M. R. et al. Fas transduces activation signals in normal human T lymphocytes. J. Exp. Med. 178, 2231-2235 (1993).

[0015] Alderson, M. R. et al. Regulation of apoptosis and T cell activation by Fas-specific mAb. Int. Immunol. 6, 1799-1806 (1994).

[0016] Alegre, M. L., J. Y. Tso, H. A. Sattar, J. Smith, F. Desalle, M. Cole, J. A. Bluestone. 1995. An anti-murine CD3 monoclonal antibody with a low affinity for Fc receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J. Immunol. 155:1544.

[0017] Allen R C, Armitage R J, Conley M E, et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 1993; 259:990-3.

[0018] Arias M, Campistol J M, Vincenti F. Evolving Evolving trends in induction therapy. Transplant Rev (Orlando). 2009 April; 23(2):94-102.

[0019] Armitage R J, Fanslow W C, Strockbine L, et al. Molecular and biological characterization of a murine ligand for CD40. Nature 1992; 357:80-2.

[0020] Aruffo, A. & Seed, B. Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system. Proc. Natl Acad. Sci. USA 84, 8573-8577 (1987).

[0021] Assohou-Luty C, Gerspach J, Siegmund D, Muller N, Huard B, Tiegs G, Pfizenmaier K, Wajant H. A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95. J Mol Med. 2006 September; 84(9):785-97.

[0022] Azuma, M. et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366, 76-79 (1993).

[0023] Beaucage and Caruthers, Tetrahedron Letts. 22:1859-1862 (1981).

[0024] Beauchesne P R, Chung N S, Wasan K M. Cyclosporine A: a review of current oral and intravenous delivery systems. Drug Dev Ind Pharm. 2007 March; 33(3):211-20.

[0025] Becher, B., D'Souza, S. D., Troutt, A. B. & Antel, J. P. Fas expression on human fetal astrocytes without susceptibility to Fas-mediated cytotoxicity. Neurosciences 84, 627-634 (1998).

[0026] Bennett S R, Carbone F R, Karamalis F, Flavell R A, Miller J F, Heath W R. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998; 393:478-80.

[0027] Beyersdorf N, Hanke T, Kerkau T, Hunig T. Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases. Ann Rheum Dis. 2005 November; 64 Suppl 4:iv91-5.

[0028] Biancone, L. et al. Development of inflammatory angiogenesis by local stimulation of Fas in vivo. J. Exp. Med. 186, 147-152 (1997).

[0029] Boise, L., Minn, A., Noel, P. & Thompson, C. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xl. Immunity 3, 87-98 (1995).

[0030] Bremer E, ten Cate B, Samplonius D F, Mueller N, Wajant H, Stel A J, Chamuleau M, van de Loosdrecht A A, Stieglmaier J, Fey G H, Helfrich W. Superior activity of fusion protein scFvRit: sFasL over cotreatment with rituximab and Fas agonists Cancer Res. 2008 Jan. 15; 68(2):597-604.

[0031] Brodie C, Gelfand E W. Functional nerve growth factor receptors on human B lymphocytes. Interaction with IL-2. J Immunol. 1992 Jun. 1; 148(11):3492-7.

[0032] Bulfone-Paus S, Ruckert R, Krause H, von Bernuth H, Notter M, Pohl T, Tran T H, Paus R, Kunzendorf U. An interleukin-2-IgG-Fas ligand fusion protein surppresses delayed-type hypaersensitivity in mice by triggering apoptosis in activated T cells as a novel strategy for immunosuppression. Transplantation. 2000 Apr. 15; 69(7):1386-91.

[0033] Castigli E, Alt F W, Davidson L, et al. CD40-deficient mice generated by recombination-activating gene-2-deficient blastocyst complementation. Proc Natl Acad Sci USA 1994; 91:12135-9.

[0034] Chambers, C. A., Kuhns, M. S., Egen, J. G. & Allison, J. P. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy Annu. Rev. Immunol. 19, 565-594 (2001).

[0035] Cheema, Z. F. et al. Fas/Apo (apoptosis)-1 and associated proteins in the differentiating cerebral cortex: induction of caspase-dependent cell death and activation of NF-kB. J. Neurosci. 19, 1754-1770 (1999).

[0036] Current Protocols in Molecular Biology (Ausubel et al, eds., 1994-2009).

[0037] Daubenberger C A.TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines. Curr Opin Mol Ther. 2007; 9:45-52.

[0038] Deng Z B, Lu C M, Huang W D, Shen L Q, Zhu W, Ma H B, Fan P S, Zhang X G. Expression of recombinant human ICOS and in vitro characterization of its bioactivity on B lymphocytes. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2003 July; 35(7):601-5.

[0039] Desbarats, J. & Newell, M. K. Fas engagement accelerates liver regeneration after partial hepatectomy. Nature Med. 6, 920-923 (2000).

[0040] Etzioni A, Ochs H D. The hyper IgM syndrome--an evolving story. Pediatr Res 2004; 56:519-25.

[0041] Ferrari S, Giliani S, Insalaco A, et al. Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc Natl Acad Sci USA 2001; 98:12614-9.

[0042] Freedman, A. S. et al. B7, a B cell restricted antigen which identifies pre-activated B cells. J. Immunol. 137, 3260-3267 (1987).

[0043] Freeman, G. J. et al. Cloning of B7-2: a CTLA4 counter-receptor that costimulates human T cell proliferation. Science 262, 909-911 (1993).

[0044] Freeman, G. J. et al. Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin-2 production. J. Exp. Med. 178, 2185-2192 (1993).

[0045] Freeman, G. J. et al. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J. Exp. Med. 174, 625-631 (1991).

[0046] Fukunaga, K. & Miyamoto, E. Role of MAP kinase in neurons. Mol. Neurobiol. 16, 79-95 (1998).

[0047] Galanaud P M, Crevon C, Delfraissy J F, et al. Antigen-induced and polyclonal B-cell responses in human peripheral blood lymphocyte cultures. Cell. Immunol. 1987; 106:234-241.

[0048] Gomez, C. et al. Low concentrations of 1-methyl-4-phenylpyridinium ion induce caspase-mediated apoptosis in human SH-SY5Y neuroblastoma cells. J. Neurosci. Res. 63, 421-428 (2001).

[0049] Goumenos D S. What have we learned from the use of ciclosporin A in the treatment of nephrotic patients with idiopathic membranous nephropathy? Expert Opin Pharmacother. 2008 July; 9(10):1695-704.

[0050] Grewal I S, Flavell R A. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998; 16:111-35.

[0051] Gross, J. A., St John, T. & Allison, J. P. The murine homologue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression. J. Immunol. 144, 3201-3210 (1990).

[0052] Holmstrom, T. et al. MAPK/ERK signaling in activated T cells inhibits CD95/Fas-mediated apoptosis downstream of DISC assembly. EMBO J. 19, 5418-5428 (2000).

[0053] Irmler, M. et al. Inhibition of death receptor signals by cellular FLIP. Nature 388, 190-195 (1997).

[0054] Karandikar, N. J., Vanderlugt, C. L., Bluestone, J. A. & Miller, S. D. Targeting the B7/CD28:CTLA-4 costimulatory system in CNS autoimmune disease. J. Neuroimmunol. 89, 10-18 (1998).

[0055] Kataoka, T. et al. The caspase-8 inhibitor FLIP promotes activation of NF-kB and ERK signaling pathways. Curr. Biol. 10, 640-648 (2000).

[0056] Kawabe T, Naka T, Yoshida K, et al. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1994; 1:167-78.

[0057] Kotzin B L, Leung D Y, Kappler J, Marrack P. Superantigens and their potential role in human disease. Adv Immunol. 1993; 54:99-166.

[0058] Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990).

[0059] Lim L C, England D M, Glowacki N J, DuChateau B K, Schell R F. Involvement of CD4+T lymphocytes in induction of severe destractive Lyme arthritis in inbred LSH hamsters. Infect Immun. 1995 December; 63(12):4818-25.

[0060] Lucas, P. J. et al. Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response. J. Immunol. 154, 5757-5768 (1995).

[0061] Matsushita, K. et al. Fas receptor and neuronal cell death after spinal cord ischemia. J. Neurosci. 20, 6879-6887 (2000).

[0062] Medema, J. P. et al. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 16, 2794-2804 (1997).

[0063] Mock B A, Liu L, LePaslier D, Huang S. The B-lymphocyte maturation promoting transcription factor BLIMP1/PRDI-BF1 maps to D6S447 on human chromosome 6q21-q22.1 and the syntenic region of mouse chromosome 10. Genomics 1996; 37:24-28.

[0064] Nagata, S. Apoptosis by death factor. Cell 88, 355-365 (1997).

[0065] Needham-VanDevanter D R, Hurley L H, Reynolds V L, Theriault N Y, Krueger W C, Wierenga W. Characterization of an adduct between CC-1065 and a defined oligodeoxynucleotide duplex. Nucleic Acids Res. 1984 Aug. 10; 12(15):6159-68.

[0066] Ng C Y, Madsen J C, Rosengard B R, Allan J S. Immunosuppression for lung transplantation. Front Biosci. 2009 Jan. 1; 14:1627-41.

[0067] Okwor I, Uzonna J. Vaccines and vaccination strategies against human cutaneous leishmaniasis. Hum Vaccin. 2009 May 12; 5(5).

[0068] Oosterwegel, M. A., Greenwald, R. J., Mandelbrot, D. A., Lorsbach, R. B. & Sharpe, A. H. CTLA-4 and T cell activation. Curr. Opin. Immunol. 11, 294-300 (1999).

[0069] Quezada S A, Jarvinen L Z, Lind E F, Noelle R J. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 2004; 22:307-28.

[0070] Raoul, C. et al. Motoneuron death triggered by a specific pathway downstream of Fas. Potentiation by ALS-linked SOD1 mutations. Neuron 35, 1067-1083 (2002).

[0071] Raoul, C., Henderson, C. E. & Pettmann, B. Programmed cell death of embryonic motoneurons triggered through the Fas death receptor. J. Cell Biol. 147, 1049-1062 (1999).

[0072] Renshaw B R, Fanslow W C III, Armitage R J, et al. Humoral immune responses in CD40 ligand-deficient mice. J Exp Med 1994; 180:1889-900.

[0073] Ridge J P, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4.sup.+ T-helper and a T-killer cell. Nature 1998; 393:474-8.

[0074] Sakaguchi S. Prospects for preventative vaccines against prion diseases. Protein Pept Lett. 2009; 16(3):260-70.

[0075] Salomon, B. & Bluestone, J. A. Complexities of CD28/B7:CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19, 225-252 (2001).

[0076] Sambrook & Russell, Molecular Cloning, A Laboratory Manual (3rd Ed, 2001).

[0077] Sansom, D. M. CD28, CTLA-4 and their ligands: who does what and to whom? Immunology 101, 169-177 (2000).

[0078] Schoenberger S P, Toes R E, van der Voort E I, Offringa R, Melief C J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-40L interactions. Nature 1998; 393:480-3.

[0079] Shahinian, A. et al. Differential T cell costimulatory requirements in CD28-deficient mice. Science 261, 609-612 (1993).

[0080] Shinohara, H., Yagita, H., Ikawa, Y. & Oyaizu, N. Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase. Cancer Res. 60, 1766-1772 (2000).

[0081] Sperling, A. I. et al. CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation. J. Immunol. 157, 3909-3917 (1996).

[0082] Suntharalingam G, Perry M R, Ward S, Brett S J, Castello-Cortes A, Brunner M D, Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006; 355:1018-1028.

[0083] Szabo S J, Kim S T, Costa G L, Zhang X, Fathman C G, Glimcher L H. A novel transcription factor, T-bet, directs Rhl lineage commitment. Cell. 2000 Mar. 17; 100(6):655-69.

[0084] Targett G A, Greenwood B M. Malaria vaccines and their potential role in the elimination of malaria. Malar J. 2008 Dec. 11; 7 Suppl 1:S10.

[0085] Thompson, C. B. et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc. Natl Acad. Sci. USA 86, 1333-1337 (1989).

[0086] Trauth, B. C. et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245, 301-305 (1989).

[0087] Van Assche G, Vermeire S, Rutgeerts P. Immunosuppression in inflammatory bowel diseases: traditional, biological or both? Curr Opin Gastroenterol. 2009 May 5.

[0088] van Kooten C, Banchereau J. CD40-40 ligand. J Leukoc Biol 2000; 67:2-17.

[0089] Wallace R B, Johnson M J, Suggs S V, Miyoshi K, Bhatt R, Itakura K. A set of synthetic oligodeoxyribonucleotide primers for DNA sequencing in the plasmid vector pBR322. Gene 1981 December; 16(1-3):21-6

[0090] Watts T H.TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol. 2005; 23:23-68.

[0091] Wisniewski T, Konietzko U. Amyloid-beta immunisation for Alzheimer's disease. Lancet Neurol. 2008 September; 7(9):805-11.

[0092] Xu J, Foy T M, Laman J D, et al. Mice deficient for the CD40 ligand. Immunity 1994; 1:423-31.

[0093] Yokochi, T., Holly, R. D. & Clark, E. A. Lymphoblastoid antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid lines, and Burkitt's lymphomas. J. Immunol. 128, 823-827 (1982).

[0094] Yonehara, S., Ishii, A. & Yonehara, M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med. 169, 1747-1756 (1989).

[0095] Yoshida T, Yoshida R, Ma B Y., Mikolajczak S, Kelvin D J., and A. Ochi. A novel mitogen fusion protein against CD40.sup.+ cells with potent vaccine adjuvant properties. Vaccine. 2010; 28(21):3688-3695. Epub 2010 Mar. 30.

[0096] Young L S, Eliopoulos A G, Gallagher N J, Dawson C W. CD40 and epithelial cells: across the great divide. Immunol Today 1998; 19:502-6.

FIELD OF THE INVENTION

[0097] The invention generally relates to methods and compositions, which promote or repress antigen-specific immunity. The described polypeptide and DNA constructs are used as either immune adjuvants or suppressants for treating various chronic diseases including cancer, infectious diseases, autoimmune diseases, allergies and inflammatory diseases.

BACKGROUND OF THE INVENTION

[0098] Affording to Current Understanding of Molecular Mechanisms of Diseases, Reagents that Modulate Immune Responses are in Great Demand.

[0099] The body's defense system against microbes and other chronic diseases is mediated by the two main components of the immune system: the innate immune system and adaptive immune system. Recent advances in the study of the molecular and cellular mechanism of various diseases indicated that both innate and adaptive immune systems are targeted for the prevention and cure of various types of diseases. Innate immunity involves mechanisms that recognize structures, which are characteristic to microbial pathogens but are not present on mammalian cells. Examples of such structures include bacterial liposaccharides (LPS), viral double stranded DNA, and unmethylated CpG DNA nucleotides. The effector cells of the innate immune response system comprise neutrophils, macrophages, and natural killer cells (NK cells). In adaptive immunity, the body's immunological defense systems are stimulated by exposure to infectious agents and these responses increase in magnitude and effectiveness with each successive exposure to that particular antigen. There are two types of adaptive immune responses: (i) humoral immunity, which involves the production of pathogen-specific antibodies by B lymphocytes (B cells), and (ii) cell-mediated immunity, which is regulated by T lymphocytes (T cells). Immune effector cells in the innate and adaptive phases of immune responses can be directly or indirectly involved in the cause of some diseases, and are thus potentially important targets for therapeutics against these diseases. Recently, there has been an increasing number of vaccine strategies used against a variety of disease conditions. Infectious diseases caused by viruses, bacteria and parasites [Targett and Greenwood Malar J. 7 Suppl 1:S10 (2008); Okwor and Uzonna Hum Vaccin. May 12; 5 (2009)] are areas of on-going research using vaccines. Unexpectedly, vaccine strategies may also be effective against diseases such as Alzheimer's and prion diseases, in which the scavenger functions of immune response cells against pathogenic metabolic deposits is ineffective [Wisniewski and Konietzko, Lancet Neurol. 7:805 (2008); Sakaguchi, Protein Pept Lett., 16:260 (2009)]. Autoimmune diseases are also an area in which immune responses against the host self-components could potentially be inhibited at pathogenic level by using vaccine strategies to specific self-reactive T cells and B cells. As the list of diseases that are potential targets for treatment by immunological approaches increases, modulators for the immune competent cells are in greater demand. Improved methods for increasing or repressing immune responses, while following safe guidelines for use in humans, represent a major unmet demand in modern medicine.

[0100] B Cell- and APC-Targeting Immunotherapies

[0101] The cell surface molecule CD40 is a member of the tumor necrosis factor receptor superfamily and is broadly expressed by immune, hematopoietic, vascular, epithelial, and other cells, including a wide range of tumor cells. CD40 itself lacks intrinsic kinase or other signal transduction activity, but rather mediates its diverse effects via an intricate series of downstream adapter molecules that differentially alter gene expression depending on cell type and microenvironment. As a potential target for novel cancer therapy, CD40 may mediate tumor regression through both an indirect effect of immune activation and a direct cytotoxic effect on the CD40-expressing tumor.

[0102] CD40 is best known as a critical regulator of cellular and humoral immunity via its expression on B lymphocytes, dendritic cells, and monocytes [Grewal and Flavell, Annu Rev Immunol., 16:111 (1998); van Kooten and Banchereau, J Leukoc Biol., 67:2 (2000)].

[0103] CD40 is also expressed on the cell surface of many other non-immune cells, including endothelial cells, fibroblasts, hematopoietic progenitors, platelets and basal epithelial cells [Grewal and Flavell, Annu Rev Immunol., 16:111 (1998); van Kooten and Banchereau, J Leukoc Biol., 67:2 (2000); Young et al., Immunol Today, 9:502(1998); Quezada et al., Annu Rev Immunol., 22:307 (2004)]. The CD40 ligand (CD40L), also known as CD154, is the chief ligand described for CD40 and is expressed primarily by activated T lymphocytes and platelets [van Kooten and Banchereau, J Leukoc Biol., 67:2 (2000); Armitage et al., Nature, 357:80 (1992)]. Atherosclerosis, graft rejection, coagulation, infection control, and autoimmunity are all regulated by CD40-CD40L interactions [Grewal and Flavell, Annu Rev Immunol., 16:111 (1998); van Kooten and Banchereau, J Leukoc Biol., 67:2 (2000)]. Many tumor cells also express CD40, including nearly 100% of B-cell malignancies and up to 70% of solid tumors.

[0104] Physiologically, CD40-induced signal transduction represents a major component of a process known as T-cell "help." Ligation of CD40 on dendritic cells, for example, induces cellular maturation and activation as manifested by increased surface expression of co-stimulatory and MHC molecules, production of proinflammatory cytokines such as interleukin 12, and enhanced T-cell activation [van Kooten and Banchereau, J Leukoc Biol., 67:2 (2000); Quezada et al., Annu Rev Immunol., 22:307 (2004)]. CD40 ligation of resting B cells also increases antigen-presenting function and, in addition, induces proliferation and immunoglobulin class switching [van Kooten and Banchereau, J Leukoc Biol., 67:2 (2000); Quezada et al., Annu Rev Immunol., 22:307 (2004)]. Patients with germ line mutations in either CD40 or CD40L are markedly immunosuppressed, susceptible to opportunistic infections, and have deficient T-cell-dependent immune reactions, including IgG production, germinal center formation, and memory B-cell induction [Allen et al., Science, 259:990 (1993); Ferrari et al., Proc Natl Acad Sci USA, 98:12614 (2001); Etzioni A, Ochs H D. Pediatr Res., 56:519 (2004)]. Similar immunophenotypes are observed in mice deficient in CD40 or CD40L [Castigli et al., Proc Natl Acad Sci USA, 91:12135 (1994); Kawabe et al., Immunity, 1:167 (1994); Renshaw et al., J Exp Med., 180:1889 (1994); Xu et al., Immunity, 1:423 (1994)]. Agonistic CD40 antibodies have been shown to mimic the signal of CD40L and substitute for the function of CD4.sup.+ T lymphocytes in murine models of T-cell-mediated immunity [Bennett et al., Nature, 393:478 (1998); Ridge et al., Nature, 393:474 (1998); Schoenberger et al., Nature, 393:480 (1998)]. A key mechanism of this effect is thought to be CD40/CD40L-mediated activation of host dendritic cells. Growing evidence shows that stimulating APC with soluble CD40L or an agonistic anti-CD40 antibody can, at least in part, replace the need for T helper cells and generate antigen presenting cells (APCs) that are capable of priming cytotoxic T lymphocytes (CTL). To develop pharmacotherapeutic reagents targeting the CD40/CD40L pathway, series of soluble CD40L fusion proteins were disclosed. In one invention, CD40L was joined to antigens to deliver CD40-costimulation signal and antigens together to B cells and APCs (WO/2003/063899). In another invention, the conjugate of CD40L and a Toll-like receptor ligand, Flagellin, was created to trigger a synergistic activation signaling between CD40 and TLR5 in B cells and APCs (WO/2007/103048). All these innovations aimed to use CD40L fusion proteins as vaccines by stimulating antigen-specific B cell and APCs in vivo.

[0105] T Cell Targeting Immunotherapies

[0106] Two types of major T lymphocytes have been described, CD8.sup.+ cytotoxic lymphocytes (CTLs) and CD4.sup.+ helper cells (Th cells). CD8.sup.+ T cells are effector cells that, via the T cell receptor (TCR), recognize foreign antigens presented by class I major histocompatibility complex (MEW) molecules on, for instance, virally or bacterially infected cells. T helper cells are involved in both humoral and cell-mediated forms of effector immune responses. With respect to the humoral or antibody immune response, antibodies are produced by B lymphocytes through interactions with Th cells. Specifically, extracellular antigens, such as circulating microbes, are taken up by specialized APCs, processed, and presented in association with class II MEW molecules to CD4.sup.+ Th cells. These Th cells in turn activate B lymphocytes, resulting in antibody production. In contrast, the cell-mediated immune response functions to neutralize microbes that inhabit intracellular locations after infection of a target cell.

[0107] According to the two-signal model, optimal activation of antigen-specific T lymphocytes requires specific antigen recognition by lymphocytes (signal 1') and additional signals (called `signal 2` or co-stimulatory signals). In the absence of signal 2, lymphocytes fail to respond effectively and are rendered anergic. Signal 1 is provided by the interaction of the peptide-antigen-MHC complex with the TCR. Signal 2 is delivered to T cells by co-stimulatory cell surface molecules expressed on APCs. The process of co-stimulation is of therapeutic interest because the manipulation of co-stimulatory signals might provide a means either to enhance or to terminate immune responses.

[0108] The B7-1/B7-2-CD28/CTLA-4 pathway is the best-characterized T-cell co-stimulatory pathway and is crucial in T-cell activation and tolerance [Karandikar et al., J. Neuroimmunol. 89:10 (1998); Oosterwegel et al., Curr. Opin. Immunol. 11:294 (1999); Salomon and Bluestone, Annu. Rev. Immunol. 19:225 (2001); Sansom, Immunology, 101:169 (2000); Chambers et al., Annu. Rev. Immunol., 19:565 (2001)]. The B7-1/B7-2-CD28/CTLA-4 pathway includes two B7 family members, B7-1 (CD80) [Freeman et al., J. Exp. Med. 174:625 (1991); Freedman et al., J. Immunol. 137:3260 (1987); Yokochi et al., J. Immunol. 128:823 (1982)] and B7-2 (CD86) [Freeman et al., Science 262:909 (1993); Freeman, et al., J. Exp. Med. 178:2185 (1993); Azuma, et al. Nature 366:76 (1993)], that have dual specificity for two CD28 family members, the stimulatory receptor CD28 antigen-receptor signaling [Aruffo and Seed, Proc. Natl Acad. Sci. USA 84:8573 (1987); Gross et al., J. Immunol., 144:3201 (1990)], by promoting T-cell survival and thereby enabling cytokines to initiate T-cell clonal expansion and differentiation [Thompsonet et al., Proc. Natl. Acad. Sci. USA 86:1333 (1989); Lucas et al., J. Immunol., 154:5757 (1995); Shahinian et al., Science 261:609 (1993); Sperling et al., J. Immunol., 157:3909 (1996); Boise et al., Immunity 3:87 (1995)]. CD28 also optimizes the responses of previously activated T cells, promoting interleukin 2 (IL-2) production and T-cell survival.

[0109] Several members of the tumor necrosis factor receptor (TNFR) family function as co-stimulatory receptors after initial T cell activation. These include CD27, 4-1BB (CD137), OX40 (CD134), HVEM, CD30 and GITR [reviewed in Watts, Annu Rev Immunol., 23:23 (2005)].

[0110] To develop immunotherapeutic reagents targeting T cells, soluble co-stimulatory receptor extracellular fragments, soluble ligand extracellular fragments, fusion proteins or agonistic antibodies against receptors or specific ligands have been studied. Alternatively, un-agonistic soluble ligands or un-agonistic antibodies have been used to block co-stimulatory receptor signaling. Either by increasing or reducing the extent of T cell costimulation, the use of ligand-fusion proteins or antibodies has shown pharmaceutical benefits to diseases including autoimmune diseases, proliferative disorders such as cancer, or infectious diseases.

[0111] Death Receptor "Fas" and Disease Therapy

[0112] Fas (CD95), a member of the tumour-necrosis factor receptor (TNFR) superfamily, was originally described as a lymphocyte receptor that can induce apoptosis [Yonehara et al., J. Exp. Med., 169:1747 (1989); Trauth et al., Science, 245:301 (1989)]. Fas is expressed in many types of tissue including glia cells, neurons and neuronal cell lines [Shinohara et al., Cancer Res., 60:1766 (2000); Gomez et al., J. Neurosci. Res., 63:421 (2001); Becher et al., Neurosciences, 84:627 (1998); Raoul et al., J. Cell Biol. 147:1049 (1999); Raoul et al., Neuron, 35:1067 (2002); Matsushita et al. J. Neurosci. 20:6879 (2000); Cheema et al., J. Neurosci., 19:1754 (1999)]. The interaction between CD95 (Fas) and its ligand (Fas-ligand, or FasL) functions to limit the duration of the immune response and/or life-span of activated lymphocytes. Apoptosis induced by Fas-FasL binding serves to clear activated self-reactive lymphocytes. Problems caused by altering this pathway have been demonstrated in animals with defects in FasFas-ligand interactions. Mice having mutations, which inactivate Fas or FasL, develop numerous disorders including autoimmune pathology resembling that seen in patients with rheumatoid arthritis or systemic lupus. It has been demonstrated that injection of FasL-expressing virus into the joints of mice with collagen-induced-arthritis, results in apoptosis of synovial cells and relief of arthritis symptoms [Zhang et al., in J. Clin. Invest., 100:1951 (1997)]. Expression of the Fas ligand reduces the number of activated inflammatory cells, which play a role in the pathogenesis of autoimmune disease. Therefore, a gene therapy strategy for introducing FasL into the joints of rheumatoid arthritis patients could function to improve disease pathology by leading to destruction of the infiltrating mononuclear cells.

[0113] Soluble Fas ligand and receptor have also been shown to be associated with tissue damage and other adverse effects. Administering an agonistic anti-Fas antibody resulted in organ damage to mice [Galle et al., J. Exp. Med. 182:1223 (1995)]. Mice injected intraperitoneally with the agonistic antibody died within several hours, and analyses revealed that severe liver damage by apoptosis was the most likely cause of death.

[0114] Fas engagement by FasL, or by antibodies against Fas, initiates binding of the intracellular death domain of Fas to an adaptor protein, the Fas-associated death domain (FADD), which couples Fas to the caspase cascade. Caspase 8 (also known as FADD-like interleukin-1 converting enzyme; FLICE) is the most upstream caspase in the apoptosis pathway, and its cleavage is a hallmark of Fas-induced death [Nagata, Cell 88: 355 (1997); Medema et al. EMBO J. 16:2794 (1997)]. Fas-mediated death signals can be inhibited by the FLICE inhibitory protein (FLIP), which blocks caspase 8 binding to FADD [Irmler et al. Nature 388:190 (1997)]. The activation of a cascade of successive caspase cleavages finally results in the activation of endonucleases that catalyse DNA breakdown into nucleosome-sized fragments, a characteristic feature of apoptosis [Nagata, Cell 88:355 (1997)].

[0115] In addition to apoptosis, Fas has been reported to mediate diverse proliferative and regenerative functions, including co-stimulatory signalling during T-cell activation [Alderson et al. J. Exp. Med., 178:2231 (1993); Alderson et al. Int. Immunol. 6:1799 (1994); Desbarats et al. Proc. Natl. Acad. Sci. USA 96:8104 (1999)], induction of angiogenesis [Biancone et al. J. Exp. Med. 186:147 (1997)], and liver regeneration after partial hepatectomy [Desbarats and Newell, Nature Med. 6:920 (2000)].

[0116] In contrast to the well-characterized apoptotic pathway, relatively little is known about the signalling pathways involved in Fas-mediated growth induction, although Fas has been shown to activate the extracellular-signal regulated kinase (ERK) pathway [Trauth et al., Science 245:301 (1989)]. ERK, a serine/threonine kinase activated by mitogen-activated protein kinase (MAPK)/ERK kinase (MEK1), mediates the cellular response to many different growth and differentiation factors [reviewed in Fukunaga and Miyamoto, Mol. Neurobiol., 16:79 (1998)]. Notably, activation of ERK prevents Fas-induced apoptosis and, conversely, inhibition of ERK prevents Fas-induced proliferation, suggesting that the MEK1/ERK pathway is involved in the transduction of Fas-mediated growth signals [Trauth et al., Science 245:301 (1989); Holmstrom et al., EMBO J., 19:5418 (2000); Kataoka, et al. Curr. Biol., 10:640 (2000)]. At present, it is not clear how Fas engagement in T-cell co-stimulation, and in the regeneration of liver and nerves, bypasses an apoptotic signal and promotes a regenerative or co-stimulation signal.

[0117] Soluble Fas-ligands has been useful reagents to induce pathological cell-specific cell death. For example, a fusion protein that connected interleukin-2-IgFc-FasL was used to kill auto-reactive T cells in autoimmune disease therapy [Bulfone-Paus et al., Transplantation. 69:1386 (2000)]. In a similar approach, the fusion protein of CD40 extracellular domain and FasL extracellular domain, CD40-FasL, showed that cell death is contingent on the binding of CD40 to CD40L expressed on target cells [Siegmund et al., J Mol Med. 84:785(2006)]. A fusion construct comprised of VEGF and FasL was found to effectively kill cancer cells by a synergistic effect between VEGF signaling and Fas signaling (WO/2007/022273). Additionally, a fusion protein containing a DC20-specific antibody fragment and soluble FasL, ScFvRit:sFasL [Bremer et al., Cancer Res., 68:597 (2008)], was applied to non-Hodgkin lymphoma and B cell chronic lymphocytic leukemia. This fusion protein efficiently activated CD20 signaling and Fas cell death signaling, resulting in a far superior proapoptotic activity, compared with co-treatment with anti-CD20 antibody (rituximab) and soluble FasL. Therefore Fas ligand-based fusion proteins have shown promising results in the field of autoimmune diseases and cancer therapy by stimulating Fas-induced death signaling in pathological cells. Fas-associated regenerative or co-stimulation signaling has not been exploited for target cell specific therapy.

[0118] Immune Suppressive Molecules

[0119] Traditionally, various steroids and inhibitors that block the cell activation and growth signaling, such as FK506 or Rapamycin, are broadly used. Some drawbacks to the use of these reagents are that they are not specific to lymphocytes and their use is often accompanied by serious side effects. The first therapeutic agents (immune suppressors) were mostly non-specific and inhibited cellular proliferation [Van Assche et al., Curr Opin Gastroenterol. May 5 (2009); Arias et al., Transplant Rev (Orlando) 23:94 (2009); Ng et al., Front Biosci., 14:1627 (2009)]. These treatments generally led to serious side effects due to intrinsic lack of pharmacospecificity. Later, cyclosporin A (CsA) was the first of a new generation of immunosuppressants with a `site-specific` mode of action. Mechanistically, CsA mediates its in vivo effects by repressing lymphocyte activation at an early stage. Due to a low degree of myelotoxicity, CsA was considered as an attractive therapeutic drug in clinical transplantation for inhibiting lymphocytic activities without affecting either phagocytosis or migration of the reticulo-endothelial system. In 1978, CsA was tested clinically and due to its strong efficacy was used worldwide in a majority of the transplant centers to maintain graft survival post surgery [Goumenos, Expert Opin Pharmacother. 9:1695 (2008); Beauchesne, Drug Dev Ind Pharm. 33:211 (2007)]. In the meantime, much work has been put into the design of new therapeutic strategies that would present lower side effects but retain substantial efficacy. Based on research on the antigen specific T cell activation by TCR and in the recent application of the non-stimulatory CD3-specific humanized antibody (Alegre et al., J. Immunol., 155:1544 (1995), blockade of co-stimulatory receptors (i.e. CD28) with CTLA4-Ig and CD40 with anti-CD40L antibody has been attempted. Human-specific humanized non-activating anti-CD3 antibody (teplizumab) was FDA approved to prevent the T cell response that causes T cell immune deficiencies in human.

[0120] Thus far, inhibition of co-stimulatory receptors or T cell receptors (by non-activating anti-CD3 antibody) has been partially effective in inducing antigen-specific immunological tolerance.

[0121] APCs and T cells, or between T cells and B cells are tightly regulated by cell surface receptors and their counter-receptors (ligands). Therefore various techniques and reagents to facilitate or repress major receptor interactions and their signaling mechanisms have been developed for disease therapeutic purposes. Receptor agonistic or blocking antibodies, soluble extracellular domain of ligand fusion proteins, soluble death receptor ligand fusion proteins and mitogenic or immunosuppressive substances of bacterial or plant origin as described supra showed levels of efficacy beneficial to the disease therapy, although the toxic side effects are often accompanied by strong pharmacotherapeutic efficacy.

[0122] The present invention provides methods to develop powerful target cell-specific immune-stimulating fusion proteins, which could lead to the effective immunotherapy of various diseases.

SUMMARY OF THE INVENTION

[0123] This invention is based on the discovery that nucleic acid constructs that encode a minimum of (i) one functional moiety of the extracellular domain of the TNF/TNF receptor (TNFR) family agonist or the extracellular domain of the immunoglobulin family agonist or cytokine family, (ii) a second functional moiety of the extracellular domain of the TNF/TNFR family agonist or a functional moiety of the extracellular domain of the immunoglobulin family agonist or cytokine family, (iii) an immunoglobulin Fc domain (designated as IgGFc or IgFc in the text) (optional) and (iv) an antigen and the corresponding polypeptide, which the corresponding soluble fusion peptides expressed thereby (optional). A construct containing these components, when cultured with immune cells, will elicit a de novo effect to cause cell activation (i.e. cell proliferation, cytokine expression or immunoglobulin production in T cells and B cells).

[0124] This invention is also based on the discovery that the nucleic acid constructs or the expressed soluble fusion polypeptide, when administered to a host, elicits a de novo effect on immunity (i.e. increased or repressed B cell immunity and T cell immunity responses).

[0125] The function of the nucleic acids or soluble fusion protein is termed as a "synergistic" de novo effect on immunity. Specifically, the intended effect of the nucleic acid or soluble fusion protein construct is a significantly increased immune response relative to when either of the respective agonistic polypeptides contained therein are administered alone.

[0126] Particularly, this invention provides nucleic acid constructs containing genes encoding soluble fusion proteins which comprises (i) a CD40 ligand, a Fas ligand extracellular domain and an immunoglobulin IgG Fc domain [Yoshida et al., Vaccine 28: 3688 (2010)], (ii) a CD28 ligand (B7-2), a Fas ligand extracellular domain and an immunoglobulin IgG Fc domain, (iii) a OX40 ligand, a 4-1BB ligand extracellular domain and an immunoglobulin IgG Fc domain, (iv) a CD40 ligand, a ICOS extracellular domain and an immunoglobulin IgG Fc domain, (v) a NGF.beta. ligand, a Fas ligand extracellular domain and an immunoglobulin IgG Fc domain, (vi) an IL-2 ligand, a Fas ligand extracellular domain and an immunoglobulin IgG Fc domain. The fusion proteins will preferably elicit a de novo effect to cause immune cell activation relative to when any of the respective agonistic polypeptides contained therein are administered alone.

[0127] As described in detail infra, these nucleic acid constructs or the corresponding encoded fusion polypeptides may be administered to a host in need of such treatment as a means of:

[0128] generating enhanced (significantly greater) primary and memory B cell responses relative to immunization with antigen alone

[0129] generating enhanced (significantly greater) primary and memory CD4.sup.+ and/or CD8.sup.+ T cell responses relative to immunization with antigen alone

[0130] inducing repressed (significantly lower) antigen-specific B cell and/or T cell responses relative to immunization with antigen alone

[0131] These nucleic acid constructs or the corresponding encoded fusion polypeptides may be used in treating any disease or condition in which the above-identified enhanced or repressed humoral and cellular immune responses are required therapeutically. This applies specifically to infectious diseases, proliferative disorders such as cancer, allergies, inflammatory disorders, and other chronic diseases where enhanced cellular immunity is required. Alternatively, these reagents can be used in cases where repressed cellular immunity is required, such as organ transplant rejection, autoimmune disorders and graft versus host response.

[0132] As described in detail infra, DNA constructs may comprise linear DNA, a bacterial plasmid, a viral vector such as adenoviral, baculovirus, or other viral vectors commonly used for gene therapy. Additionally, as described infra these DNA constructs or fusion polypeptides may comprise extracellular domains of other TNF/TNFR family member agonists, immunoglobulin family member agonists and cytokines. Examples of TNF/TNFR family member agonists include Fas, Fas ligand, CD27, CD30 ligand, HVEM, TROY, RELT, TNF-alpha, TNF-beta, CD70, RANK ligand, LT-alpha, LT-beta, GITR ligand and LIGHT. Examples of immunoglobulin family member agonists include B7-1, B7-2, CD28, CTLA4, ICOS and ICOS-ligand. Further, these DNA constructs may comprise genes encoding antigens of bacterial/viral pathogens and tumor specific proteins. Examples of bacterial and viral antigens include human immunodeficiency virus-1 (HIV-1)env, HIV-1pol, HIV-1gag. Examples of tumor-specific antigens include human melanoma-associated glycoprotein p97, MART-1 and Her2/neu breast cancer antigen.

[0133] Various other features and advantages of the present invention should become readily apparent with reference to the following description, definitions, examples, claims and appended Figures. In several places throughout the specification guidance is provided through lists of examples. In each instance, the recited list serves only as a representative group and should not be interpreted as an exclusive list.

BRIEF DESCRIPTION OF THE DRAWINGS

[0134] FIG. 1. Schematic diagram of the presumed structure of the multi-ligand fusion protein and the interaction with target cells to induce cell activation.

[0135] FIG. 2A-C. Registered sequence of CD40 ligand of human origin (SEQ ID NO: 1).

[0136] FIG. 3A-C. Registered sequence of oncostatin M of human origin (SEQ ID NO: 3).

[0137] FIG. 4A, B. Registered sequence of IgG1 Fc of human origin (SEQ ID NO: 5).

[0138] FIG. 5A-C. Nucleotide sequence and amino acid sequence of the CD40L-IgFc fusion protein (SEQ ID NO: 7).

[0139] FIG. 6A-C. Registered sequence of Fas ligand of human origin (SEQ ID NO: 9).

[0140] FIG. 7A-C. Nucleotide sequence and amino acid sequence of the FasL-IgFc fusion protein (SEQ ID NO: 11).

[0141] FIG. 8A-D. Nucleotide sequence and amino acid sequence of the CD40L-FasL-IgFc fusion protein (SEQ ID NO: 13).

[0142] FIG. 9. Western blotting analysis of CD40L-FasL-IgFc. A: anti-human IgG, B: anti-human FasL.

[0143] FIG. 10. Study of Fas binding by CD40L-FasL-IgFc.

[0144] FIG. 11. Proliferation of human PBMC induced with CD40L-FasL-IgFc.

[0145] FIG. 12. Non-T cell-specific stimulation by CD40L-FasL-IgFc.

[0146] FIG. 13. Effects of Polymixin B pre-absorption on the stimulation by CD40L-FasL-IgFc.

[0147] FIG. 14. Reduction of CD40L-FasL-IgFc-induced activation by signaling inhibitors.

[0148] FIG. 15. Induction of IgG secretion in PBL cells stimulated with CD40L-FasL-IgFc.

[0149] FIG. 16. The expression of PRDI-BF1 in response to CD40L-FasL-IgFc stimulation.

[0150] FIG. 17. Adjuvant activity of CD40L-FasL-IgFc in mice against OVA.

[0151] FIG. 18. Adjuvant activity of CD40L-FasL-IgFc in mice against Influenza hemaglutinin.

[0152] FIG. 19. Adjuvant activity of Plasmid DNA of CD40L-FasL-IgFc in mice against Influenza hemaglutinin.

[0153] FIG. 20. Adjuvant activity of CD40L-FasL-IgFc in mice against Influenza hemaglutinin-specific T cell response. A: total T cell response; B: CD8.sup.+ T cell response.

[0154] FIG. 21A-C. Registered sequence of B7-2 of human origin (SEQ ID NO: 15).

[0155] FIG. 22A-D. Nucleotide sequence and amino acid sequence of the B7-2-FasL-IgFc fusion protein (SEQ ID NO: 17).

[0156] FIG. 23A-C. Nucleotide sequence and amino acid sequence of the B7-2-IgFc fusion protein (SEQ ID NO: 19).

[0157] FIG. 24. Western blotting analysis of B7-2-FasL-IgFc. A: anti-human IgG, B: anti-human FasL.

[0158] FIG. 25. Study of Fas binding by B7-2-FasL-IgFc.

[0159] FIG. 26. Activation of CD4.sup.+ and CD8.sup.+ T cells by B7-1-FasL-IgFc.

[0160] FIG. 27. B7-2-FasL-IgFc stimulates IL-2 production of T cells.

[0161] FIG. 28. Induction of T-bet by B7-2-FasL-IgFc activation.

[0162] FIG. 29. Reduction of B7-2-FasL-IgFc-induced activation by signaling inhibitors.

[0163] FIG. 30. Immunosuppressant activity of B7-2-FasL-IgFc in mice against Influenza hemaglutinin.

[0164] FIG. 31. Suppressant activity of plasmid DNA of B7-2-FasL-IgFc in mice against Influenza hemaglutinin.

[0165] FIG. 32. Immunosuppressant activity of B7-2-FasL-IgFc in mice against Influenza hemaglutinin-specific T cell response. A: total T cell response; B: CD8.sup.+ T cell response.

[0166] FIG. 33. The repression of SEB-induced splenomegaly by co-administrated Plasmid DNA of B7-2-FasL-IgFc.

[0167] FIG. 34A-C. Registered sequence of the OX40 ligand of human origin (SEQ ID NO: 21).

[0168] FIG. 35A-C. Registered sequence of the 4-1BB ligand of human origin (SEQ ID NO: 23).

[0169] FIG. 36A-D. Nucleotide sequence and amino acid sequence of the OX40L-4-1BBL-IgFc (SEQ ID NO: 25).

[0170] FIG. 37A-C. Nucleotide sequence and amino acid sequence of the OX40L-IgFc (SEQ ID NO: 27).

[0171] FIG. 38A-C. Nucleotide sequence and amino acid sequence of the 4-1BBL-IgFc (SEQ ID NO: 29).

[0172] FIG. 39. Western blotting analysis of OX40L-4-1BBL-IgFc. A: anti-human IgG, B: anti-human FasL.

[0173] FIG. 40. Activation of PBMCs by OX40L-4-1BBL-IgFc.

[0174] FIG. 41. Adjuvant activity of OX40L-4-1BBL-IgFc/PCIneo in mice against Influenza hemaglutinin.

[0175] FIG. 42. Adjuvant activity of OX40L-4-1BBL-IgFc in mice against Influenza hemaglutinin-specific T cell response. A: total T cell response; B: CD8.sup.+ T cell response.

[0176] FIG. 43A-C. Registered sequence of ICOS of human origin (SEQ ID NO: 31).

[0177] FIG. 44A-D. Nucleotide sequence and amino acid sequence of CD40L-ICOS-IgFc (SEQ ID NO: 33).

[0178] FIG. 45. Western blotting analysis of CD40L-ICOS-IgFc. A: anti-human IgG, B: anti-human FasL.

[0179] FIG. 46. Adjuvant activity of Plasmid DNA of CD40L-ICOS-IgFc in mice against Influenza hemaglutinin.

[0180] FIG. 47. Adjuvant activity of CD40L-ICOS-IgFc/PCIneo in mice against Influenza hemaglutinin-specific T cell response. A: total T cell response; B: CD8.sup.+ T cell response.

[0181] FIG. 48A, B. Registered sequences of NGF.beta. of human origin (SEQ ID NO: 35).

[0182] FIG. 49A-C. Nucleotide sequence and amino acid sequence of the NGF.beta.-FasL-IgFc fusion protein (SEQ ID NO: 37).

[0183] FIG. 50. Western blotting analysis of NGF.beta.-FasL-IgFc. A: anti-human IgG, B: anti-human FasL.

[0184] FIG. 51. Adjuvant activity of Plasmid DNA of NGF.beta.-FasL-IgFc in mice against Influenza hemaglutinin.

[0185] FIG. 52. Adjuvant activity of NGF.beta.-FasL-IgFc/PCIneo in mice against Influenza hemaglutinin-specific T cell response. A: total T cell response; B: CD8.sup.+ T cell response.

[0186] FIG. 53A, B. Registered sequence of IL-2 of human origin (SEQ ID NO: 39).

[0187] FIG. 54A-D. Nucleotide sequence and amino acid sequence of IL-2-FasL-IgFc (SEQ ID NO: 41).

[0188] FIG. 55. Western blotting analysis of IL-2-FasL-IgFc. A: anti-human IgG, B: anti-human FasL.

[0189] FIG. 56. Adjuvant activity of Plasmid DNA of IL-2-FasL-IgFc in mice against Influenza hemaglutinin.

[0190] FIG. 57. Suppressant activity of IL-2-FasL-IgFc/PCIneo in mice against Influenza hemaglutinin-specific T cell response.

DETAILED DESCRIPTION OF THE INVENTION

[0191] The present invention is based on the discovery that the soluble protein expression products of fusion cDNA constructs, composed of a co-stimulation ligand extracellular domain linked with a Fas death receptor ligand extracellular domain and immunoglobulin Fc domain, stimulates human lymphocytes to proliferate and produce cytokines rather than inducing cell death or cell co-stimulation.

[0192] One embodiment of the invention provides cDNA constructs encoding a novel synergistic agonistic polypeptide combination comprising (i) a cDNA encoding a specific TNF family agonistic extracellular domain polypeptide (i.e. CD40 ligand extracellular domain) and (ii) a cDNA encoding a different TNF family agonistic extracellular domain specific to Fas agonist (Fas ligand extracellular domain). Optional components of these constructs include (iii) cDNA encoding an immunoglobulin Fc domain and (iv) the cDNA encoding the desired antigen polypeptide. The soluble expression products of these gene constructs, designated as CD40 ligand (L)-Fas ligand (L)-IgFc (SEQ ID NO: 13), when cultured with a host cells stimulate CD40 expressing cells, inducing cell proliferation and cytokine production. These DNA constructs, either the vectors themselves or the purified protein they encode, when administered to a host may be used to generate enhanced humoral and cellular antigen-specific immune responses.

[0193] The present invention provides expression vectors and host cells containing a cDNA construct encoding this novel synergistic agonistic polypeptide combination comprising (i) a cDNA encoding a specific TNF family agonistic extracellular domain polypeptide (i.e. CD40 ligand extracellular domain) and (ii) a cDNA encoding a different TNF family agonistic extracellular domain specific to Fas (Fas ligand extracellular domain). Optional components of these constructs include (iii) cDNA encoding an immunoglobulin Fc domain and (iv) cDNA encoding the desired antigen against which enhanced antigen specific cellular immune response is a desirable outcome.

[0194] Another embodiment of the present invention provides DNA constructs encoding a novel synergistic agonistic polypeptide combination comprising (i) a cDNA encoding a specific immunoglobulin family agonistic extracellular domain polypeptide, preferably a CD28 agonist (i.e. B7-2 extracellular domain), and (ii) a cDNA encoding a different agonistic TNF family polypeptide extracellular domain of Fas agonist (Fas ligand extracellular domain). Optional components of these constructs include (iii) a cDNA encoding an immunoglobulin Fc domain and (iv) a cDNA encoding the desired antigen to which desired antigen-specific cellular immune response are elicited. The expression products of these gene constructs, designated as B7-2-FasL-IgFc (SEQ ID NO: 17), stimulate CD28 expressing cells resulting in the induction of cell proliferation and cytokine production. These DNA constructs, vectors containing or the expression product of these DNA constructs, when administered to a host, may be used to generate enhanced or repressed antigen-specific humoral or cellular immune responses.

[0195] The present invention further provides expression vectors and host cells containing a cDNA construct encoding novel synergistic agonistic polypeptide combination comprising (i) a cDNA encoding a specific immunoglobulin gene family agonistic extracellular domain polypeptide, preferably a CD28 agonist (B7-2 extracellular domain) and (ii) a cDNA encoding a different agonistic TNF family polypeptide extracellular domain of Fas agonist (Fas ligand extracellular domain). Optional components of these constructs include. Optional components of these constructs include (iii) cDNA encoding an immunoglobulin Fc domain and (iv) cDNA encoding the desired antigen against which repressed antigen specific cellular immune response are desirable outcome.

[0196] Another embodiment of the present invention provides cDNA constructs encoding a novel synergistic agonistic polypeptide combination comprising (i) a cDNA encoding a specific TNF family agonistic extracellular domain polypeptide, preferably a OX40 agonist (OX40 ligand extracellular domain) and (ii) a cDNA encoding a different TNF family agonistic extracellular domain of 4-1BB agonist (4-1BB ligand extracellular domain). Optional components of these constructs include (iii) cDNA encoding an immunoglobulin Fc domain and (iv) cDNA encoding the desired antigen. The expression products of these gene constructs, designated as OX40L-4-1BBL-IgFc (SEQ ID NO: 25), when cultured with a host cell, stimulate OX40 and 4-1BB expressing cells resulting in activation of T cells and regulatory T cells inducing cell proliferation and cytokine productions. These cDNA constructs, vectors containing or the protein expression product of these constructs, when administered to a host, may be used to generate enhanced antigen-specific humoral and cellular immune responses.

[0197] The present invention further provides expression vectors and host cells containing a cDNA construct encoding novel synergistic agonistic polypeptide combination comprising (i) a cDNA encoding a specific TNF family agonistic extracellular domain polypeptide, preferably a OX40 agonist (OX40 ligand extracellular domain) and (ii) a cDNA encoding a different TNF family agonistic extracellular domain of 4-1BB agonist (4-1BB ligand extracellular domain). Optional components of these constructs include (iii) cDNA encoding an immunoglobulin Fc domain and (iv) desired antigen to which enhanced antigen-specific cellular immune response is a desirable outcome.

[0198] Another embodiment of the present invention provides DNA constructs encoding a novel synergistic agonistic polypeptide combination comprising (i) a cDNA encoding a specific TNF family agonistic extracellular domain of specific CD40 agonist (CD40 ligand extracellular domain), and (ii) a cDNA encoding a specific immunoglobulin family receptor extracellular domain polypeptide, preferably a ICOS (i.e. ICOS extracellular domain). Optional components of these constructs include (iii) a cDNA encoding an immunoglobulin Fc domain and (iv) a cDNA encoding the desired antigen to which desired antigen-specific cellular immune response are elicited. The expression products of these gene constructs, designated as CD40L-ICOS-IgFc (SEQ ID NO: 33), stimulate ICOS ligand expressing cells resulting in the induction of cell proliferation and cytokine production. These DNA constructs, vectors containing or the expression product of these DNA constructs, when administered to a host, may be used to generate enhanced or repressed antigen-specific humoral or cellular immune responses.

[0199] The present invention further provides expression vectors and host cells containing a cDNA construct encoding novel synergistic agonistic polypeptide combination comprising (i) a cDNA encoding a specific different TNF family agonistic extracellular domain polypeptide of specific CD40 agonist (CD40 ligand extracellular domain), and (ii) a cDNA encoding a specific immunoglobulin family receptor extracellular domain polypeptide, preferably a ICOS (i.e. ICOS extracellular domain). Optional components of these constructs include (iii) a cDNA encoding a immunoglobulin Fc domain and (iv) a cDNA encoding the desired antigen against which repressed antigen specific cellular immune response are desirable outcome.

[0200] Another embodiment of the present invention provides cDNA constructs encoding a novel synergistic agonistic polypeptide combination comprising (i) a cDNA encoding a specific, neuro growth factor (NGF) family polypeptide, preferably NGF.beta. and (ii) a cDNA encoding a specific TNF family agonistic extracellular domain polypeptide of Fas agonist (Fas ligand extracellular domain). Optional components of these constructs include (iii) cDNA encoding an immunoglobulin Fc domain and (iv) cDNA encoding the desired antigen to which enhanced antigen-specific cellular immune responses are a desired outcome. The expression products of these gene constructs, designated as NGF-FasL-IgFc (SEQ ID NO: 37), when cultured with a host cells in vitro preferably, stimulate NGF receptor expressing cells (i.e. neuronal cells and B cells) resulting in the induction of cell proliferation, cell differentiation and cytokine production. These cDNA constructs, vectors containing or the expression product of these DNA constructs, when administered to a host may be used to generate (i) growth promotion of nerve cells and (ii) enhanced antigen-specific humoral and cellular immune responses.

[0201] The present invention further provides expression vectors and host cells containing a cDNA construct encoding novel synergistic agonistic polypeptide combination comprising (i) a cDNA encoding a specific NGF family polypeptide, preferably NGF.beta. and (ii) a cDNA encoding a specific TNF family agonistic extracellular domain polypeptide of Fas agonist (Fas ligand extracellular domain). Optional components of the constructs include (iii) cDNA encoding an immunoglobulin Fc domain and (iv) cDNA encoding the desired antigen to which enhanced antigen specific cellular immune response are targeted.

[0202] Another embodiment of the present invention provides cDNA constructs encoding a novel synergistic agonistic polypeptide combination comprising (i) a cDNA encoding a specific interleukin 2 family agonistic polypeptide, preferably a interleukin 2 and (ii) a cDNA encoding a specific TNF family agonistic extracellular domain polypeptide of Fas agonist (Fas ligand extracellular domain). Optional components of these constructs include (iii) cDNA encoding an immunoglobulin Fc domain and (iv) desired antigen to which enhanced antigen-specific cellular immune response are desirable outcome. The protein expression products of these gene constructs, designated as IL-2-FasL-IgFc (SEQ ID NO: 41) when cultured with a host cells in vitro stimulate IL-2 receptor expressing cells resulting in activated T cells and B cells and the induction of cell proliferation and cytokine production. These cDNA constructs, vectors containing or the expression product of these cDNA constructs, when administered to a host, may be used to generate enhanced antigen-specific humoral and repressed cellular immune responses.

[0203] The present invention further provides expression vectors and host cells containing a cDNA construct encoding novel synergistic agonistic polypeptide combination comprising (i) a cDNA encoding a specific interleukin 2 family agonistic polypeptide (i.e. interleukin 2 itself) and (ii) a cDNA encoding a specific TNF family agonistic extracellular domain polypeptide of Fas agonist (Fas ligand extracellular domain). Optional components of these constructs also include (iii) cDNA encoding an immunoglobulin Fc domain and (iv) cDNA encoding the desired antigen to which enhanced antigen-specific cellular immune responses are a desirable outcome.

[0204] In addition, the invention provides methods of using vectors and host cells to produce a composition containing the novel synergistic conjugates (i) CD40 ligand/Fas ligand [Yoshida et al., Vaccine 28: 3688 (2010)], (ii) B7-2/Fas ligand, (iii) OX40 ligand/4-1BB ligand, (iv) CD40 ligand/ICOS, (v) NGF.beta./Fas ligand or (vi) IL-2/Fas ligand. In each of the 6 vectors described, there is an option to link to an Fc/antigen polypeptide conjugate.

[0205] Further, the invention provides methods of administering the DNA or fusion proteins into a host in which an antigen-specific immune response is required to be elicited or repressed. For example, administration of these reagents to a subject with a chronic disease such as cancer, an infectious or autoimmune disease, or an allergic disorder, may be beneficial.

[0206] The invention also provides compositions comprising novel synergistic fusion constructs containing antigen polypeptide conjugates, which are suitable for administration to a host in order to elicit an enhanced antigen-specific humoral or cellular immune response.

[0207] The invention provides novel methods of immunotherapy comprising the administration of said novel synergistic fusion constructs of agonists-antigen polypeptide conjugate or a cDNA encoding said fusion protein polypeptide to a host in need of such treatment in order to elicit an enhanced antigen-specific humoral and cellular immune response. In preferred embodiments, these compositions and conjugates will be administered to a subject with or at risk of developing a cancer, an infection, particularly a chronic infectious diseases (i.e. involving a virus, bacteria or parasite) or an autoimmune, inflammatory or allergic condition. As an example, in the preferred embodiment described infra, the invention is used to elicit antigen-specific cellular immune responses against chronic viral infections such as type A Influenza virus and human immunodeficiency virus HIV-1. HIV-1 infection is a well-recognized example of a disease where protective immunity almost certainly will require the generation of potent and long-lived cellular immune responses against the virus.

[0208] Further, the invention provides novel methods of immunotherapy comprising the administration of said novel synergistic fusion proteins encoding agonists-antigen polypeptide conjugates or cDNA constructs encoding said fusion protein polypeptide to a host in need of such treatment in order to elicit a repressed antigen specific humoral and cellular immune response. In preferred embodiments, these compositions and conjugates will be administered to a subject with or at risk of developing an organ rejection reaction against transplanted allo or xeno organs (i.e. kidney, heart, liver) or autoimmune, inflammatory or allergic conditions.

[0209] As used herein the following terms shall have the meanings set forth. Otherwise all terms shall have the meaning they would normally be accorded by a person skilled in the relevant art.

[0210] The term "agonist" refers to a compound that in combination with a receptor can produce a cellular response. An agonist may be a ligand that directly binds to the receptor. Alternatively an agonist may combine with a receptor indirectly by for example (a) forming a complex with another molecule that directly binds to the receptor, or (b) otherwise resulting in the modification of another compound so that the other compound directly binds to the receptor. An agonist herein will typically refer to a TNF family agonist, TNFR family agonist, an immunoglobulin family agonist or a cytokine family agonist.

[0211] The term "antigen" herein refers to any substance that is capable of being the target of an immune response. An antigen may be the target, for example, of a cell-mediated and/or humoral immune response (i.e. immune cell maturation, production of cytokines, production of antibodies, etc.) when contacted with immune cells. Examples of antigens include bacterial, viral, fungal polypeptides, autoantigens, allergens, and the like.

[0212] The term "synergy" and variations thereof refers to activity such as immuno-stimulatory activity achieved when administering a combination of active agents that is greater than the additive activity of the active agents administered individually.

[0213] The term "conjugate" herein refers to a single molecule, typically a DNA fusion or polypeptide fusion that contains a plurality of agonists or genes encoding and optionally an antigen or gene encoding wherein each are directly or indirectly attached to one another, e.g., by the use of linkers, and wherein these agonists and antigen, if present, may be in any order relative to one another in the conjugate.

[0214] Herein "(i) CD40 ligand (CD40L), (ii) Fas ligand (FasL), (iii) B7-2, (iv) IL-2, (v) NGF.beta., (vi) OX40 ligand (OX40L), (vii) 4-1BB ligand (4-1BBL) and (viii) ICOS" includes any polypeptide or protein that specifically recognizes and activates the (i) CD40 receptor, (ii) Fas receptor, (iii) CD28 receptor, (iv) IL-2 receptor, (v) NGF receptor, (vi) OX40 receptor, (vii) 4-1BB receptor and (viii) ICOS ligand respectively, and activates its biological activity. Preferably they are human corresponding proteins or derivatives or polymers or fragments thereof. Particularly the invention embraces CD40L, FasL, B7-2, IL-2, NGF, OX40L, 4-1BBL and ICOS proteins and fragments possessing at least 75-80% identity, more preferably at least 90%-95% sequence identity or more to the native polypeptide or a fragment thereof which recognize and activate the specific receptors. The amino acid sequence and corresponding nucleic acid sequence of each polypeptide is disclosed; CD40L in U.S. Pat. Nos. 6,410,711 and 5,962,406; FasL in U.S. Pat. No. 6,046,310, WIPO Patent No. WO/1997/033617, WO/1995/013293 and; B7-2 in U.S. Pat. No. 5,942,607; OX40L in U.S. Pat. No. 5,457,035; 4-1BBL in U.S. Pat. No. 6,838,262; IL-2 in Genbank No. NM_000586; NGF.beta. in GenBank No. NM_002506 and ICOS in GenBank No. NM_012092 all incorporated by reference in their entirety herein.

[0215] "TNF/TNFR" refers to a member of the tumor necrosis factor superfamily or the tumor necrosis factor receptor superfamily. Examples thereof include CD40, CD40L, 4-1 BB, 4-IBBL, CD27, CD70, CD30, CD30 ligand (CD153), OX40, OX-40L, Fas, FasL, TNF-alpha, TNF-beta, TNFR2, RANK, LT-beta, LT-alpha, HVEM. GITR, TROY, RELT, of any species and allelic variants and derivatives thereof.

[0216] The term "cytokine" is understood to mean any protein or peptide, analog or functional fragment thereof, which is capable of stimulating or inducing a pro survival effect against a pre-selected cell-type, for example, a lymphocyte or a monocyte, in a mammal. Accordingly, it is contemplated that a variety of cytokines can be incorporated into the cytokines of the invention. Useful cytokines include, for example, tumor necrosis factors (TNFs), interleukins (ILs), lymphokines (Ls), colony stimulating factors (CSFs), interferons (IFNs) including species variants, truncated analogs thereof which are capable of stimulating or inducing such pro survival responses. Useful neuro growth factors include, for example, NGF.beta.. Useful lymphokines include, for example, LT. Useful colony stimulating factors include, for example, GM-CSF and M-CSF. Useful interleukins include, for example, IL-2, IL-4, IL-5, IL-7, IL-12, IL-15 and IL-18. Useful interferons, include, for example, IFN-.alpha., IFN-.beta. and IFN-.gamma..

[0217] The terms "treatment" and "therapeutic method" refer to both therapeutic treatment and prophylactic/preventative measures. Those in need of treatment may include individuals already having a particular medical disorder as well as those who may ultimately acquire the disorder (i.e., those needing preventative measures).

[0218] The term "isolated" refers to a molecule that is substantially free of its natural environment. For instance, an isolated protein is substantially free of cellular material or other proteins from the cell or tissue source from which it is derived. The term "isolated" also refers to preparations where the isolated protein is sufficiently pure to be administered as a pharmaceutical composition, or at least 70-80% (w/w) pure, more preferably, at least 80-90% (w/w) pure, even more preferably, 90-95% pure; and, most preferably, at least 95%, 96%, 97%, 98%, 99%, or 100% (w/w) pure.

[0219] The term "co-stimulate" with reference to activated immune cells includes the ability of a co-stimulatory molecule to provide a second, non-activating receptor mediated signal (a "costimulatory signal") that induces proliferation or effector function. For example, a co-stimulatory signal can result in cytokine secretion (i.e. in a T cell that has received a T cell-receptor-mediated signal).

[0220] As used herein the term "co-stimulatory molecule" includes molecules, which are present on (i) antigen presenting cells (i.e. B7-1, B7-2, B7RP-1, ICOSL, OX40L, 4-1BBL and/or related molecules that bind to co-stimulatory receptors (i.e., CD28, CTLA4, ICOS, OX40, 4-1BB and/or related molecules) on T cells, and (ii) T cells (i.e. CD40L, ICOS and/or related molecules that bind to costimulatory receptors (i.e. CD40, ICOSL and/or related molecules) on antigen presenting cells and B cells.

[0221] The term "soluble" includes molecules, such as co-stimulatory molecules, which are not cell associated. Soluble co-stimulatory molecules retain the function of the cell-associated molecules from which they are derived in that they are capable of binding to their cognate ligands on T cells and mediating signal transduction via (i) CD28, CTLA4, OX40, 4-1BB and/or related molecules on a T cell, and (ii) CD40, ICOSL and/or related molecules on antigen presenting cells and B cells, however, they are in soluble form (i.e. they are not membrane bound).

[0222] The term "fusion" or "fusion protein" as used herein refers to the combination of amino acid sequences in one polypeptide chain, preferably by in frame fusion of corresponding coding nucleotide sequences. In nature, the X and Y entities normally exist in separate proteins, which are brought together in the fusion protein of the invention. In the fusion protein of the present invention, the coding sequence of the first polypeptide (X) is fused in frame with the coding sequence of the second polypeptide (Y) either directly or through a linker. By "fused in frame", it is meant that the expression of the fused coding sequences results in the fusion protein comprising both the first and the second polypeptides. This means, for example, that there is no translational terminator between the reading frames of the X and Y polypeptides. Even through the fusion between the X and Y entities can take place internally at any site, the Y entity is preferably fused to either the COOH or the NH2 terminus of the X entity (resulting in a fusion of the formula X-Y and Y-X respectively). As used herein, the term "directly" refers to a fusion of the polypeptides X and Y without a peptide linker in between (i.e. the codons encoding the X entity are contiguous with the codons encoding the Y entity). In addition, the fusion protein may also include further elements (Z) apart from X, Y and a linker, such as an initiator methionine, a signal peptide, an anchor polypeptide (e.g., immunoglobulin Fc domain) and an antigen polypeptide. Fusion proteins essentially consisting of X and Y, Z (optional) and a linker (optional) are preferred embodiments in the context of the present invention.

[0223] The fusion proteins encompassed by the present invention are not limited by the particular identity of X and Y, nor by the number of X and/or Y entities employed in the fusion protein. The X and the Y polypeptides are different (i.e. heterologous with respect to one another). The difference may be in terms of structure (i.e. below 40% identity between their respective amino acid sequences) and/or in terms of their respective biological activity (i.e. X and Y are involved in different pathways of the immune system). The X and Y entities involved in the fusion protein of the invention may individually originate (be obtained, isolated) from human or animal origin (i.e. canine, avian, bovine, murine, ovine, porcine, feline, simian and the like). The fusion protein may also comprise X and Y entities of diverse origins (i.e. X of human origin and Y of animal origin).

[0224] The current invention is based on the discovery in that the immunoglobulin IgG Fc domain-conjugated fusion protein comprising an extracellular domain of B7-2 (the ligand of CD28 T cell co-stimulation receptor, Fas antigen), and an extracellular domain of Fas-ligand (the ligand of cell death receptor), did not induce cell death in human Fas-apoptosis-sensitive Jurkat T cell line or human peripheral blood T lymphocytes. The net effect of this fusion protein, designated as B7-2-FasL-IgFc (SEQ ID NO: 17), was a strong activation of proliferation in peripheral blood T lymphocytes. The observed activation was comparable to that induced by the well-known T cell mitogen PHA. The binding of B7-2 with the CD28 co-stimulation receptor alone does not cause T cell proliferation or cytokine production, while treatment with Fas-ligand alone renders T lymphocytes highly susceptible to cell death. According to understanding, the strong cell activation by simultaneous stimulation of a co-stimulation receptor and another death receptor is not a predictable outcome. Indeed, the additive stimulation of Fas and CD28 by Fas- and CD28-specific specific monoclonal antibodies does not cause T cell activation. Similarly, the T cell activation was caused only by the B7-2-FasL-IgFc fusion protein and not by treatment with a mixture of the B7-2-IgFc (SEQ ID NO: 19) and FasL-IgFc (SEQ ID NO: 11) fusion proteins. A possible explanation for the strong activation in CD28.sup.+/Fas.sup.+ T cells is that B7-2 and FasL must be located in the close proximity to each other, as is the case when linked together in the B7-2-FasL-IgFc fusion protein. Interestingly, although B7-2-FasL-IgFc polypeptide induced a mitogenic response in T cells cultured in vitro, the administration of the polypeptide or the plasmid DNA in vivo resulted in the severe repression of humoral and cellular immune responses.

[0225] Since Fas is expressed in almost the entire population of lymphocytes, the specificity of B7-2-FasL-IgFc to T cells is presumed to be determined by the binding of the B7-2 domain CD28 on T cells. To investigate this further, the inventor asked if the replacement of B7-2 extracellular domain with an extracellular domain of the B cell costimulatory ligand (a CD40 ligand), could change the specificity of the resulting CD40L-FasL-IgFc fusion protein. Indeed, the treatment with this fusion protein, designated CD40L-FasL-IgFc, did not activate T lymphocytes but resulted in a strong mitogenic activity against B cells.

[0226] The experiments described supra demonstrated that a fusion protein, which conjugates "X" (an extracellular domain of a co-stimulatory receptor ligand) with "Y" (a Fas ligand extracellular domain) and "Z" (IgFc domain) possesses de novo mitogenic activity. This formula to create the mitogen fusion protein was further exploited by testing if both X and Y portions could be replaced with extracellular domains of other costimulation receptors (FIG. 1). When the ligand of T cell OX40 costimulatory receptor, and the ligand of 4-1BB T cell costimulatory receptor were used as the "X" and "Y" respectively, the resulting fusion protein (OX40L-4-1BBL-IgFc, SEQ ID NO: 25) acquired a strong mitogen activity in human peripheral blood mono nuclear cells. When stimulated by either OX40L-IgFc (SEQ ID NO: 27) or 4-BBL-IgFc (SEQ ID NO: 29) alone, however, no significant mitogen activity was observed.

[0227] In further studies, the fusion protein which conjugates "X" (the extracellular domain of CD40L with "Y" (the extracellular domain of ICOS, a costimulatory receptor of activated T cells) was constructed and designated CD40L-ICOS-IgFc (SEQ ID NO: 33). By replacing the Fas ligand with immunoglobulin family polypeptide, ICOS, the resulting fusion protein was expected to target B cells, which express both CD40 and ICOS ligand. When injected into mice along with influenza hemaglutinin (HA) antigens, the CD40L-ICOS-IgFc gene construct (SEQ ID NO: 33) caused a significantly increased HA-specific antibody response. The reason for this was that the CD40L-ICOS-IgFc plasmid DNA functioned as a DNA adjuvant. These results demonstrated that it is possible to create various functional fusion proteins with different target cell specificity by changing the combination of the "X" and "Y" components.

[0228] In another expansion, the fusion protein comprising NGF.beta. as "X" and FasL as "Y" was generated. This fusion protein, designated NGF.beta.-FasL-IgFc (SEQ ID NO: 37), was expected to target nerve cells and B cells as in previous reports showed that NGF.beta. could promote B cell growth. As expected, the fusion protein caused a strong B cell antibody response in vivo when the expression plasmid was co-administrated with influenza HA antigens. This fusion protein gene construct also induced a strong HA-specific CD8.sup.+ T cell response in mice co-administrated with the HA antigens.

[0229] Another fusion protein, in which interleukin 2 (IL-2) was inserted to the domain "X", was designated IL-2-FasL-IgFc (SEQ ID NO: 41). Based on the properties of its conjugated proteins, IL-2-FasL-IgFc was expected to stimulate IL-2 receptor-positive T cells and B cell. Our data indicates that IL-2-FasL-IgFc treatment resulted in a repressive effect on cellular responses against the co-administrated influenza HA antigens in mice. Interestingly, the in vivo function of IL-2-FasL-IgFc was similar to that shown by B7-FasL-IgFc administration in that is also targeted T cells.

[0230] It has been long established that many receptors and their contra-receptors (ligands) expressed trigger bi-directional signaling. Thus receptor extracellular domains become ligands to the contra-receptors during receptor/contra-receptor-mediated cell-cell communication. Accordingly, many receptor extracellular domains would be available for "X" or "Y" in the fusion protein constructs described herein to create target cell-specific mitogens.

[0231] The provided examples of fusion proteins and their functions demonstrate the robust potential of the fusion proteins generated based on the construct of "X"-"Y"-IgFc paradigm. Moreover, IgG Fc could be replaced with other domains of immunoglobulins such as IgM Fc domain, which would result in the formation of pentamers of the fusion protein.

[0232] The beneficial characteristics of the fusion proteins in the current invention would include:

[0233] i) The fusion protein comprises the polypeptides derived from extracellular domains of co-stimulation receptors, death receptors and their ligands to activate T cells, B cells or antigen presenting cells. This will allow lymphocytes still capable of recognizing antigens by T cell antigen receptors or B cell immunoglobulin receptors during the activation by fusion protein mitogens.

[0234] ii) Following the recipe "X"-"Y"-IgFc, the target specific mitogens could be customized for any target molecule by choosing target cell-specific co-stimulatory or death receptor ligands.

[0235] iii) Following the recipe "X"-"Y"-IgFc, the desirable function could be designed as a single molecule stimulation fusion protein by choosing specific receptor ligands.

[0236] As described by example in the study of B7-2-FasL-IgFc and IL-2-FasL-IgFc, the administration of the fusion protein or expression plasmid DNA represses the in vivo immune response against co-administrated antigens. This feature of the fusion protein would be applicable to the disease therapies, in which there is a need to apply immunosuppressive treatment.

[0237] The fusion protein, B7-2-FasL-IgFc, could be used as is to cause adjuvant activity or repressant activity to the immune response in vivo against the co-administrated antigens.

[0238] The fusion protein, B7-2-FasL-IgFc, could be conjugated with antigen polypeptides by recombinant DNA techniques to create single molecule adjuvant-antigen vaccines or single molecule immunorepressant-antigen tolerance inducers.

[0239] The plasmid DNA consisting of the fusion protein, B7-2-FasL-IgFc, could be used as DNA adjuvant or DNA suppressant by in vivo administration.

[0240] These characteristics make the described the fusion protein, B7-2-FasL-IgFc, excellent immunological adjuvant or suppressant candidates, which would satisfy unmet demands in broad areas of medicine.

[0241] Some of the innovations aimed to apply the soluble death receptor ligand extracellular domain fusion proteins to target the death receptor of pathological cells, such as cancer cells or auto-reactive immune cells. In other instances, co-stimulatory receptor ligands were used to block the co-stimulatory receptor signaling. In addition, co-stimulatory receptor-specific monoclonal antibodies were often used to enhance the activation of T cells, B cells or antigen presenting cells as to cause adjuvant effects. In some cases, Fas ligand was conjugated with other functional molecules such as interleukin-2 or VEGF, in order to navigate the fusion protein to specific target cells and increase their sensitivity to cell death. In these examples, Fas ligand domains in the fusion constructs are carefully positioned to the C-terminal ends of the polypeptides to cause cell death in target cells following ligation with the endogenous Fas receptor. The current invention should be construed as unique because the manner in which Fas ligand domain is integrated does not result in cell death in Fas.sup.+ cells.

[0242] The in vivo repressor function by some fusion proteins and their plasmid DNAs could be valuable for the immune-suppressive therapy against both organ transplant rejection and autoimmune diseases. For example, B7-2-FasL-IgFc is an outstanding candidate for the induction of antigen-specific immunological tolerance in vivo--a function which no known current medicine can fulfill. Other than plant lectins (i.e. Con A and PHA) or bacterial enterotoxins (i.e. SEB and SEA), only few molecules are known to be T cell mitogens. Specific potential example is superagonistic anti-CD28 antibody [Beyersdorf et al., Ann Rheum Dis. 64:91 (2005)]. Recent studies of superagonistic anti-CD28 antibody (WO/2006/050949) showed the potential of desirable effects in vivo by increasing the activity of T regulatory cells, which repressed disease symptoms in animal autoimmune disease models [Beyersdorf et al., Ann Rheum Dis. 64:91 (2005)]. The administration of superagonistic anti-CD28 antibody to humans, however, resulted in serious toxic side effects in clinical trials [Suntharalingam et al., N Engl J Med., 355:1018 (2006)]. Thus antigen-specific T lymphocyte repressants remain in great demand. The B7-2-FasL-IgFc of the current invention could ease the shortage of the T lymphocyte mitogens usable to induce antigen-specific tolerance in vivo.

[0243] Immune adjuvant effects in vivo by fusion proteins and their plasmid DNAs of the current invention will be highly useful in the development of effective vaccines. Until now, the development of vaccine adjuvants has heavily weighed on the ligands for the Toll like receptor (TLR) family receptors. The stimulation of the TLR family receptors expressed by antigen presenting cells causes increased expression of ligands and cytokines in turn causing increased the T cell and B cell co-stimulation signaling. This co-stimulation signaling is crucial for the efficient vaccination by inducing T cell differentiation, T cell memory development, B cell differentiation and B cell antibody-affinity maturation. Therefore the TLR ligands indirectly facilitate the events essential for the efficient vaccination. The fusion proteins and their plasmid DNAs of the current invention will become very effective adjuvants by directly stimulating co-stimulation signaling in B cells and antigen presenting cells, thereby enhancing the CD8.sup.+ T cell memory and B cell immunoglobulin affinity maturation to a great extent.

[0244] Exemplification of the Invention with Model Fusion Proteins

Example 1

[0245] Methods and Materials

[0246] 1. General Recombinant DNA Methods

[0247] Unless otherwise indicated, for generating nucleic acids encoding the fusion proteins of the present invention and for expression of the fusion proteins, routine techniques in the field of recombinant genetics were employed. Basic texts disclosing the general methods of use in this invention include Sambrook & Russell, Molecular Cloning, A Laboratory Manual (3rd Ed, 2001); Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990); and Current Protocols in Molecular Biology (Ausubel et al, eds., 1994-2009).

[0248] For proteins, sizes are given in kilodaltons (kDa) or number of amino acid residues. Proteins sizes are estimated from gel electrophoresis, protein sequencing, amino acid sequences deduced from cDNA, or from published protein sequences.

[0249] Oligonucleotides that are not commercially available can be chemically synthesized according to the solid phase phosphoramidite triester [Beaucage and Caruthers, Tetrahedron Letts. 22:1859-1862 (1981)], using an automated synthesizer [Van Devanter et al, Nucleic Acids Res. 12:6159 (1984)]. Purification of oligonucleotides is performed by either native acrylamide gel electrophoresis or by anion-exchange HPLC [Pearson and Reanier, J. Chrom. 255:137 (1983)]. The sequence of the cloned genes and synthetic oligonucleotides can be verified after cloning using the chain termination method for sequencing double-stranded templates [Wallace et al, Gene 16:21 (1981)].

[0250] 2. Western Blotting

[0251] Antibodies against the extracellular domain of Fas ligand (sc-957), OX40 ligand (sc-11404), CD40 ligand (sc-978) and horse raddish peroxidase (HRP)-conjugated human IgG (sc-2923) were purchased from Santa Cruz Biotechnology. The ligand-specific antibodies were used for Western blotting at a final concentration of 1.0 .mu.g/ml. The secondary antibodies used were goat anti-rabbit IgG horse HRP-conjugated antibody (sc-2054, Santa Cruz Biotechnology). Both secondary antibodies were used at a final concentration of 0.4 .mu.g/ml. Bands were visualized using chemiluminescence (ECL reagents from Amersham).

[0252] 3. Proliferation and ELISA Assays

[0253] Human lymphocytes were stimulated for 3 days in 96 U-bottom well plates with various concentrations of recombinant fusion proteins. In some experiments, a NF-.kappa.B inhibitor (SN50, 18 .mu.M, Calbiochem, San Diego, Calif., USA) and a MEK1/2 inhibitor (PD98059, 1 .mu.g/ml, Calbiochem) were added to the cell culture media. Cell proliferation was assessed by thymidine uptake assays. Cultured cells were pulsed with 1 .mu.Ci/well of [.sup.3H]thymidine (ICN, Costa Mesa, Calif., USA) for 18 hours and then harvested onto glass fiber filters. [.sup.3H]thymidine incorporation was measured by standard liquid scintillation counting techniques. In some experiments, HA antigen-specific cell proliferation response was assayed by the MTT assay [van de Loosdrecht et al., J. Immunol. Methods, 174:311(1994)], which is a direct measure of cell viability.

[0254] The relative concentrations of TNP-specific human IgG and IgM in supernatants from 4 day cultures were determined by ELISA assays. TNP.sub.22-BSA (1 .mu.g/ml) was used to coat assay plates, and alkaline phosphatase-conjugated anti-human IgG (Fab-specific) (Sigma) or anti-human IgM (.mu.-chain-specific) (Sigma) were used as the detection reagents. The concentration of IL-2 in fusion protein-stimulated culture supernatants was measured by human-IL-2-specific ELISA kit (Roche, Laval, QC, Canada). The lower limit of detection was 30 pg/ml in IL-2 assay.

[0255] 4. Assay for PRDI-BF1, T-Bet and GATA3 RNAs Concentration

[0256] Using specific primers, PRDI-BF1 RNA was amplified by RT-PCR (20 cycles) from cytoplasmic RNA derived from PBL cells stimulated for three days with fusion proteins (0.1 .mu.M). T-bet and GATA3 RNAs were amplified by RT-PCR (25 cycles) from cytoplasmic RNA derived from CD4.sup.+ T cells stimulated for five days with fusion proteins (0.1 .mu.M). Each sample was subjected to electrophoresis on agarose gels and stained with ethidium bromide (EtBr) to detect amplified fragments: 594 bp for PRDI-BF1, 206 bp for T-bet and 131 bp for GATA3.

[0257] 5. Vaccination of Mice

[0258] Balb/c mice (4-6 wks of age) were primed intra peritoneal (i.p.) route with 0.1 ml of protein antigens, OVA albumin (Sigma) or GSK VAXIGRIP (GlaxoSmithKline, Mississauga, Ontario, Canada), in the presence and absence of fusion protein or cDNA harboring plasmid. Serum samples were collected from lateral tail vain at time points indicated in the Figures. To determine the antigen-specific IgG titer in the serum of the individual mouse, ELISA were performed using 0.1 .mu.g/ml antigen-coated assay plates (Maxisorp, Nunc 44-2404-21) following the standard procedure.

Example 2 [Yoshida et al., Vaccine 28: 3688 (2010)]

[0259] Construction of X:TNF-Family Extracellular Domain Polypeptide and Y: TNF-Family Extracellular Domain Polypeptide Fusion Protein.

[0260] Construction of CD40L-FasL-IgFc plasmid DNA

[0261] To prepare the CD40.sup.+ B cell-specific CD40L-FasL-IgFc fusion protein mitogen gene construct, cDNAs encoding the extracellular domain of human CD40 ligand, extracellular domain of human Fas ligand, signaling sequence of oncostain M and CH2-CH3 domain of human IgG1 was generated by reverse transcriptase polymerase chain reaction (RT-PCR).

[0262] The extracellular domain of human CD40L [NM_000074, Homo sapiens CD40 ligand (CD40LG)] (amino acid residues 46-261) was amplified from human thymic RNA (Clontech B-D, Palo Alto, Calif., USA) using the following primers: forward 5'-CTTCATAGAAGGTTGGACAAGATA-3' (SEQ ID NO: 43) and reverse 5'-GAGTTTGAGTAAGCC AAAGGACGT-3' (SEQ ID NO: 44). The registered human CD40L message sequence is shown in FIG. 2 (SEQ ID NO: 1).

[0263] The signal peptide of Oncostatin M [NM_020530, Homo sapiens oncostatin M (OSM)] (amino acid residues 1-25) was amplified using the following primers: forward 5'-ATGGGGGTACTGCTCACACAGAGG-3' (SEQ ID NO: 45) and reverse 5'-CATGCTCGCCATGCTTG GAAACAG-3' (SEQ ID NO: 46). The registered human Oncostatin M message sequence is shown in FIG. 3 (SEQ ID NO: 3). These PCR products were subsequently utilized in a second round of PCR. Primers encoding the 3' sequence of the Oncostatin M fragment and the 5' portion of human CD40L were designed to overlap; annealing of the PCR products yielded a hybrid template. The template encoding the chimeric construct was selectively amplified using external primers specific for the 5' region of Oncostatin M and the 3' region of human CD40L. Each primer containing appropriate restriction sites (Nhe I/Xho I) for subcloning into the mammalian expression vector PCIneo (Promega, Madison, Wis.). The resulting PCR fragment was ligated into the PCIneo vector (OncoM-hCD40L/PCIneo), and transfected into E. coli competent cells, which were selected on an ampicillin-containing agar plate.

[0264] The hinge region, consisting of CH2 and CH3 domains (amino acid residues 219-447) of human IgG1, was amplified by RT-PCR from total human peripheral lymphocytes RNA, using the following primers: forward 5'-AAACTCGAGAAATCT TGTGACAAAACTCACACATGCCCACCGTG-3' (SEQ ID NO: 47) and reverse 5'-CGTCTAGATCATTTACCCGGAGACAGGG AGAG-3' (SEQ ID NO: 48), introducing the Xho I and Xba I sites, respectively (sites are underlined). The registered human IgG1 message sequence is shown in FIG. 4 (SEQ ID NO: 5). This PCR product was cloned into OncoM-hCD40L/PCIneo after digestion and purification (the resultant product coded as OncoM-CD40L-IgFc/PCIneo). The cDNA sequence of OncoM-CD40L-IgFc is shown in FIG. 5 (SEQ ID NO: 7). This fusion protein was a .about.50 kDa molecular mass in reduced SDS-PAGE and was designated as CD40L-IgFc in the text.

[0265] Chimeric Ig molecules expressing the extracellular portion of the human FasL gene and the human IgG1 constant domains were created as follows: the extracellular domain of human FasL (amino acid residues 108-281) was amplified by RT-PCR from total RNA of human thymus, using the following primers: forward 5'-CCGCTCGAGCAGCTCTTCC ACCTACAG-3' (SEQ ID NO: 49) and reverse 5'-GGCCTCGAGCTTATATAAGCCGAAAAACGTC-3' (SEQ ID NO: 50), including the Xho I sites, respectively (sites are underlined). The registered human FasL message sequence is shown in FIG. 6 (SEQ ID NO: 9). External primers encoding the 5' portion and the 3' portion of Oncostatin M, FasL and IgG1 were used to amplify the OncoM-hCD40L-hFasL-IgFc/PCIneo. Each primer contained appropriate restriction sites for subcloning into the PCIneo vector, yielding OncoM-hFasL-IgFc/PCIneo. This fusion protein was a .about.40 kDa molecular mass in reduced SDS-PAGE and was designated as FasL-IgFc in text. The cDNA sequence of OncoM-FasL-IgFc is shown in FIG. 7 (SEQ ID NO:

[0266] The extracellular domain of human FasL (amino acid residues 108-281) was cloned in frame at the 3'end of the hCD40L in the OncoM-hCD40L-IgFc/PCIneo (the resultant product coded as CD40L-FasL-IgFc/PCIneo). This fusion protein was detected as a .about.70 kDa molecular mass in reduced SDS-PAGE and was designated as CD40L-FasL-IgFc in the text. All constructs were confirmed by DNA sequencing. The cDNA sequence of OncoM-CD40L-FasL-IgFc is shown in FIG. 8 (SEQ ID NO: 13). Plasmid DNA was purified by cesium chloride gradient ultracentrifugation.

[0267] Expression of CD40L-FasL-IgFc in Mammalian Cell Lines and Protein Purification from the Cell Culture Supernatants of Transfected Cells.

[0268] The pCI-neo harboring CD40L-FasL-IgFc cDNA construct, CD40L-FasL-IgFc/PCIneo was transfected in Chinese hamster ovarian fibroblastic cell (CHO cell) by electroporation technique. CHO cells (ATCC, CRL-9606) were maintained in Dulbecco's modified MEM (Invitrogen) supplemented with 1.times. Penicillin and Streptomycin (100.times. stock solution, Invitrogen), 1.times. L-glutamine (100.times. stock solution, Invitrogen) and 5% fetal bovine serum (FBS, Invitrogen). CHO cells were maintained in Culture flasks (Falcon 175 cm.sup.2) in 5% CO2 at 37.degree. C. Cells were passaged weekly by 1/10 into a new flask. To split CHO cells to a new flask, medium was discarded from flask and replaced 3 ml 0.25% trypsin-EDTA medium (Invitrogen). After a 5 minute incubation at 37.degree. C., cells were agitated by 5 ml pipette (Becton-Dickinson, Falcon) and harvested as a single cell suspension. Cells were pelleted by centrifuge (Sorvall RT 6000 Series tabletop centrifuge, 900 rpm for 6 minutes), resuspended to 1 ml of DMEM, and then 0.1 ml of cell suspension was seeded to new flask with 20 ml of culture medium.

[0269] To transfect CD40L-FasL-IgFc/PCIneo expression vector to CHO cells, CHO cells were harvested by trypsin on day 4 after the split, washed once, then resuspended at a density of 10.sup.7 cells/ml in Na-phosphate buffered 0.9% NaCl solution. Expression plasmid (5 .mu.g) was added to 0.5 ml of cell suspension in electroporation cuvette (Bio-Rad, 165-2081). The cuvette was chilled on ice 5 minutes prior to electroporation with a Gene-Pulser (Bio-Rad) at 250V, 975 .mu.F. The cuvette was chilled again on ice for 30 minutes. The cells were washed once, resuspended with 10 mL DMEM tissue culture medium containing 5% FBS and then distributed to a 96 well flat bottom tissue culture plate at 100 .mu.l/well. Twenty-four hours later, 100 .mu.l of tissue culture medium containing 1 mg/ml of G418-sulfate (Geneticin, Invitrogen) was added to each well to select G418 resistant (positively transfected) cells. In 10 days, G418-resistant cells formed colonies detectable by microscopy. Supernatants were screened for the presence of the fusion protein by human immunoglobulin G Fc-specific ELISA, which detects the secreted fusion proteins. Cells expressing the fusion proteins were expanded in culture and harvested spent medium for protein purification. To obtain cell culture spent medium of the CD40L-FasL-IgFc CHO transfectant cell, cells were maintained in flasks (Falcon 300 cm.sup.2) with 300 ml of DMEM supplemented with 5% FBS.

[0270] Fusion proteins secreted in the spent medium of the CHO transfected cells were purified by Protein G column (HiTrap.TM. Protein G HP Columns GE Healthcare). Protein G columns (1 ml bed volume) were loaded with 500 ml of spent medium at flow rate 0.5 ml/min using chromatography pump (P500, Pharmacia) at 4.degree. C. The column was washed with 20 ml of phosphate buffered saline (PBS) then, CD40L-FasL-IgFc was eluted with 2 ml of pH 2.7, 0.2 M Glycine-HCl. The eluate was neutralized with 0.2 ml of pH 9.0, 1.0 M potassium phosphate buffer, then dialyzed against 0.01M Sodium phosphate buffer (pH 7.2) for two days before filtered with 0.22 .mu.m Millipore syringe filter (EW-29950-30) to make sterile fusion protein stock suitable for downstream cellular and biochemical analysis. The protein concentrations were measured using Pierce BCA protein assay kit (Thermo Scientific, 23225).

[0271] Purified CD40L-FasL-IgFc was First Analysed by the Western Blotting Analysis.

[0272] Two .mu.g of protein was subjected to SDS-PAGE under reduced conditions and probed by human IgG specific Western blotting. Twelve well precast gels, 10% Nu-PAGE (Invitrogen) were used with a MOPS-based running buffer. Thirteen .mu.l of protein solution, 5 .mu.l of loading buffer and 2 .mu.l of 0.5 M DTT were mixed in 1.5 ml micro centrifuge tube, heated at 75.degree. C. for 10 minutes before loading to each well of the Nu-PAGE Gel. The reduced protein samples were resolved for 50 minutes at 200 V in 1.times. MOPS running buffer (Invitrogen). Separated proteins were then transferred to PVDF membranes using transfer buffer containing 10% Methanol (Sigma). The PVDF membranes were blocked with 3% fat free milk in 0.1% Tween 20 (Sigma)-PBS for an hour at room temperature, then incubated with goat anti-human IgG HRP or rabbit anti-human FasL over night. The membrane was washed with 0.1% Tween 20 PBS and developed using chemiluminescence substrate [ECL detection buffer (Pierce)] and exposed to X-ray film (Kodak).

[0273] A dominant band at .about.75 kDa was observed and determined to be glycosylated CD40L-FasL-IgFc (FIG. 9A). The predicted molecular weight of the CD40L-FasL-IgFc is 70.6 kDa without glycosylation. The same protein sample was also subjected to SDS-PAGE under reduced conditions and probed by human FasL specific Western blotting. In paralleled experiment to FIG. 9A, the PVDF membrane was probed with rabbit anti-human FasL antibody overnight, washed with 0.1% Tween 20-PBS and then probed with anti-Rabbit IgG-HRP for 1 hour at room temperature. The results obtained from chemiluminescence and exposure of the membrane to X-ray film showed a similar picture of the protein bands as observed in the human IgG-specific Western blotting (FIG. 9B). The data indicate that the 70 kDa protein is most likely the protein band representing the monomer of the fusion protein CD40L-FasL-IgFc.

[0274] FIG. 9. Western Blotting Analysis of CD40L-FasL-IgFc.

[0275] CD40L-FasL-IgFc was subjected to SDS-PAGE under reduced conditions, probed by human IgG specific (A) or human FasL specific (B) western blotting. The dominant band at .about.75 kDa and corresponds to glycosylated CD40L-FasL-IgFc. The control is the fraction derived from the protein G column and contains non-specifically proteins (confirmed by Coomassie staining).

[0276] Study of Fas Binding by CD40L-FasL-IgFc.

[0277] Previous studies have not tested Fas-containing fusion protein constructs in which Fas ligand is located in the middle of two different polypeptide domains like CD40L-FasL-IgFc. Thus, it is important to test if CD40L-FasL-IgFc can bind to the cell surface Fas antigen. We tested the binding of CD40L-FasL-IgFc to the CD40 negative/Fas positive mouse T cell line EL4 (ATCC# TIB39). EL4 cells (5.times.10.sup.6) were incubated with 2 .mu.g of CD40L-FasL-IgFc in 0.5 ml of DMEM on ice for 1 hour. Cells were washed with PBS and lysed by 0.5 ml of ice cold 1% NP-40 lysis buffer (50 mM Tris-buffer pH7.4, 250 mM NaCl, 5 mM EDTA, 0.1% NP-40, plus protease inhibitors). After removing the insoluble cell debris by micro centrifugation (11500 rpm for 1 hour at 4.degree. C.), CD40L-FasL-IgFc was precipitated by Protein A/G agarose beads (Santa Cruz # sc-2003) overnight. The beads were washed with PBS, resuspended with 40 .mu.l loading buffer containing DTT, heated for 10 minutes at 75.degree. C. and then resolved by 10% Nu-PAGE with MOPS running buffer. PVDF membrane-transferred protein blots were probed with a mouse Fas-specific rat monoclonal antibody (Jo2 Becton Dickinson #554254), washed and subsequently probed with anti-mouse IgG-HRP detection antibody (Promega).

[0278] FIG. 10. Study of Fas Binding by CD40L-FasL-IgFc.

[0279] For a positive control (in the left-end lane), Fas molecule of EL4 cell lysate was immunoprecipitated with mouse Fas-specific rat monoclonal antibody (Jo2). For another control (in the middle lane) a fusion protein, CD40L-IgFc, was used instead of CD40L-FasL-IgFc for the incubation with EL4 before cell lysate preparation.

[0280] Analysis of the Function of CD40L-FasL-IgFc In Vitro.

[0281] CD40L-FasL-IgFc Fusion Protein Activates B Cells and Macrophages.

[0282] We found that following treatment with our fusion protein, the target human B lymphoma cells (Raji ATCC, CCL 86 and Daudi ATCC, CCL213) did not undergo cell death, while an antibody against human Fas (14G5) effectively killed B lymphomas in our study. In light of this result, we wished to examine the precise function associated with this fusion protein. We cultured human PBMCs and mouse spleen cells in the presence of CD40L-FasL-IgFc. Whole blood, obtained from a healthy donor, was twice diluted with Na-PBS (pH 7.2) and peripheral blood mononuclear cells (PBMCs) were separated by Ficoll density gradients (Ficoll-Paque Plus, Amarsham Biotech) by centrifugation (Sorvall RT 6000, 1500 rpm for 15 minutes at room temperature). The peripheral blood mononuclear cells were collected from the interphase between the PBS top layer and Ficoll plus bottom layer, washed with PBS and subjected to cell proliferation assays. After measuring the concentration of the cells using a hemocytometer, the cells were diluted in proliferation assay medium (RPMI1640, 5.times.10.sup.-5 M 2-mercaptoethanol, 1.times. L-glutamine, supplemented with 10% FBS). Human lymphocytes were stimulated for 3 days in 96 U bottom plates with various concentrations of recombinant fusion proteins. A .sup.3H-Thymidine label was used to measure the uptake by the proliferating cells. Surprisingly, the cultures exhibited significant cell activation when viewed under a microscope, even at low concentration of fusion protein (0.1-0.01 .mu.g/ml) (FIG. 11).

[0283] FIG. 11. Proliferation of Human PBMC Induced with CD40L-FasL-IgFc.

[0284] PBMCs were stimulated with various fusion proteins for three days prior to proliferation assay. Data indicate the means and standard deviations of triplicate samples. The data represent the five experiments with similar results. .box-solid.: CD40L-IgFc, .circle-solid.: FasL-IgFc, .quadrature.: CD40L-IgFc+FasL-IgFc, .diamond-solid.: IgFc, .largecircle.: CD40L-FasL-IgFc.

[0285] In these experiments, the control protein used (FasL-IgFc) did not induce detectable cytotoxic activity in either the Raji human B cell line or the Fas apoptosis-sensitive Jurkat human T cell line. Culturing with FasL-IgFc also resulted in a small but increase in human PBL primary cultured cells. It was evident that our design of FasL fusion protein failed to create Fas apoptosis-inducing ligands. Another control protein, the CD40L-IgFc fusion protein, induced a mitogenic response. When the CD40L-IgFc and FasL-IgFc proteins were added as a mixture to PBMC cultures an additive effect of proliferation was observed. Overall, the CD40L-FasL-IgFc fusion protein greatly exceeded the mitogenic response induced by the co-stimulation with CD40L-IgFc and FasL-IgFc, and indeed the cell activation by CD40L-FasL-IgFc was specific for the non-T cell subsets, which contain CD40.sup.+ cells (FIG. 12). Additionally, in the study of the phenotype of CD40L-FasL-IgFc activated cells, we observed the activation in B cell (CD19.sup.+), and monocyte (CD14.sup.+) fractions increased by 30% and 15%, respectively in cultures stimulated for 5 days with CD40L-FasL-IgFc. The results suggest a novel activation mechanism of B-cell/monocyte induced by the co-clustering Fas and CD40 by CD40L-FasL-IgFc.

[0286] FIG. 12. Non-T Cell-Specific Stimulation by CD40L-FasL-IgFc.

[0287] PBL-T cells and PBL-non-T cells were stimulated with CD40L-FasL-IgFc (0.1 .mu.M) for three days prior to proliferation assay. Data indicate the means and standard deviations of triplicate samples. The data represent the three experiments with similar results. C: control response, S: response against CD40L-FasL-IgFc.

[0288] This effect was not due to inadvertent contamination with endotoxin, as adsorption with Polymixin B did not attenuate the mitogenic activity of this fusion protein (FIG. 13).

[0289] FIG. 13. Effects of Polymixin B Pre-Absorption on the Stimulation by CD40L-FasL-IgFc.

[0290] CD40L-FasL-IgFc was pre-absorbed with Polymixin B-coated beads (Sigma). PBMCs were stimulated with this Polymixin-B pre-absorbed or unabsorbed CD40L-FasL-IgFc for three days prior to proliferation assays. Filled columns show responses against absorbed CD40L-FasL-IgFc. Open columns show responses against CD40L-FasL-IgFc prior to absorption. Data indicate the means and standard deviations of triplicate samples.

[0291] The CD40L-FasL Fusion Protein Activates the NF-.kappa.B Pathway and MEK1/2 ERK Pathway.

[0292] Besides activating Caspase-dependent apoptotic pathways, Fas stimulates the NF-.kappa.B and ERK pathways. CD40 is also linked to stimulation of similar signaling pathways. Therefore, we hypothesized that the synergistic effect of Fas/CD40 activation is due to a convergence of signals at the level of the NF-.kappa.B and MEK1/2 ERK pathways. To test this, we assessed the effects of inhibitors specific for NF-.kappa.B or MEK1/2 on CD40L-FasL-IgFc-induced stimulation of PBL cells. We found that both inhibitors partially suppressed CD40L-FasL-IgFc-induced cell proliferation. Therefore the results pointed to a mechanism of activation by our fusion protein that involves both NF-.kappa.B and MEK1/2 activation (FIG. 14).

[0293] FIG. 14. Reduction of CD40L-FasL-IgFc-Induced Activation by Signaling Inhibitors.

[0294] PBMCs were stimulated with CD40L-FasL-IgFc for three days in the presence of NF-.kappa.B inhibitor (SN50) and MEK1/2 inhibitor (PD98059). Data indicate the means and standard deviations of triplicate samples. The data represent the three experiments with similar results.

[0295] CD40L-FasL Fusion Protein Induces B-Cell Differentiation In Vitro.

[0296] We next assessed the effect on IgG secretion by fusion protein-induced co-clustering of CD40 and Fas in B cells. PBL-B cells were incubated with CD40L-FasL-IgFc for four days and the supernatants were assayed for IgG- and IgM-specific trinitrophenyl (TNP) hapten [Galanaud et al., Cell. Immunol., 106:234 (1987)]. We found anti-TNP IgG was significantly increased in CD40L-FasL-IgFc-stimulated cultures, whereas cultures with either CD40L-IgFc or FasL-IgFc alone did not show significant changes in IgG secretion (FIG. 15).

[0297] FIG. 15. Induction of IgG Secretion in PBL Cells Stimulated with CD40L-FasL-IgFc.

[0298] PBMCs were stimulated with fusion proteins for four days. The relative concentrations of TNP-specific human IgG and IgM in supernatants were determined by ELISA assays. Data indicate the means and standard deviations of triplicate samples. The data represent the three experiments with similar results.

[0299] Moreover, we found an increased expression of PRDI-BF1 RNA, which indicates terminal B cell differentiation [Mock et al., Genomics, 37:24 (1996)] in cultures stimulated with CD40L-FasL-IgFc (FIG. 16). Taken together, the data suggests that co-clustering of CD40 and Fas by CD40L-FasL-IgFc induces B-cell differentiation in vitro.

[0300] FIG. 16. The Expression of PRDI-BF1 in Response to CD40L-FasL-IgFc Stimulation.

[0301] PBMCs were stimulated with fusion proteins (0.1 .mu.M) for three days. The total RNA was assayed for the message of PRDI-BF1 by RT-PCR. Each sample was electrophoresed on agarose gels and stained with ethidium bromide (EtBr) to detect amplified fragments. The data represent the results from three experiments with similar results.

[0302] Study for the Function of CD40L-FasL-IgFc In Vivo.

[0303] The CD40L-FasL Fusion Protein Boosts IgG Response In Vivo Against Antigens Administrated Simultaneously.

[0304] Stimulation of CD40.sup.+ cells by the CD40L-FasL-IgFc could allow this molecule to function as an adjuvant in vivo, by enhancing the activity of B cells and APCs. Many ligands specific for TLR family receptors act as adjuvants in experimental animals. These adjuvants augment the antibody and T cell responses against the co-injected vaccines such as type A influenza virus antigens. To determine if our fusion protein can behave as an adjuvant, we tested CD40L-FasL-IgFc in mice to see if it increases the immune response against co-injected protein antigens.

[0305] Anti-OVA Albumin (OVA) Immune Response.

[0306] Following immunization with a small dose of OVA (0.2 .mu.s) by itself, a significant primary antibody production was not observed (FIG. 17). In contrast, the immunizations with a mixture of CD40L-FasL-IgFc and the OVA, resulted in the mice producing high titers of OVA-specific IgG antibodies, and this response was increased markedly following a boost by 0.2 .mu.g OVA.

[0307] FIG. 17. Adjuvant Activity of CD40L-FasL-IgFc in Mice Against OVA.

[0308] Balb/c mice were immunized i.p. with 0.2 .mu.g of OVA and 5 .mu.g of CD40L-FasL-IgFc (indicated as Primed). On Day 14, blood samples were harvested and subsequently mice were injected with 0.2 .mu.g of OVA (indicated as Boosted). Sera from day 14 and day 21 were analysed by ELISA for the IgG activity against OVA. The titer was calculated based on the dilutions and ELISA reader readings that first showed larger than twice of pre-immune sera readings at the same dilutions. Squares indicate mice immunized with OVA alone. Circles indicate mice immunized with both OVA and CD40L-FasL-IgFc. Numbers in squares and circles indicate individual mouse. The anti-HA activity of pre-immune serum from each mouse was equally low at less than 50 in titer.

[0309] Anti-Influenza Vaccine Response.

[0310] In the study similar to the OVA immunizations, in vivo adjuvant activity of CD40L-FasL-IgFc was investigated in mice using a specific human influenza vaccine as an antigen (FIG. 18). The vaccine, GSK VAXIGRIP, contains HA antigens of H1N1, H3N2 but the preparation is adjuvant-free. The vaccine dose (3 .mu.g/mouse) used to prime was sufficient to induce a primary response detectable by vaccine-specific anti-IgG ELISA. The addition of CD40L-FasL-IgFc significantly increased the antibody response detected by ELISAs. Secondary responses following boosts were also far greater in groups primed with CD40L-FasL-IgFc than in the mice primed with vaccine only. Therefore this study demonstrated that the influenza HA antigen-specific immune response was augmented by CD40L-FasL-IgFc.

[0311] FIG. 18. Adjuvant Activity of CD40L-FasL-IgFc in Mice Against Influenza hemaglutinin.

[0312] Balb/c mice were immunized i.p. with 3 .mu.g of HA and 5 .mu.g of CD40L-FasL-IgFc (indicated as Primed). On Day 14, blood samples were harvested from tail vain and subsequently mice were injected with 3 .mu.g of HA (indicated as Boosted). Sera from day 14 and day 24 (for the study of secondary response) were analysed by ELISA for the IgG activity against HA. The titer was calculated based on the dilutions and ELISA reader readings that first showed larger than twice of pre-immune sera readings at the same dilutions. Squares indicate mice immunized with HA alone. Circles indicate mice immunized with HA and CD40L-FasL-IgFc. Numbers in squares and circles indicate individual mouse. The anti-HA activity of pre-immune serum from each mouse was equally low at less than 50 in titer.

[0313] The Plasmid DNA of CD40L-FasL-IgFc Increases Anti-Influenza HA Immune Response In Vivo.

[0314] Recently, attempts have been made to elicit pathogen-specific antibody and T cell responses using Plasmid DNAs. These Plasmid DNAs encode pathogen antigens that are to be used as vaccine reagents. In carrying out these experiments, immunizations were often performed in combination with adjuvants such as Alum or TLR ligands (i.e. CpG) [Daubenberger Curr Opin Mol Ther. 9:45(2007)]. Since we have demonstrated that our CD40L-FasL-IgFc possesses potent adjuvant effects against co-administrated protein antigens, we wished to test if the plasmid encoding the CD40L-FasL-IgFc would function as a DNA-adjuvant. Indeed, we observed an increased influenza vaccine-specific IgG response following the administration of the pCI-neo-CD40L-FasL-IgFc plasmid (CeCl.sub.2-purified) in conjunction with influenza vaccine (FIG. 19).

[0315] FIG. 19. Adjuvant Activity of Plasmid DNA of CD40L-FasL-IgFc in Mice Against Influenza Hemaglutinin.

[0316] Balb/c mice were immunized i.p. with 3 .mu.g of HA and 3 .mu.g of CD40L-FasL-IgFc/PCIneo (indicated as Primed). On Day 14, blood samples were harvested from tail vain and subsequently mice were injected with 3 .mu.g of HA (indicated as Boosted). Sera from day 14 and day 24 (for the study of secondary response) were analysed by ELISA for the IgG activity against HA. The titer was calculated as descried in FIG. 18. Squares indicate mice immunized with HA alone. Circles indicate mice immunized with HA with plasmid. Numbers in squares and circles indicate individual mouse. The anti-HA activity of pre-immune serum from each mouse was equally low at less than 20 in titer.

[0317] Adjuvant Activity of CD40L-FasL-IgFc on T Cell Responses Against Influenza Hemaglutinin.

[0318] Both the helper T cell response and the cytotoxic CD8.sup.+ T cell response are vital for the vaccine antigen-specific immune responses. Therefore this study was aimed at investigating the regulation of the HA-specific T cell response following CD40L-FasL-IgFc injection. Balb/c mice were immunized i.p. with 3 .mu.g of HA and 3 .mu.g of CD40L-FasL-IgFc. On Day 14, mice were injected with 3 .mu.g of HA. Spleen cells harvested on day 60 (for the study of memory response) were analysed by proliferation assays against HA. Under sterile conditions, harvested spleens were minced in between a pair of slide glasses and red blood cells were removed by Gey's solution-treatment for 1 minute on ice. The prepared spleen cells (10.sup.6/ml) were stimulated in 96 well U bottom plates (10.sup.5/well) with 0.1 .mu.g/ml HA for 48 hours in RPMI1640, lx L-Glutamine (Invitrogen), 5.times.10.sup.-5 M 2-mercaptoethanol (Sigma) and 10% FBS (Invitrogen). The results showed the percent viabilities of cells measured by MTT assay performed by standard procedures. To measure the activity of CD8.sup.+ cytotoxic T cell response, monoclonal anti-L3T4 (anti-CD4) antibody (GK1.5, Pharmingen, 553726, 1 .mu.g/ml) and monoclonal anti-class II MHC antibody (anti-I-E 14-4-4, Pharmingen, 558734, 1 .mu.g/ml) were added in the culture medium. The presence of these antibodies blocks the CD4 T cell response as reported [Lim et al., Infect Immun., 63:4818 (1995)].

[0319] Interestingly, the addition of CD40L-FasL-IgFc lowered the HA-specific response by total T cells compared with HA only immunized spleen cells. In contrast to the response by total T cells, the CD8.sup.+ T cell response was only detectable in spleen cells immunized with CD40L-FasL-IgFc and not in mouse cells immunized with HA alone. The data showed strong adjuvant activity by CD40L-FasL-IgFc to antigen-specific CD8.sup.+ T cell responses in vivo.

[0320] FIG. 20. Adjuvant Activity of CD40L-FasL-IgFc in Mice Against Influenza Hemaglutinin-Specific T Cell Response.

[0321] A indicates total T cell response; B indicates CD8.sup.+ T cell response.

[0322] Percent viability is calculated based on the comparison with the non-stimulated cells (100%). The data shows the average and standard deviation derived from the triplicate sample. Not immunized: normal mice, Immunized: mice were immunized with HA only.

Example 3

[0323] Construction of a Fusion Protein Comprised of X: Immunoglobulin-Family Receptor Ligand Extracellular Domain Polypeptide, Y: TNF-Family Extracellular Domain Polypeptide Fusion Protein.

[0324] The B7-1(CD80)/B7-2(CD86)-CD28 pathway is the best-characterized T-cell co-stimulatory pathway. B7-1 and B7-2 are cell surface immunoglobulin family proteins expressed on macrophages and B cells. The CD28 signaling induced by B7-1 and B7-2 does not induce cell proliferation or cytokine secretion. It does, however, promote greatly enhanced activation events when T cells are simultaneously stimulated with T cell receptors. To determine if Fas signaling incorporate with CD28 signaling to elicit T cell proliferation, we constructed a B7-2-FasL-IgFc fusion protein. The result from the study of B7-2-FasL-IgFc was expected to address whether the conjugation of an immunoglobulin family co-stimulatory receptor ligand with a TNFR family death receptor ligand in the fusion protein mitogen formula ("X"-"Y"-IgFc) results in a novel mitogen.

[0325] Construction of B7-2-FasL-IgFc Plasmid DNA.

[0326] Registered message and amino acid sequence for human B7-2 is shown in FIG. 21 (SEQ ID NO: 15).

[0327] The extracellular domain of human B7-2 (amino acid residues: 24-247) was amplified by RT-PCR, from total RNA derived from Raji cells, using the following primers: forward 5'-GGACTCGAGGCTCCTCTGAAGATTCAAGC-3' (SEQ ID NO: 51) and reverse 5'-AATCTCGAGA GGAATGTGGTCTGGGGGAG-3' (SEQ ID NO: 52). The primers introduced Xho I sites useful for DNA subcloning (underlined). The PCR product was cloned in frame at the 3' end of the hFasL in the OncoM-hFasL-IgGFc/PCIneo (the resultant product coded as OncoM-hB7-2-hFasL-IgGFc/PCIneo). The cDNA sequence and predicted amino acid sequence for this fusion construct is shown in FIG. 22 (SEQ ID NO: 17).

[0328] Chimeric Ig molecules expressing the extracellular protein of the human B7-2 gene and human IgG1 constant domains were created as follows: external primers encoding the 5' portion and the 3' portion of Oncostatin M, B7-2 and IgG1 were used to amplify the OncoM-hB7-2-IgGFc/PCIneo. Each primer contained appropriate restriction sites for subcloning into the PCIneo vector, yielding OncoM-B7-2-IgGFc/PCIneo (cDNA sequence and predicted amino acid sequence for this fusion construct is shown in FIG. 23, (SEQ ID NO: 19). This fusion protein, designated as B7-2-IgFc, was a .about.40 kDa molecular mass when subjected to SDS-PAGE under reduced conditions.

[0329] The transfection of B7-2-FasL-IgFc/PCIneo into CHO cell and the establishment of the stable transfectant cells were performed as described in the Example 2.

[0330] The Western blotting analysis for the Protein G column-purified B7-2-FasL-IgFc fusion protein was performed as described in the Example 2.

[0331] This fusion protein designated as B7-2-FasL-IgFc was detected as a .about.75 kDa molecular mass when subjected to SDS-PAGE under reduced conditions (FIG. 24).

[0332] The data indicated that the 75 kDa protein corresponds to the protein band representing the monomer of the fusion protein B7-2-FasL-IgFc.

[0333] FIG. 24. Western Blotting Analysis of B7-2-FasL-IgFc.

[0334] B7-2-FasL-IgFc was subjected to SDS-PAGE under reduced conditions, probed by human IgG specific (A) or human FasL specific (B) western blotting. The dominant band (.about.75 kDa) corresponds to glycosylated B7-2-FasL-IgFc. The predicted molecular weight of the B7-2-FasL-IgFc is 72.5 kDa without glycosylation. The control is the fraction derived from the protein G column and contains non-specific proteins (confirmed by Coomassie staining).

[0335] Study of Fas Binding by B7-2-FasL-IgFc.

[0336] To test if B7-2-FasL-IgFc binds to the cell surface Fas antigen, the binding of B7-2-FasL-IgFc to Fas positive mouse T cell line EL4 was tested using a similar approach described in Example 2.

[0337] FIG. 25. Study of Fas Binding by B7-2-FasL-IgFc.

[0338] For positive control (in the left end lane), Fas molecule of EL4 cell lysate was immunoprecipitated. In another control (in the middle lane) a fusion protein, CD40L-IgFc was used instead of B7-2-FasL-IgFc for the incubation with EL4 prior to cell lysate preparation.

[0339] Study for the Function of B7-2-FasL-IgFc In Vitro.

[0340] B7-2-FasL-IgFc Fusion Protein Activated T Cells.

[0341] PBMCs derived from normal healthy human adults were separated from whole blood using Ficoll-Paque Plus. Peripheral blood lymphocyte (PBL)-T cells, PBL-B cells, CD4.sup.+ T cells, CD8.sup.+ T cells were purified by negative selection using RosetteSep (StemCell Tec. Vancouver, BC, Canada), while non-T cells were purified by negative selection using pan-T magnet beads (M-450, Dynal, Lake Success, N.Y., USA). The purity of human PBL-T cells was greater than 97% as determined by CD3 staining and flow cytometry. The residual T cell in non-T cell subsets was observed to be less than 5%. CD4.sup.+ and CD8.sup.+ T cells were purified to greater than 90% positive for CD4 and CD8, respectively as determined by flow cytometry studies.

[0342] Strikingly, when tested in primarily cells, the B7-2-FasL-IgFc fusion protein induced a strong T cell-specific mitogenic response (FIG. 26).

[0343] FIG. 26. Activation of CD4.sup.+ and CD8.sup.+ T Cells by B7-1-FasL-IgFc.

[0344] Total T cells, CD4.sup.+ T cells and CD8.sup.+ T cells were stimulated with either B7-2-FasL-IgFc or control fusion proteins. CD4.sup.+ T cells and CD8.sup.+ T cells were stimulated with various fusion proteins. After 72 hours in culture, cell proliferation was assessed. Data indicates the average and standard deviation of quadruplicate samples. The data represent the three experiments with similar results.

[0345] .circle-solid.: B7-2-FasL-IgFc, : phytohemagglutinin, .tangle-solidup.: B7-2-IgFc, v: FasL-IgFc, .diamond.: OKT3 and .DELTA.: B7-2-IgFc+FasL-IgFc. In top panel indicates the response by B cells against B7-2-FasL-IgFc (5 .mu.g/ml).

[0346] The magnitude of proliferation induced by B7-2-FasL-IgFc was comparable to phytohemagglutinin-induced T cell mitogenesis, while neither B7-2-IgFc nor FasL-IgFc showed observable mitogenic effects in T cells. The proliferation of both CD4.sup.+ and CD8.sup.+ T cells increased by stimulation with B7-2-FasL-IgFc, but CD8.sup.+ T cells required greater than a 20 fold dose to achieve similar levels of proliferation to CD4.sup.+ T cells. The stimulation of T cells resulted in the secretion of IL-2 (FIG. 27).

[0347] FIG. 27. B7-2-FasL-IgFc Stimulates IL-2 Production of T Cells.

[0348] T cells were stimulated by B7-2-FasL-IgFc (1 .mu.g/ml) or phytohemagglutinin (5 .mu.g/ml) for 3 days. The concentration of IL-2 in culture supernatants was measured by ELISA assays. The lower limit of detection was 30 pg/ml in IL-2 assay. The data represent the three experiments with similar results.

[0349] Moreover, five days of culture with B7-2-FasL-IgFc showed a significant increase in the T-bet transcription factor RNA, but not that of GATA3 in cells (FIG. 28).

[0350] FIG. 28. Induction of T-Bet by B7-2-FasL-IgFc Activation.

[0351] CD4.sup.+ T cells were stimulated by B7-2-FasL-IgFc (0.1 .mu.M) for 5 days before total RNA was harvested and tested for increased mRNA expression of T-bet (for Th1 differentiation) and GATA-3 (for Th2 differentiation) by RT-PCR. Each sample was electrophoresed on agarose gels and stained with ethidium bromide (EtBr) to detect amplified fragments: 206 bp for T-bet and 131 bp for GATA3. The data represent the three experiments with similar results.

[0352] These results indicated that B7-2-FasL-IgFc stimulated differentiation of CD4.sup.+ T cells in vitro by skewing towards Th1 subsets [Szabo et al., Cell. 100:655 (2000)]. As was observed in CD40L-FasL-IgFc-induced stimulation of B cells, the inhibitors for NF-.kappa.B pathway and ERK pathway attenuated T cell activation by B7-2-FasL-IgFc (FIG. 29).

[0353] FIG. 29. Reduction of B7-2-FasL-IgFc-Induced Activation by Signaling Inhibitors.

[0354] PBMCs were stimulated with B7-2-FasL-IgFc (0.1 .mu.M) for three days in the presence of SN50 and PD98059. Data indicate the means and standard deviations of triplicate samples. The data represent the three experiments with similar results.

[0355] Study for the Function of B7-2-FasL-IgFc In Vivo.

[0356] B7-2-FasL-IgFc Fusion Protein Represses the IgG Response In Vivo Against Antigens Administrated Simultaneously.

[0357] In reasons analogous to CD40L-FasL-IgFc, the stimulation of CD28.sup.+ T cells by B7-2-FasL-IgFc fusion protein could indicate that this fusion protein could function as an adjuvant in vivo by enhancing the activity of T cells. To determine if the fusion protein behaves as an adjuvant, we tested B7-2-FasL-IgFc in mice to see if it increases the immune response against co-injected HA antigens.

[0358] Anti-Influenza Vaccine Response.

[0359] The potential in vivo adjuvant activity of B7-2-FasL-IgFc fusion protein was investigated in mice using a specific human influenza vaccine as an antigen (FIG. 30). The vaccine dose (3 .mu.g/mouse) used to prime was sufficient to induce a primary response detectable by HA-specific anti-IgG ELISAs. To our surprise, the administration of B7-2-FasL-IgFc repressed the antibody response detected by ELISAs. Secondary responses following boosts were also far lower in groups primed with vaccine only. Therefore this study demonstrated that the influenza HA antigen-specific immune response was repressed by B7-2-FasL-IgFc fusion protein.

[0360] FIG. 30. Immunosuppressant Activity of B7-2-FasL-IgFc in Mice Against Influenza Hemaglutinin.

[0361] Balb/c mice were immunized i.p. with 3 .mu.g of HA and 5 .mu.g of B7-2-FasL-IgFc (indicated as Primed). On Day 14, blood samples were harvested from tail vain and mice were subsequently injected with 3 .mu.g HA (indicated as Boosted). Sera from day 14 and day 24 (for the study of secondary response) were analysed by ELISA for the IgG activity against HA. The titer was calculated based on the dilutions and ELISA readings that first showed larger than twice of pre-immune sera readings at the same dilutions. Squares indicate mice immunized with HA alone. Circles indicate mice immunized with HA with B7-2-FasL-IgFc. Numbers in squares and circles indicate individual mouse. The anti-HA activity of pre-immune serum from each mouse was equally low at less than 50 in titer.

[0362] The Plasmid DNA of B7-2-FasL-Fusion Protein Represses Anti-Influenza HA Immune Response In Vivo.

[0363] As an extension from the fusion protein result shown in FIG. 30, we tested if the plasmid DNA encoding the B7-2-FasL-IgFc/PCIneo could function as DNA-suppressant to the immune response against co-administrated vaccine antigen. Indeed, it was observed that a heavily repressed influenza vaccine-specific IgG response occurred following the administration of the B7-2-FasL-IgFc/PCIneo plasmid in conjunction with influenza vaccine (FIG. 31).

[0364] FIG. 31. Suppressant Activity of Plasmid DNA of B7-2-FasL-IgFc in Mice Against Influenza Hemaglutinin.

[0365] Balb/c mice were immunized i.p. with 3 .mu.g of HA and 3 .mu.g of B7-2-FasL-IgFc plasmid (indicated as Primed). On Day 14, blood samples were harvested from tail vain and mice were subsequently injected with 3 .mu.g of HA (indicated as Boosted). Sera from day 14 and day 24 (for the study of secondary response) were analysed by ELISA for the IgG activity against HA. The titer was calculated as described in Example 2. Squares indicate mice immunized with HA alone. Circles indicate mice immunized with HA with plasmid. Numbers in squares and circles indicate individual mouse. The anti-HA activity of pre-immune serum from each mouse was equally low at less than 20 in titer.

[0366] Suppressant Activity of B7-2-FasL-IgFc on T Cell Responses Against Influenza Hemaglutinin.

[0367] The results from the study of the antibody response in HA antigen and B7-FasL-IgFc administrated mice could indicate that T cell response to HA antigen is also suppressed in the mice. The study of B7-2-FasL-IgFc, therefore, investigated how the Influenza hemaglutinin-specific T cell response is regulated following B7-2-FasL-IgFc injection. As we expected, the addition of B7-2-FasL-IgFc suppressed the HA-specific response by total T cells compared with spleen cells from mice immunized with HA alone (FIG. 32 A). The CD8.sup.+ T cell response was also undetectable in spleen cells from mice immunized with B7-2-FasL-IgFc (FIG. 32B). The data showed the strong immunosuppressant activity by B7-2-FasL-IgFc to antigen-specific T cell responses in vivo.

[0368] FIG. 32. Immunosuppressant Activity of B7-2-FasL-IgFc in Mice Against Influenza Hemaglutinin-Specific T Cell Response.

[0369] Balb/c mice were immunized i.p. with 3 .mu.g of HA and 5 .mu.g of B7-2-FasL-IgFc. On Day 14, mice were injected with an additional 3 .mu.g HA. Spleen cells from day 60 were analysed by proliferation assay against HA. Spleen cells stimulated for 48 hours with HA and were analysed for viability by MTT assay as described in the Example 2. A indicates total T cell response; B indicates CD8.sup.+ T cell response.

[0370] Percent viability is calculated based on the comparison with the non-stimulated cells (100%). The data shows the average and standard deviation derived from the triplicate samples. Not immunized: normal mice, Immunized: mice were immunized with HA alone.

[0371] Repression of Staphyloccocal Enterotoxin B (SEB) Induced Splenomegaly by Plasmid DNA of B7-2-FasL-IgFc.

[0372] Staphylococcal enterotoxins (SEA, SEB, SEC etc.) are a group of bacterial toxins, which activate T cells upon combining with class II MEW antigens on B cells or antigen presenting cells [Kotzin et al., Adv Immunol., 54:99 (1993)]. Those toxins are called "superantigens" and are known to activate T cells in vivo. Resulting from the in vivo activation of T cells, the injection of a superantigen such as SEB into mice causes splenomegaly within 48 hours. To characterize the repressor effect against T cell by plasmid DNA of B7-2FasL-IgFc, Balb/c mice (6 weeks of age) were intraperitonealy injected with 20 .mu.g of SEB and 3 .mu.g of B7-2-FasL-IgFc/PCIneo. Two days later, spleens were harvested aseptically and the weight of the spleen was measured by analytical balance (Mettler). The data indicated in FIG. 33 showed a strong repression of SEB-induced splenomegaly by plasmid DNA of B7-2-FasL-IgFc.

[0373] FIG. 33. The Repression of SEB-Induced Splenomegaly by Co-Administrated Plasmid DNA of B7-2-FasL-IgFc.

[0374] Three mice were used to each group. The data indicates the spleen weight average of three and the standard deviation. The spleen weight* indicates the weight at milligram order.

[0375] The data strongly suggests that the B7-2-FasL-IgFc construct could be used as the DNA suppressant in vivo and showed a potential of this fusion protein to apply to the diseases where in the immune suppression is necessary, such as autoimmune diseases and transplant rejection reaction.

Example 4

[0376] Construction of a Fusion Protein Comprising X: TNF-Family Extracellular Domain Polypeptide and Y: TNF-Family Extracellular Domain Polypeptide Fusion Protein.

[0377] Both CD40L-FasL-IgFc in Example 2 and B7-2-FasL-IgFc in Example 3 employed the death receptor ligand (FasL) extracellular domain as the domain "Y". To further our understanding about the combination of the "Y" domain and "X" domain, which render the fusion protein mitogenic to target cells, a new set of T cell co-stimulatory receptor ligands were chosen. In the new gene construct, "X" is OX40 ligand (OX40L) extracellular domain and "Y" is 4-1BB ligand (4-1BBL) extracellular domain. Both OX40L and 4-1BBL are the TNF family ligands for TNFR family T cell co-stimulatory receptor OX40 and 4-1BB respectively. OX40 signal has a critical role in the T cell maintenance of an immune response to generate an antigen-specific memory response due to its ability to promote survival. 4-1BB signal contributes to the clonal expansion, survival, and development of T cells. 4-1BB can also enhance T cell apoptosis induced by TCR/CD3 triggered activation, and regulate CD28 co-stimulation to promote IL-2/interferon-.gamma. producing Th1 cell responses.

[0378] Construction of OX40L-4-1BBL-IgFc Plasmid DNA.

[0379] Registered messages and amino acid sequences for human OX40L and 4-1BBL is shown in FIG. 34 (SEQ ID NO: 21) and FIG. 35 (SEQ ID NO: 23) respectively.

[0380] The extracellular domain of human OX40L [HUMGP34M, Homo sapiens mRNA for glycoprotein 34, complete cds] (amino acid residues: 51-183) was amplified by RT-PCR from human monocyte cell line THP-1, using the following primers: forward 5'-GGACTCGAGCAGGTATCACATCGGTATCC-3' (SEQ ID NO: 53) including the Xho I site and reverse 5'-GGAACGCGTAAGGACACAGAATTCACCAG-3' (SEQ ID NO: 54), including the Mlu I sites, respectively (sites are underlined). The PCR product was cloned in frame at the Xho I-Mlu I site of PCIneo.

[0381] The extracellular domain of human 4-1BBL (NP 003802, Homo sapiens tumor necrosis factor (ligand) superfamily, member 9) (amino acid residues: 49-254) was first amplified by RT-PCR from human monocyte cell line THP-1, using the following primers: forward 5'-GGAACGCGTGCCTGCCCTGGCCGTGTCCG-3' (SEQ ID NO: 55) inducing the Mlu I site and reverse 5'-AATCTCGAGTTCCGACCTCGGTGAAGGGA-3' (SEQ ID NO: 56), including the Kpn I sites, respectively (sites are underlined). The PCR product was cloned in frame at the Mlu I-Kpn I site of PCIneo.

[0382] Xba I fragment of IgFc was inserted in frame into Xba I site of PCIneo.

[0383] hOncoM fragment with Nhe I/Xho I restriction sites was the same as used to generate OncoM-B7-2-IgFc and inserted into the Nhe I-Xho I restriction site of PCIneo.

[0384] OX40L-IgFc/PCIneo or 4-1BB-IgFc/PCIneo was prepared by removing 4-1BBL or OX40L from OncoM-OX40L-4-1BBL-IgFc/PCIneo (designated as OX40L-4-1BBL-IgFc/PCIneo described previously in the text.

[0385] The cDNA sequence for of the fusion constructs, OX40L-4-1BBL-IgFc/PCIneo, OX40L-IgFc/PCIneo and 4-1BB-IgFc/PCIneo are shown in FIG. 36 (SEQ ID NO: 25), 37 (SEQ ID NO: 27) and 38 (SEQ ID NO: 29) respectively.

[0386] The transfection of OX40L-4-1BBL-IgFc/PCIneo into CHO cell and the establishment of the stable transfectant cells were performed as described in the Example 2.

[0387] The Western blotting analysis for the Protein G column purified OX40L-4-1BBL-IgFc fusion protein was performed as described in the Example 2

[0388] This fusion protein designated as OX40L-4-1BBL-IgFc was detected as a .about.70 kDa molecular mass in reduced SDS-PAGE (FIG. 39). The data indicate that the 70 kDa protein corresponds to the protein band representing the monomer of the fusion protein OX40L-4-1BBL-IgFc.

[0389] FIG. 39. Western Blotting Analysis of OX40L-4-1BBL-IgFc.

[0390] The OX40L-4-1BBL-IgFc fusion protein was subjected to SDS-PAGE under reduced conditions and probed by human IgG specific (A) or human OX40 ligand specific (B) western blotting. The dominant band at .about.70 kDa corresponds to glycosylated OX40L-4-1BBL-IgFc protein. The presumed molecular weight of OX40L-4-1BBL-IgFc is 66.4 kDa without post-translational modification.

[0391] Study for the Function of OX40L-4-1BBL-IgFc In Vitro.

[0392] OX40L-4-1BBL-IgFc Fusion Protein Activated PBMCs.

[0393] Peripheral blood mononuclear cells from normal healthy human adults were separated from whole blood using Ficoll-Paque Plus. Unexpectedly, when tested in PBMCs, the mixture of OX40L-IgFc and 4-1BBL-IgFc induced a mitogenic response. The OX40L-4-1BBL-IgFc fusion protein, however, induced a far greater mitogenic response (FIG. 40).

[0394] FIG. 40. Activation of PBMCs by OX40L-4-1BBL-IgFc.

[0395] PBMCs were stimulated with OX40L-4-1BBL-IgFc (1 .mu.g/ml) and control fusion proteins: OX40L-IgFc (1 .mu.g/ml), 4-1BBL-IgFc (1 .mu.g/ml) and OX40L-IgFc (0.5 .mu.g/ml)+4-1BBL-IgFc (0.5 .mu.g/ml). Cell proliferation was assessed following 72 hours in culture. Data indicates the average and standard deviation of quadruplicate samples.

[0396] The Plasmid DNA of OX40L-4-1BBL-IgFc Fusion Protein Increases Anti-Influenza Hemaglutinin Immune Response In Vivo.

[0397] We next tested if the plasmid encoding the OX40L-4-1BBL-IgFc fusion protein would function as DNA-adjuvant. Significantly, we observed an increased influenza vaccine-specific IgG response following the administration of the OX40L-4-1BBL-IgFc/PCIneo plasmid in conjunction with influenza vaccine in mice (FIG. 41).

[0398] FIG. 41. Adjuvant Activity of OX40L-4-1BBL-IgFc/PCIneo in Mice Against Influenza Hemaglutinin.

[0399] Balb/c mice were immunized i.p. with 3 .mu.g of HA and 3 .mu.g of OX40L-4-1BBL-IgFc/PCIneo plasmid (indicated as Primed). On Day 14, blood samples were harvested and mice were subsequently injected with 3 .mu.g of HA (indicated as Boosted). Sera from day 14 and day 24 were analysed by ELISA for the IgG activity against HA. The titer was calculated as described in Example 2. Squares indicate mice immunized with HA alone. Circles indicate mice immunized with HA with plasmid. Numbers in squares and circles indicate individual mouse. The anti-HA activity of pre-immune serum from each mouse was equally low at less than 20 in titer.

[0400] Poor Activity of OX40L-4-1BBL-IgFc/PCIneo on T Cell Responses Against Influenza Hemaglutinin.

[0401] The study of OX40L-4-1BBL-IgFc was extended to investigate how the Influenza hemaglutinin-specific T cell response is regulated following OX40L-4-1BBL-IgFc/PCIneo injection (FIG. 42). Interestingly, the addition of OX40L-4-1BBL-IgFc/PCIneo repressed the HA-specific response by total T cells compared with spleens from mice immunized with HA alone. The response by total T cells and CD8.sup.+ T cell response was undetectable in spleen cells from mice immunized with HA and OX40L-4-1BBL-IgFc/PCIneo and it was nearly identical to cells from mice immunized with HA alone. The data showed poor adjuvant activity by OX40L-4-1BBL-IgFc/PCIneo to antigen-specific T cell responses in vivo, which contrasted to the strong adjuvant activity to antibody response by B cells.

[0402] FIG. 42. Adjuvant Activity of OX40L-4-1BBL-IgFc in Mice Against Influenza Hemaglutinin-Specific T Cell Response.

[0403] Balb/c mice were immunized intraperionealy with 3 .mu.g of HA and 3 .mu.g of OX40L-4-1BBL-IgFc/PCIneo plasmid. On Day 14, mice were injected with and additional 3 .mu.g of HA. Spleen cells from day 60 were analysed by proliferation assay against HA. Spleen cells stimulated for 48 hours with HA and were analysed for viability by MTT assay as described in the Example 2. A indicates total T cell response; B indicates the CD8.sup.+ T cell response.

[0404] Percent viability is calculated based on the comparison with the non-stimulated cells (100%). The data shows the average and standard deviation derived from the triplicate samples. Not immunized: normal mice; Immunized: mice were immunized with HA only.

Example 5

[0405] Construction of a Fusion Protein Comprising X: TNF-Family Ligand Extracellular Domain Polypeptide and Y: Immunoglobulin-Family Receptor Extracellular Domain Polypeptide Fusion Protein.

[0406] In the additional combination of "X" and "Y" of the X-Y-IgFc fusion protein mitogens, "X" the extracellular domain of CD40L and "Y" the extracellular domain of ICOS were chosen. ICOS is an inducible co-stimulatory molecule on T cells and its expression depends on the activation state of T cells. ICOS, a member of CD28/CTLA4 family, is not categorized as the ligand but is a receptor of which the ligand (ICOS ligand) is expressed on B cells and antigen presenting cells. Like the CD40/CD40L interaction and many other receptor/cell surface-expressed contra-receptor (ligand) interaction, the interaction between ICOS and ICOS ligand is known to stimulate bi-directional signaling, which co-stimulates both T cell (by ICOS signaling) and B cell (by ICOS ligand signaling). Accordingly, the CD40L-ICOS-IgFc could stimulate both B cells and antigen presenting cells. The purpose of developing this fusion protein was to test if the extracellular domain of the immunoglobulin family co-stimulation receptor can be used as the domain "Y" of a fusion protein mitogen.

[0407] Construction of CD40L-ICOS-IgFc Plasmid DNA.

[0408] Registered RNA message and predicted amino acid sequence for human ICOS is shown in FIG. 43 (SEQ ID NO: 31).

[0409] The extracellular domain of human ICOS [NM_012092, Homo sapiens inducible T-cell co-stimulator (ICOS)] (amino acid residues: 20-141) was first amplified by RT-PCR from total RNA of PHA-stimulated human PBMCs, using the following primers: forward 5'-GGACTCGAGGGAGAAATCAATGGTTCTGC-3' (SEQ ID NO: 57) and reverse 5'-AATCTCGAGG AACTTCAGCTGGCAACAAA-3' (SEQ ID NO: 58), including the Xho I sites, respectively (sites are underlined). The PCR product was cloned in frame at the 3' end of the hCD40L in the OncoMCD40L-IgGFc/PCIneo. The resultant product, OncoM-hCD40L-hICOS-IgGFc/PCIneo was designated as CD40L-ICOS-IgFc/PCIneo.

[0410] The cDNA sequence for this fusion construct is shown in FIG. 44 (SEQ ID NO: 33).

[0411] CHO cells were transfected with CD40L-ICOS-IgFc/PCIneo as described in Example 2. The CD40L-ICOSL-IgFc protein secreted in the culture supernatant of the stable CHO transfectant was purified by protein G column. Purified CD40L-ICOSL-IgFc was analysed by SDS-PAGE Western blotting specific for human IgG and human CD40 ligand (FIG. 45).

[0412] FIG. 45. Western Blotting Analysis of CD40L-ICOS-IgFc.

[0413] Purified CD40L-ICOS-IgFc was subjected to SDS-PAGE under reduced conditions, probed by human IgG specific (A) or human CD40L specific (B) western blotting. The dominant band at .about.70 kDa corresponds to glycosylated

[0414] CD40L-ICOS-IgFc. The predicted molecular weight of the CD40L-ICOS-IgFc is 64.4 kDa without post-translational modification. The data indicate that the .about.70 kDa protein is the protein band representing the monomer of the fusion protein CD40L-ICOS-IgFc.

[0415] Study for the Function of CD40L-ICOS-IgFc/PCIneo In Vivo.

[0416] The Plasmid DNA of CD40L-ICOS-IgFc-Fusion Protein Increases Anti-Influenza Hemaglutinin Immune Response In Vivo.

[0417] We tested if the plasmid DNA encoding the CD40L-ICOS-IgFc fusion protein would function as a DNA-adjuvant similar to CD40L-FasL-IgFc in Example 2. Indeed, increased influenza vaccine-specific IgG response was observed following the administration of the CD40L-ICOS-IgFc/PCIneo plasmid in conjunction with influenza vaccine (FIG. 46).

[0418] FIG. 46. Adjuvant Activity of Plasmid DNA of CD40L-ICOS-IgFc in Mice Against Influenza Hemaglutinin.

[0419] Balb/c mice were immunized i.p. with 3 .mu.g of HA and 3 .mu.g of CD40L-ICOS-IgFc plasmid. On Day 14, mice were injected with an additional 3 .mu.g HA. Sera from day 14 and day 24 were analysed by ELISA for the IgG activity against HA. The titer was calculated as descried in Example 2. Squares indicate mice immunized with HA alone. Circles indicate mice immunized with HA with plasmid. Numbers in squares and circles indicate individual mouse. The anti-HA activity of pre-immune serum from each mouse was equally low at less than 20 in titer.

[0420] Effect of Plasmid DNA of CD40L-ICOS-IgFc on T Cell Responses Against Influenza Hemaglutinin.

[0421] The study of CD40L-ICOS-IgFc was furthered by investigating how the Influenza hemaglutinin-specific T cell response is regulated following CD40L-ICOS-IgFc/PCIneo injection (FIG. 47). Interestingly, the addition of CD40L-ICOS-IgFc/PCIneo lowered the HA-specific response by total T cells compared with spleen cells derived from mice immunized with HA alone. In contrast to the response by total T cells, the CD8.sup.+ T cell response was only detectable in spleen cells from mice immunized with HA and CD40L-ICOS-IgFc/PCIneo whereas it was not detected in spleen cells from mice immunized with HA alone. The data showed the adjuvant activity by CD40L-ICOS-IgFc/PCIneo to antigen-specific CD8.sup.+ T cell responses in vivo. The activation of CD8.sup.+ T cells, however, was lower than that observed by CD40L-FasL-IgFc treated mice spleen cells.

[0422] FIG. 47. Adjuvant Activity of CD40L-ICOS-IgFc/PCIneo in Mice Against Influenza Hemaglutinin-Specific T Cell Response.

[0423] Balb/c mice were immunized i.p. with 3 .mu.g of HA and 3 .mu.g of CD40L-ICOS-IgFc/PCIneo plasmid. On Day 14, mice were injected with an additional 3 .mu.g of HA. Spleen cells from day 60 were analysed by proliferation assay against HA. Spleen cells stimulated for 48 hours with HA and were analysed for viability by MTT assay as described in the Example 2. A indicates total T cell response; B indicates CD8.sup.+ T cell response. Percent viability is calculated based on the comparison with the non-stimulated cells (100%). The data shows the average and standard deviation derived from the triplicate samples. Not immunized: normal mice; Immunized: mice were immunized with HA only.

[0424] The results indicated that the extracellular domain of immunoglobulin family co-stimulation receptor, but not the ligand itself, is also usable to create a novel fusion protein mitogen.

Example 6

[0425] Construction of a Fusion Protein Comprised of X: NGF.beta.-Family Cytokine, Y: TNF Family Extracellular Domain Polypeptide Fusion Protein.

[0426] In another variation of "X" and "Y" of the X--Y-IgFc fusion protein mitogens, "X" nerve growth factor (NGF.beta.) and "Y" the extracellular domain of FasL were chosen. NGF.beta. is a NGF.beta. family cytokine and an important factor for the survival, differentiation and maintenance of the sensory and sympathetic neurons. Like other members of NGF.beta. family cytokines, NGF.beta. possesses various functions, one of which is to promote B cell growth [Brodie and Gelfand, J Immunol. 148:3492 (1992)]. Accordingly, the NGF.beta.-FasL-IgFc could stimulate B cells and antigen presenting cells, which will promote the antibody response by B cells in vivo. This fusion protein will also tested to see whether the NGF-family cytokine can be used as the domain of a fusion protein mitogen.

[0427] Construction of NGF.beta.-FasL-IgFc Plasmid DNA.

[0428] Registered RNA message and amino acid sequence for human NGF.beta. is shown in FIG. 48 (SEQ ID NO: 35).

[0429] The human NGF.beta. (NM_002506, Homo sapiens nerve growth factor (beta polypeptide)) (amino acid residues: 122-241) was first amplified by RT-PCR from total RNA of PHA-stimulated human PBMCs, using the following primers: forward 5'-GGACTCGAGTCA TCATCCCATCCCATCTT-3' (SEQ ID NO: 59) and reverse 5'-AATCTCGAG GGCTCTTCTCACAGCC TTCC-3' (SEQ ID NO: 60), including the Xho I sites, respectively (sites are underlined). The PCR product was cloned in frame at the 5' end of the hFasL in the OncoMFasL-IgGFc/PCIneo. The resultant product OncoM-hNGF.beta.-hFasL-IgGFc/PCIneo was designated as NGF.beta.-FasL-IgFc/PCIneo.

[0430] The cDNA sequence for this fusion construct is shown in FIG. 49 (SEQ ID NO: 37).

[0431] CHO cells were transfected with NGF.beta.-FasL-IgFc/PCIneo as described in Example 2. The NGF.beta.-FasL-IgFc protein secreted in the culture supernatant of the stable CHO transfectant was purified by protein G column. Purified NGF.beta.-FasL-IgFc was analysed by SDS-PAGE Western blotting specific for human IgG and human Fas ligand (FIG. 50).

[0432] FIG. 50. Western Blotting Analysis of NGF.beta.-FasL-IgFc.

[0433] Purified NGF.beta.-FasL-IgFc was subjected to SDS-PAGE under reduced conditions, and probed by human IgG specific (A) or human FasL specific (B) western blotting. The dominant band at .about.65 kDa corresponds to glycosylated NGF.beta.-FasL-IgFc protein. The predicted molecular weight of the NGF.beta.-FasL-IgFc is 60.5 kDa without post-translational modification. The data indicate that the .about.65 kDa protein the protein band representing the monomer of the fusion protein NGF.beta.-FasL-IgFc.

[0434] Study for the Function of NGF.beta.-FasL-IgFc/PCIneo In Vivo.

[0435] The Plasmid DNA of the NGF.beta.-FasL-IgFc Fusion Protein Increases Anti-Influenza HA Immune Response In Vivo.

[0436] We tested if the plasmid DNA encoding the NGF.beta.-FasL-IgFc fusion protein would function as DNA-adjuvant in a manner similar to the CD40L-FasL-IgFc fusion protein described in Example 2. Indeed, a largely increased influenza vaccine-specific IgG response was observed following the administration of the NGF.beta.-FasL-IgFc/PCIneo plasmid in conjunction with influenza vaccine (FIG. 51).

[0437] FIG. 51. Adjuvant Activity of Plasmid DNA of NGF.beta.-FasL-IgFc in Mice Against Influenza Hemaglutinin.

[0438] Balb/c mice were immunized i.p. with 3 .mu.g of HA and 3 .mu.g of NGF.beta.-FasL-IgFc plasmid (indicated as Primed). On Day 14, blood samples were harvested from tail vain and mice were injected with and additional 3 .mu.g HA (indicated as Boosted). Sera from day 14 and day 24 were analysed by ELISA for the IgG activity against HA. The titer was calculated as described in Example 2. Squares indicate mice immunized with HA alone. Circles indicate mice immunized with HA with plasmid. Numbers in squares and circles indicate individual mouse. The anti-HA activity of pre-immune serum from each mouse was equally low at less than 20 in titer.

[0439] Effect of Plasmid DNA of NGF.beta.-FasL-IgFc on T Cell Responses Against Influenza Hemaglutinin.

[0440] The study of NGF.beta.-FasL-IgFc investigated how the HA-specific T cell response is regulated following NGF.beta.-FasL-IgFc/PCIneo injection (FIG. 52). Similarly to results observed following CD40L-FasL-IgFc injection, the addition of NGF.beta.-FasL-IgFc/PCIneo lowered the HA-specific response by total T cells compared with spleen cells derived from mice immunized with HA alone. In contrast to the response by total T cells, CD8.sup.+ T cell response was increased to the level nearly equal to that observed by CD40L-FasL-IgFc-treated mouse cells and only detectable in spleen cells immunized HA and NGF.beta.-FasL-IgFc/PCIneo. The data showed significant adjuvant activity by NGF.beta.-FasL-IgFc/PCIneo to HA-specific CD8.sup.+ T cell responses in vivo.

[0441] FIG. 52. Adjuvant Activity of NGF.beta.-FasL-IgFc/PCIneo in Mice Against Influenza Hemaglutinin-Specific T Cell Response.

[0442] Balb/c mice were immunized i.p. with 3 .mu.g of HA and 3 .mu.g of NGF.beta.-FasL-IgFc/PCIneo plasmid. On Day 14, mice were injected with an additional 3 .mu.g of HA. Spleen cells from day 60 were analysed by proliferation assay against HA. Spleen cells stimulated for 48 hours and were analysed for viability by MTT assay as described in the Example 2. A indicates total T cell response; B indicates CD8.sup.+ T cell response. Percent viability is calculated based on the comparison with the non-stimulated cells (100%). The data shows the average and standard deviation derived from the triplicate samples. Not immunized: normal mice, Immunized: mice were immunized with HA only.

Example 7

[0443] Construction of a X: Interleukin 2-Family Cytokine, Y: TNF Family Extracellular Domain Polypeptide Fusion Protein.

[0444] In another variation of "X" and "Y" of the X--Y-IgFc fusion protein mitogens, "X" interleukin-2 (IL-2) and "Y" the extracellular domain of FasL were chosen. IL-2 is an IL-2 family cytokine and an important factor for the growth of T cells and the survival of T cells and B cells. Both T cells and B cells express receptors for IL-2 and it is possible both T and B cells would both be stimulated by the fusion protein IL-2-FasL-IgFc administration in vivo. This study also tested if the IL-2-family cytokines (IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21) can be used as the domain of a fusion protein mitogen.

[0445] Construction of IL-2-FasL-IgFc Plasmid DNA.

[0446] Registered RNA message and amino acid sequence for human IL-2 is shown in FIG. 53 (SEQ ID NO: 39).

[0447] The human IL-2 (NM_000586, Homo sapiens interleukin-2) (amino acid residues: 21-154) was amplified by RT-PCR from amplified by RT-PCR from total RNA of PHA-stimulated human PBMCs, using the following primers: forward 5'-GGAGAATTCGCA CCTACTTCAAGTTCTAC-3' (SEQ ID NO: 61). and reverse 5'-AATACGCGTAGTCAGTGTTGAGAT GCTGCT-3' (SEQ ID NO: 62), including the EcoRI and Mlu I sites, respectively (sites are underlined). The PCR product was cloned in frame at the 5' end of the hFasL by replacing the EcoR I/Mlu I fragment of hB7-2 of OncoM-hB7-2-hFasL-IgGFc/PCIneo following the double digestion with EcoRI and Mlu I. The resultant product OncoM-hIL-2-hFasL-IgGFc/PCIneo was designated as IL-2-FasL-IgFc/PCIneo.

[0448] The cDNA sequence for this fusion construct is shown in FIG. 54 (SEQ ID NO: 41).

[0449] CHO cells were transfected with IL-2-FasL-IgFc/PCIneo as described in Example 2. The IL-2-FasL-IgFc/PCIneo protein secreted in the culture supernatant of the stable CHO transfectant was purified by protein G column. Purified IL-2-FasL-IgFc/PCIneo was analysed by SDS-PAGE Western blotting specific for human IgG and human Fas ligand (FIG. 55).

[0450] FIG. 55. Western Blotting Analysis of IL-2-FasL-IgFc.

[0451] Purified IL-2-FasL-IgFc was subjected to SDS-PAGE under reduced conditions and probed by human IgG specific (A) or human FasL specific (B) western blotting. The dominant band at .about.70 kDa corresponds to glycosylated IL-2-FasL-IgFc protein. The predicted molecular weight of IL-2-FasL-IgFc protein is 65.4 kDa without post-translational modification. The data indicate that the .about.70 kDa protein is the protein band representing the monomer of the fusion protein IL-2-FasL-IgFc.

[0452] Study for the Function of IL-2-FasL-IgFc/PCIneo In Vivo.

[0453] The Plasmid DNA of the IL-2-FasL-IgFc Fusion Protein Increases Anti-Influenza Hemaglutinin Immune Response In Vivo.

[0454] We tested if the plasmid DNA encoding the IL-2-FasL-IgFc fusion protein would function as a DNA-adjuvant similar to that observed with the CD40L-FasL-IgFc fusion protein outlined in Example 2. Indeed, increased influenza vaccine-specific IgG responses were observed following the administration of the IL-2-FasL-IgFc/PCIneo plasmid in conjunction with influenza vaccine (FIG. 56).

[0455] FIG. 56. Adjuvant Activity of Plasmid DNA of IL-2-FasL-IgFc in Mice Against Influenza Hemaglutinin.

[0456] Balb/c mice were immunized i.p. with 3 .mu.g of HA and 3 .mu.g of IL-2-FasL-IgFc plasmid (indicated as Primed). On Day 14, blood samples were harvested from tail vain and mice were injected with an additional 3 .mu.g HA (indicated as Boosted). Sera from day 14 and day 24 were analysed by ELISA for the IgG activity against HA. The titer was calculated as described in Example 2. Squares indicate mice immunized with HA alone. Circles indicate mice immunized with HA with plasmid. Numbers in squares and circles indicate individual mouse. The anti-HA activity of pre-immune serum from each mouse was equally low at less than 20 in titer.

[0457] Effect of Plasmid DNA of IL-2-FasL-IgFc on T Cell Responses Against Influenza Hemaglutinin.

[0458] The inventor investigated how the Influenza hemaglutinin-specific T cell response is regulated following IL-2-FasL-IgFc/PCIneo injection in mice (FIG. 57). Interestingly, the addition of IL-2-FasL-IgFc/PCIneo repressed the HA-specific response by total T cells compared with spleen cells derived from mice immunized with HA alone. The CD8.sup.+ T cell response was not increased significantly but still a little higher than that observed by treatment of mice with B7-2-FasL-IgFc described earlier. The data showed that the adjuvant activity by IL-2-FasL-IgFc/PCIneo to antigen-specific T cell response in vivo is marginal.

[0459] FIG. 57. Suppressant Activity of IL-2-FasL-IgFc/PCIneo in Mice Against Influenza Hemaglutinin-Specific T Cell Response.

[0460] Balb/c mice were immunized i.p. with 3 .mu.g of HA and 3 .mu.g of IL-2-FasL-IgFc/PCIneo plasmid. On Day 14, mice were injected with an additional 3 .mu.g of HA. Spleen cells from day 60 were analysed by proliferation assay against HA. Spleen cells stimulated for 48 hours with HA and were analysed for viability by MTT assay as described in the Example 2. A indicates total T cell response; B indicates CD8.sup.+ T cell response.

[0461] Percent viability is calculated based on the comparison with the non-stimulated cells (100%). The data shows the average and standard deviation derived from the triplicate samples. Not immunized: normal mice, Immunized: mice were immunized with HA only.

[0462] The Examples presented supra indicate that the current invention can generate a variety of fusion protein mitogens, which acquire different functions. Some of the fusion proteins possessed unique characteristics, which could be beneficial in the treatment of various human diseases. It is also anticipated that, based on these examples, the present invention will provide novel methods of treatment of diseases that either enhance or repress cellular and humoral immunity. Diseases or conditions that are viable targets for this mode of treatment include chronic and debilitating human diseases such as cancer and other proliferative diseases, infectious diseases, autoimmunity, allergic conditions, inflammatory conditions such as arteriosclerosis and organ transplant rejection. The invention broadly encompasses the use of the fusion proteins and plasmid DNAs for treatment or prevention of diseases wherein enhanced or reduced antigen specific cellular immunity is desirable.

[0463] It is to be understood that the invention is not limited to the embodiments listed above and the right is reserved to the illustrated embodiments and all modifications coming within the scope of the following claims.

[0464] The various references to journals, patents, and other publications which are cited herein comprise the state of the art and are incorporated by reference as though fully set forth.

Sequence CWU 1

1

6211834DNAHomo sapiensCDS(73)..(855) 1actttgacag tcttctcatg ctgcctctgc caccttctct gccagaagat accatttcaa 60ctttaacaca gc atg atc gaa aca tac aac caa act tct ccc cga tct gcg 111 Met Ile Glu Thr Tyr Asn Gln Thr Ser Pro Arg Ser Ala 1 5 10 gcc act gga ctg ccc atc agc atg aaa att ttt atg tat tta ctt act 159Ala Thr Gly Leu Pro Ile Ser Met Lys Ile Phe Met Tyr Leu Leu Thr 15 20 25 gtt ttt ctt atc acc cag atg att ggg tca gca ctt ttt gct gtg tat 207Val Phe Leu Ile Thr Gln Met Ile Gly Ser Ala Leu Phe Ala Val Tyr 30 35 40 45 ctt cat aga agg ttg gac aag ata gaa gat gaa agg aat ctt cat gaa 255Leu His Arg Arg Leu Asp Lys Ile Glu Asp Glu Arg Asn Leu His Glu 50 55 60 gat ttt gta ttc atg aaa acg ata cag aga tgc aac aca gga gaa aga 303Asp Phe Val Phe Met Lys Thr Ile Gln Arg Cys Asn Thr Gly Glu Arg 65 70 75 tcc tta tcc tta ctg aac tgt gag gag att aaa agc cag ttt gaa ggc 351Ser Leu Ser Leu Leu Asn Cys Glu Glu Ile Lys Ser Gln Phe Glu Gly 80 85 90 ttt gtg aag gat ata atg tta aac aaa gag gag acg aag aaa gaa aac 399Phe Val Lys Asp Ile Met Leu Asn Lys Glu Glu Thr Lys Lys Glu Asn 95 100 105 agc ttt gaa atg caa aaa ggt gat cag aat cct caa att gcg gca cat 447Ser Phe Glu Met Gln Lys Gly Asp Gln Asn Pro Gln Ile Ala Ala His 110 115 120 125 gtc ata agt gag gcc agc agt aaa aca aca tct gtg tta cag tgg gct 495Val Ile Ser Glu Ala Ser Ser Lys Thr Thr Ser Val Leu Gln Trp Ala 130 135 140 gaa aaa gga tac tac acc atg agc aac aac ttg gta acc ctg gaa aat 543Glu Lys Gly Tyr Tyr Thr Met Ser Asn Asn Leu Val Thr Leu Glu Asn 145 150 155 ggg aaa cag ctg acc gtt aaa aga caa gga ctc tat tat atc tat gcc 591Gly Lys Gln Leu Thr Val Lys Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala 160 165 170 caa gtc acc ttc tgt tcc aat cgg gaa gct tcg agt caa gct cca ttt 639Gln Val Thr Phe Cys Ser Asn Arg Glu Ala Ser Ser Gln Ala Pro Phe 175 180 185 ata gcc agc ctc tgc cta aag tcc ccc ggt aga ttc gag aga atc tta 687Ile Ala Ser Leu Cys Leu Lys Ser Pro Gly Arg Phe Glu Arg Ile Leu 190 195 200 205 ctc aga gct gca aat acc cac agt tcc gcc aaa cct tgc ggg caa caa 735Leu Arg Ala Ala Asn Thr His Ser Ser Ala Lys Pro Cys Gly Gln Gln 210 215 220 tcc att cac ttg gga gga gta ttt gaa ttg caa cca ggt gct tcg gtg 783Ser Ile His Leu Gly Gly Val Phe Glu Leu Gln Pro Gly Ala Ser Val 225 230 235 ttt gtc aat gtg act gat cca agc caa gtg agc cat ggc act ggc ttc 831Phe Val Asn Val Thr Asp Pro Ser Gln Val Ser His Gly Thr Gly Phe 240 245 250 acg tcc ttt ggc tta ctc aaa ctc tgaacagtgt caccttgcag gctgtggtgg 885Thr Ser Phe Gly Leu Leu Lys Leu 255 260 agctgacgct gggagtcttc ataatacagc acagcggtta agcccacccc ctgttaactg 945cctatttata accctaggat cctccttatg gagaactatt tattatacac tccaaggcat 1005gtagaactgt aataagtgaa ttacaggtca catgaaacca aaacgggccc tgctccataa 1065gagcttatat atctgaagca gcaaccccac tgatgcagac atccagagag tcctatgaaa 1125agacaaggcc attatgcaca ggttgaattc tgagtaaaca gcagataact tgccaagttc 1185agttttgttt ctttgcgtgc agtgtctttc catggataat gcatttgatt tatcagtgaa 1245gatgcagaag ggaaatgggg agcctcagct cacattcagt tatggttgac tctgggttcc 1305tatggccttg ttggaggggg ccaggctcta gaacgtctaa cacagtggag aaccgaaacc 1365cccccccccc ccccgccacc ctctcggaca gttattcatt ctctttcaat ctctctctct 1425ccatctctct ctttcagtct ctctctctca acctctttct tccaatctct ctttctcaat 1485ctctctgttt ccctttgtca gtctcttccc tcccccagtc tctcttctca atcccccttt 1545ctaacacaca cacacacaca cacacacaca cacacacaca cacacacaca cacacagagt 1605caggccgttg ctagtcagtt ctcttctttc caccctgtcc ctatctctac cactatagat 1665gagggtgagg agtagggagt gcagccctga gcctgcccac tcctcattac gaaatgactg 1725tatttaaagg aaatctattg tatctacctg cagtctccat tgtttccaga gtgaacttgt 1785aattatcttg ttatttattt tttgaataat aaagacctct taacattaa 18342261PRTHomo sapiens 2Met Ile Glu Thr Tyr Asn Gln Thr Ser Pro Arg Ser Ala Ala Thr Gly 1 5 10 15 Leu Pro Ile Ser Met Lys Ile Phe Met Tyr Leu Leu Thr Val Phe Leu 20 25 30 Ile Thr Gln Met Ile Gly Ser Ala Leu Phe Ala Val Tyr Leu His Arg 35 40 45 Arg Leu Asp Lys Ile Glu Asp Glu Arg Asn Leu His Glu Asp Phe Val 50 55 60 Phe Met Lys Thr Ile Gln Arg Cys Asn Thr Gly Glu Arg Ser Leu Ser 65 70 75 80 Leu Leu Asn Cys Glu Glu Ile Lys Ser Gln Phe Glu Gly Phe Val Lys 85 90 95 Asp Ile Met Leu Asn Lys Glu Glu Thr Lys Lys Glu Asn Ser Phe Glu 100 105 110 Met Gln Lys Gly Asp Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser 115 120 125 Glu Ala Ser Ser Lys Thr Thr Ser Val Leu Gln Trp Ala Glu Lys Gly 130 135 140 Tyr Tyr Thr Met Ser Asn Asn Leu Val Thr Leu Glu Asn Gly Lys Gln 145 150 155 160 Leu Thr Val Lys Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln Val Thr 165 170 175 Phe Cys Ser Asn Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile Ala Ser 180 185 190 Leu Cys Leu Lys Ser Pro Gly Arg Phe Glu Arg Ile Leu Leu Arg Ala 195 200 205 Ala Asn Thr His Ser Ser Ala Lys Pro Cys Gly Gln Gln Ser Ile His 210 215 220 Leu Gly Gly Val Phe Glu Leu Gln Pro Gly Ala Ser Val Phe Val Asn 225 230 235 240 Val Thr Asp Pro Ser Gln Val Ser His Gly Thr Gly Phe Thr Ser Phe 245 250 255 Gly Leu Leu Lys Leu 260 31880DNAHomo sapiensCDS(53)..(808)sig_peptide(53)..(127)mat_peptide(128)..(808) 3agccgagagg tgtcaccccc agcgggcgcg ggccggagca cgggcaccca gc atg ggg 58 Met Gly -25 gta ctg ctc aca cag agg acg ctg ctc agt ctg gtc ctt gca ctc ctg 106Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val Leu Ala Leu Leu -20 -15 -10 ttt cca agc atg gcg agc atg gcg gct ata ggc agc tgc tcg aaa gag 154Phe Pro Ser Met Ala Ser Met Ala Ala Ile Gly Ser Cys Ser Lys Glu -5 -1 1 5 tac cgc gtg ctc ctt ggc cag ctc cag aag cag aca gat ctc atg cag 202Tyr Arg Val Leu Leu Gly Gln Leu Gln Lys Gln Thr Asp Leu Met Gln 10 15 20 25 gac acc agc aga ctc ctg gac ccc tat ata cgt atc caa ggc ctg gat 250Asp Thr Ser Arg Leu Leu Asp Pro Tyr Ile Arg Ile Gln Gly Leu Asp 30 35 40 gtt cct aaa ctg aga gag cac tgc agg gag cgc ccc ggg gcc ttc ccc 298Val Pro Lys Leu Arg Glu His Cys Arg Glu Arg Pro Gly Ala Phe Pro 45 50 55 agt gag gag acc ctg agg ggg ctg ggc agg cgg ggc ttc ctg cag acc 346Ser Glu Glu Thr Leu Arg Gly Leu Gly Arg Arg Gly Phe Leu Gln Thr 60 65 70 ctc aat gcc aca ctg ggc tgc gtc ctg cac aga ctg gcc gac tta gag 394Leu Asn Ala Thr Leu Gly Cys Val Leu His Arg Leu Ala Asp Leu Glu 75 80 85 cag cgc ctc ccc aag gcc cag gat ttg gag agg tct ggg ctg aac atc 442Gln Arg Leu Pro Lys Ala Gln Asp Leu Glu Arg Ser Gly Leu Asn Ile 90 95 100 105 gag gac ttg gag aag ctg cag atg gcg agg ccg aac atc ctc ggg ctc 490Glu Asp Leu Glu Lys Leu Gln Met Ala Arg Pro Asn Ile Leu Gly Leu 110 115 120 agg aac aac atc tac tgc atg gcc cag ctg ctg gac aac tca gac acg 538Arg Asn Asn Ile Tyr Cys Met Ala Gln Leu Leu Asp Asn Ser Asp Thr 125 130 135 gct gag ccc acg aag gct ggc cgg ggg gcc tct cag ccg ccc acc ccc 586Ala Glu Pro Thr Lys Ala Gly Arg Gly Ala Ser Gln Pro Pro Thr Pro 140 145 150 acc cct gcc tcg gat gct ttt cag cgc aag ctg gag ggc tgc agg ttc 634Thr Pro Ala Ser Asp Ala Phe Gln Arg Lys Leu Glu Gly Cys Arg Phe 155 160 165 ctg cat ggc tac cat cgc ttc atg cac tca gtg ggg cgg gtc ttc agc 682Leu His Gly Tyr His Arg Phe Met His Ser Val Gly Arg Val Phe Ser 170 175 180 185 aag tgg ggg gag agc ccg aac cgg agc cgg aga cac agc ccc cac cag 730Lys Trp Gly Glu Ser Pro Asn Arg Ser Arg Arg His Ser Pro His Gln 190 195 200 gcc ctg agg aag ggg gtg cgc agg acc aga ccc tcc agg aaa ggc aag 778Ala Leu Arg Lys Gly Val Arg Arg Thr Arg Pro Ser Arg Lys Gly Lys 205 210 215 aga ctc atg acc agg gga cag ctg ccc cgg tagcctcgag agcacccctt 828Arg Leu Met Thr Arg Gly Gln Leu Pro Arg 220 225 gccggtgaag gatgcggcag gtgctctgtg gatgagagga accatcgcag gatgacagct 888cccgggtccc caaacctgtt cccctctgct actagccact gagaagtgca ctttaagagg 948tgggagctgg gcagacccct ctacctcctc caggctggga gacagagtca ggctgttgcg 1008ctcccacctc agccccaagt tccccaggcc cagtggggtg gccgggcggg ccacgcggga 1068ccgactttcc attgattcag gggtctgatg acacaggctg actcatggcc gggctgactg 1128cccccctgcc ttgctccccg aggcctgccg gtccttccct ctcatgactt gcagggccgt 1188tgcccccaga cttcctcctt tccgtgtttc tgaaggggag gtcacagcct gagctggcct 1248cctatgcctc atcatgtccc aaaccagaca cctggatgtc tgggtgacct cactttaggc 1308agctgtaaca gcggcagggt gtcccaggag ccctgatccg ggggtccagg gaatggagct 1368caggtcccag gccagccccg aagtcgccac gtggcctggg gcaggtcact ttacctctgt 1428ggacctgttt tctctttgtg aagctaggga gttagaggct gtacaaggcc cccactgcct 1488gtcggttgct tggattccct gacgtaaggt ggatattaaa aatctgtaaa tcaggacagg 1548tggtgcaaat ggcgctggga ggtgtacacg gaggtctctg taaaagcaga cccacctccc 1608agcgccggga agcccgtctt gggtcctcgc tgctggctgc tccccctggt ggtggatcct 1668ggaattttct cacgcaggag ccattgctct cctagagggg gtctcagaaa ctgcgaggcc 1728agttccttgg agggacatga ctaatttatc gatttttatc aatttttatc agttttatat 1788ttataagcct tatttatgat gtatatttaa tgttaatatt gtgcaaactt atatttaaaa 1848cttgcctggt ttctaaaaaa aaaaaaaaaa aa 18804252PRTHomo sapiens 4Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val Leu Ala -25 -20 -15 -10 Leu Leu Phe Pro Ser Met Ala Ser Met Ala Ala Ile Gly Ser Cys Ser -5 -1 1 5 Lys Glu Tyr Arg Val Leu Leu Gly Gln Leu Gln Lys Gln Thr Asp Leu 10 15 20 Met Gln Asp Thr Ser Arg Leu Leu Asp Pro Tyr Ile Arg Ile Gln Gly 25 30 35 Leu Asp Val Pro Lys Leu Arg Glu His Cys Arg Glu Arg Pro Gly Ala 40 45 50 55 Phe Pro Ser Glu Glu Thr Leu Arg Gly Leu Gly Arg Arg Gly Phe Leu 60 65 70 Gln Thr Leu Asn Ala Thr Leu Gly Cys Val Leu His Arg Leu Ala Asp 75 80 85 Leu Glu Gln Arg Leu Pro Lys Ala Gln Asp Leu Glu Arg Ser Gly Leu 90 95 100 Asn Ile Glu Asp Leu Glu Lys Leu Gln Met Ala Arg Pro Asn Ile Leu 105 110 115 Gly Leu Arg Asn Asn Ile Tyr Cys Met Ala Gln Leu Leu Asp Asn Ser 120 125 130 135 Asp Thr Ala Glu Pro Thr Lys Ala Gly Arg Gly Ala Ser Gln Pro Pro 140 145 150 Thr Pro Thr Pro Ala Ser Asp Ala Phe Gln Arg Lys Leu Glu Gly Cys 155 160 165 Arg Phe Leu His Gly Tyr His Arg Phe Met His Ser Val Gly Arg Val 170 175 180 Phe Ser Lys Trp Gly Glu Ser Pro Asn Arg Ser Arg Arg His Ser Pro 185 190 195 His Gln Ala Leu Arg Lys Gly Val Arg Arg Thr Arg Pro Ser Arg Lys 200 205 210 215 Gly Lys Arg Leu Met Thr Arg Gly Gln Leu Pro Arg 220 225 5768DNAHomo sapiensCDS(1)..(765) 5atg aaa aag aca gct atc gcg att gca gtg gca ctg gct ggt ttc gct 48Met Lys Lys Thr Ala Ile Ala Ile Ala Val Ala Leu Ala Gly Phe Ala 1 5 10 15 acc gta gcg cag gcc gac gtc gag tcc aaa tct tgt gac aaa act cac 96Thr Val Ala Gln Ala Asp Val Glu Ser Lys Ser Cys Asp Lys Thr His 20 25 30 aca tgc cca ccg tgc cca gca cct gaa ctc ctg ggg gga ccg tca gtc 144Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val 35 40 45 ttc ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc 192Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 50 55 60 cct gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag 240Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 65 70 75 80 gtc aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag 288Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 85 90 95 aca aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc 336Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 100 105 110 gtc ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag 384Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 115 120 125 tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc 432Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 130 135 140 tcc aaa gcc aaa ggg cag ccc cga gag cca cag gtg tac acc ctg ccc 480Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 145 150 155 160 cca tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg 528Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 165 170 175 gtc aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat 576Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 180 185 190 ggg cag ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc 624Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 195 200 205 gac ggc tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag agc agg 672Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 210 215 220 tgg cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg 720Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 225 230 235 240 cac aac cac tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa tga 768His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 245 250 255 6255PRTHomo sapiens 6Met Lys Lys Thr Ala Ile Ala Ile Ala Val Ala Leu Ala Gly Phe Ala 1 5 10 15 Thr Val Ala Gln Ala Asp Val Glu Ser Lys Ser Cys Asp Lys Thr His 20 25 30 Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val 35 40 45 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 50 55 60 Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 65 70 75

80 Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 85 90 95 Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 100 105 110 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 115 120 125 Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 130 135 140 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 145 150 155 160 Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 165 170 175 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 180 185 190 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 195 200 205 Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 210 215 220 Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 225 230 235 240 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 245 250 255 71434DNAHomo sapiensCDS(7)..(1425)sig_peptide(7)..(81)mat_peptide(82)..(1425) 7gctagc atg ggg gta ctg ctc aca cag agg acg ctg ctc agt ctg gtc 48 Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val -25 -20 -15 ctt gca ctc ctg ttt cca agc atg gcg agc atg ctt cat aga agg ttg 96Leu Ala Leu Leu Phe Pro Ser Met Ala Ser Met Leu His Arg Arg Leu -10 -5 -1 1 5 gac aag ata gaa gat gaa agg aat ctt cat gaa gat ttt gta ttc atg 144Asp Lys Ile Glu Asp Glu Arg Asn Leu His Glu Asp Phe Val Phe Met 10 15 20 aaa acg ata cag aga tgc aac aca gga gaa aga tcc tta tcc tta ctg 192Lys Thr Ile Gln Arg Cys Asn Thr Gly Glu Arg Ser Leu Ser Leu Leu 25 30 35 aac tgt gag gag att aaa agc cag ttt gaa ggc ttt gtg aag gat ata 240Asn Cys Glu Glu Ile Lys Ser Gln Phe Glu Gly Phe Val Lys Asp Ile 40 45 50 atg tta aac aaa gag gag acg aag aaa gaa aac agc ttt gaa atg caa 288Met Leu Asn Lys Glu Glu Thr Lys Lys Glu Asn Ser Phe Glu Met Gln 55 60 65 aaa ggt gat cag aat cct caa att gcg gca cat gtc ata agt gag gcc 336Lys Gly Asp Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser Glu Ala 70 75 80 85 agc agt aaa aca aca tct gtg tta cag tgg gct gaa aaa gga tac tac 384Ser Ser Lys Thr Thr Ser Val Leu Gln Trp Ala Glu Lys Gly Tyr Tyr 90 95 100 acc atg agc aac aac ttg gta acc ctg gaa aat ggg aaa cag ctg acc 432Thr Met Ser Asn Asn Leu Val Thr Leu Glu Asn Gly Lys Gln Leu Thr 105 110 115 gtt aaa aga caa gga ctc tat tat atc tat gcc caa gtc acc ttc tgt 480Val Lys Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln Val Thr Phe Cys 120 125 130 tcc aat cgg gaa gct tcg agt caa gct cca ttt ata gcc agc ctc tgc 528Ser Asn Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile Ala Ser Leu Cys 135 140 145 cta aag tcc ccc ggt aga ttc gag aga atc tta ctc aga gct gca aat 576Leu Lys Ser Pro Gly Arg Phe Glu Arg Ile Leu Leu Arg Ala Ala Asn 150 155 160 165 acc cac agt tcc gcc aaa cct tgc ggg caa caa tcc att cac ttg gga 624Thr His Ser Ser Ala Lys Pro Cys Gly Gln Gln Ser Ile His Leu Gly 170 175 180 gga gta ttt gaa ttg caa cca ggt gct tcg gtg ttt gtc aat gtg act 672Gly Val Phe Glu Leu Gln Pro Gly Ala Ser Val Phe Val Asn Val Thr 185 190 195 gat cca agc caa gtg agc cat ggc act ggc ttc acg tcc ttt ggc tta 720Asp Pro Ser Gln Val Ser His Gly Thr Gly Phe Thr Ser Phe Gly Leu 200 205 210 ctc aaa ctc gag ccc aaa tct tgt gac aaa act cac aca tgc cca ccg 768Leu Lys Leu Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro 215 220 225 tgc cca gca cct gaa ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc 816Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro 230 235 240 245 cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct gag gtc aca 864Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 250 255 260 tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc aag ttc aac 912Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn 265 270 275 tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg 960Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 280 285 290 gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc 1008Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 295 300 305 ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc 1056Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser 310 315 320 325 aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa 1104Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 330 335 340 ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc cgg gat 1152Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp 345 350 355 gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc 1200Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 360 365 370 tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg cag ccg gag 1248Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 375 380 385 aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc 1296Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 390 395 400 405 ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg cag cag ggg 1344Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 410 415 420 aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac tac 1392Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 425 430 435 acg cag aag agc ctc tcc ctg tct ccg ggt aaa tgatctaga 1434Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 440 445 8473PRTHomo sapiens 8Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val Leu Ala -25 -20 -15 -10 Leu Leu Phe Pro Ser Met Ala Ser Met Leu His Arg Arg Leu Asp Lys -5 -1 1 5 Ile Glu Asp Glu Arg Asn Leu His Glu Asp Phe Val Phe Met Lys Thr 10 15 20 Ile Gln Arg Cys Asn Thr Gly Glu Arg Ser Leu Ser Leu Leu Asn Cys 25 30 35 Glu Glu Ile Lys Ser Gln Phe Glu Gly Phe Val Lys Asp Ile Met Leu 40 45 50 55 Asn Lys Glu Glu Thr Lys Lys Glu Asn Ser Phe Glu Met Gln Lys Gly 60 65 70 Asp Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser Glu Ala Ser Ser 75 80 85 Lys Thr Thr Ser Val Leu Gln Trp Ala Glu Lys Gly Tyr Tyr Thr Met 90 95 100 Ser Asn Asn Leu Val Thr Leu Glu Asn Gly Lys Gln Leu Thr Val Lys 105 110 115 Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln Val Thr Phe Cys Ser Asn 120 125 130 135 Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile Ala Ser Leu Cys Leu Lys 140 145 150 Ser Pro Gly Arg Phe Glu Arg Ile Leu Leu Arg Ala Ala Asn Thr His 155 160 165 Ser Ser Ala Lys Pro Cys Gly Gln Gln Ser Ile His Leu Gly Gly Val 170 175 180 Phe Glu Leu Gln Pro Gly Ala Ser Val Phe Val Asn Val Thr Asp Pro 185 190 195 Ser Gln Val Ser His Gly Thr Gly Phe Thr Ser Phe Gly Leu Leu Lys 200 205 210 215 Leu Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 220 225 230 Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 235 240 245 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 250 255 260 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 265 270 275 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 280 285 290 295 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 300 305 310 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 315 320 325 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln 330 335 340 Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu 345 350 355 Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 360 365 370 375 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 380 385 390 Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 395 400 405 Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val 410 415 420 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln 425 430 435 Lys Ser Leu Ser Leu Ser Pro Gly Lys 440 445 91909DNAHomo sapiensCDS(158)..(1000) 9gaggtgtttc ccttagctat ggaaactcta taagagagat ccagcttgcc tcctcttgag 60cagtcagcaa cagggtcccg tccttgacac ctcagcctct acaggactga gaagaagtaa 120aaccgtttgc tggggctggc ctgactcacc agctgcc atg cag cag ccc ttc aat 175 Met Gln Gln Pro Phe Asn 1 5 tac cca tat ccc cag atc tac tgg gtg gac agc agt gcc agc tct ccc 223Tyr Pro Tyr Pro Gln Ile Tyr Trp Val Asp Ser Ser Ala Ser Ser Pro 10 15 20 tgg gcc cct cca ggc aca gtt ctt ccc tgt cca acc tct gtg ccc aga 271Trp Ala Pro Pro Gly Thr Val Leu Pro Cys Pro Thr Ser Val Pro Arg 25 30 35 agg cct ggt caa agg agg cca cca cca cca ccg cca ccg cca cca cta 319Arg Pro Gly Gln Arg Arg Pro Pro Pro Pro Pro Pro Pro Pro Pro Leu 40 45 50 cca cct ccg ccg ccg ccg cca cca ctg cct cca cta ccg ctg cca ccc 367Pro Pro Pro Pro Pro Pro Pro Pro Leu Pro Pro Leu Pro Leu Pro Pro 55 60 65 70 ctg aag aag aga ggg aac cac agc aca ggc ctg tgt ctc ctt gtg atg 415Leu Lys Lys Arg Gly Asn His Ser Thr Gly Leu Cys Leu Leu Val Met 75 80 85 ttt ttc atg gtt ctg gtt gcc ttg gta gga ttg ggc ctg ggg atg ttt 463Phe Phe Met Val Leu Val Ala Leu Val Gly Leu Gly Leu Gly Met Phe 90 95 100 cag ctc ttc cac cta cag aag gag ctg gca gaa ctc cga gag tct acc 511Gln Leu Phe His Leu Gln Lys Glu Leu Ala Glu Leu Arg Glu Ser Thr 105 110 115 agc cag atg cac aca gca tca tct ttg gag aag caa ata ggc cac ccc 559Ser Gln Met His Thr Ala Ser Ser Leu Glu Lys Gln Ile Gly His Pro 120 125 130 agt cca ccc cct gaa aaa aag gag ctg agg aaa gtg gcc cat tta aca 607Ser Pro Pro Pro Glu Lys Lys Glu Leu Arg Lys Val Ala His Leu Thr 135 140 145 150 ggc aag tcc aac tca agg tcc atg cct ctg gaa tgg gaa gac acc tat 655Gly Lys Ser Asn Ser Arg Ser Met Pro Leu Glu Trp Glu Asp Thr Tyr 155 160 165 gga att gtc ctg ctt tct gga gtg aag tat aag aag ggt ggc ctt gtg 703Gly Ile Val Leu Leu Ser Gly Val Lys Tyr Lys Lys Gly Gly Leu Val 170 175 180 atc aat gaa act ggg ctg tac ttt gta tat tcc aaa gta tac ttc cgg 751Ile Asn Glu Thr Gly Leu Tyr Phe Val Tyr Ser Lys Val Tyr Phe Arg 185 190 195 ggt caa tct tgc aac aac ctg ccc ctg agc cac aag gtc tac atg agg 799Gly Gln Ser Cys Asn Asn Leu Pro Leu Ser His Lys Val Tyr Met Arg 200 205 210 aac tct aag tat ccc cag gat ctg gtg atg atg gag ggg aag atg atg 847Asn Ser Lys Tyr Pro Gln Asp Leu Val Met Met Glu Gly Lys Met Met 215 220 225 230 agc tac tgc act act ggg cag atg tgg gcc cgc agc agc tac ctg ggg 895Ser Tyr Cys Thr Thr Gly Gln Met Trp Ala Arg Ser Ser Tyr Leu Gly 235 240 245 gca gtg ttc aat ctt acc agt gct gat cat tta tat gtc aac gta tct 943Ala Val Phe Asn Leu Thr Ser Ala Asp His Leu Tyr Val Asn Val Ser 250 255 260 gag ctc tct ctg gtc aat ttt gag gaa tct cag acg ttt ttc ggc tta 991Glu Leu Ser Leu Val Asn Phe Glu Glu Ser Gln Thr Phe Phe Gly Leu 265 270 275 tat aag ctc taagagaagc actttgggat tctttccatt atgattcttt 1040Tyr Lys Leu 280 gttacaggca ccgagaatgt tgtattcagt gagggtcttc ttacatgcat ttgaggtcaa 1100gtaagaagac atgaaccaag tggaccttga gaccacaggg ttcaaaatgt ctgtagctcc 1160tcaactcacc taatgtttat gagccagaca aatggaggaa tatgacggaa gaacatagaa 1220ctctgggctg ccatgtgaag agggagaagc atgaaaaagc agctaccagg tgttctacac 1280tcatcttagt gcctgagagt atttaggcag attgaaaagg acacctttta actcacctct 1340caaggtgggc cttgctacct caagggggac tgtctttcag atacatggtt gtgacctgag 1400gatttaaggg atggaaaagg aagactagag gcttgcataa taagctaaag aggctgaaag 1460aggccaatgc cccactggca gcatcttcac ttctaaatgc atatcctgag ccatcggtga 1520aactaacaga taagcaagag agatgttttg gggactcatt tcattcctaa cacagcatgt 1580gtatttccag tgcaattgta ggggtgtgtg tgtgtgtgtg tgtgtgtgtg tgtgtatgac 1640taaagagaga atgtagatat tgtgaagtac atattaggaa aatatgggtt gcatttggtc 1700aagattttga atgcttcctg acaatcaact ctaatagtgc ttaaaaatca ttgattgtca 1760gctactaatg atgttttcct ataatataat aaatatttat gtagatgtgc atttttgtga 1820aatgaaaaca tgtaataaaa agtatatgtt aggatacaaa aaaaaaaaaa aaaaaaaaaa 1880aaaaaaaaaa aaaaaaaaaa aaaaaaaaa 190910281PRTHomo sapiens 10Met Gln Gln Pro Phe Asn Tyr Pro Tyr Pro Gln Ile Tyr Trp Val Asp 1 5 10 15 Ser Ser Ala Ser Ser Pro Trp Ala Pro Pro Gly Thr Val Leu Pro Cys 20 25 30 Pro Thr Ser Val Pro Arg Arg Pro Gly Gln Arg Arg Pro Pro Pro Pro 35 40 45 Pro Pro Pro Pro Pro Leu Pro Pro Pro Pro Pro Pro Pro Pro Leu Pro 50 55 60 Pro Leu Pro Leu Pro Pro Leu Lys Lys Arg Gly Asn His Ser Thr Gly 65 70 75 80 Leu Cys Leu Leu Val Met Phe Phe Met Val Leu Val Ala Leu Val Gly 85 90 95 Leu Gly Leu Gly Met Phe Gln Leu Phe His Leu Gln Lys Glu Leu Ala 100 105 110 Glu Leu Arg Glu Ser Thr Ser Gln Met His Thr Ala Ser Ser Leu Glu 115 120 125 Lys Gln Ile Gly His Pro Ser Pro Pro Pro Glu Lys Lys

Glu Leu Arg 130 135 140 Lys Val Ala His Leu Thr Gly Lys Ser Asn Ser Arg Ser Met Pro Leu 145 150 155 160 Glu Trp Glu Asp Thr Tyr Gly Ile Val Leu Leu Ser Gly Val Lys Tyr 165 170 175 Lys Lys Gly Gly Leu Val Ile Asn Glu Thr Gly Leu Tyr Phe Val Tyr 180 185 190 Ser Lys Val Tyr Phe Arg Gly Gln Ser Cys Asn Asn Leu Pro Leu Ser 195 200 205 His Lys Val Tyr Met Arg Asn Ser Lys Tyr Pro Gln Asp Leu Val Met 210 215 220 Met Glu Gly Lys Met Met Ser Tyr Cys Thr Thr Gly Gln Met Trp Ala 225 230 235 240 Arg Ser Ser Tyr Leu Gly Ala Val Phe Asn Leu Thr Ser Ala Asp His 245 250 255 Leu Tyr Val Asn Val Ser Glu Leu Ser Leu Val Asn Phe Glu Glu Ser 260 265 270 Gln Thr Phe Phe Gly Leu Tyr Lys Leu 275 280 111329DNAHomo sapiensCDS(7)..(1320)sig_peptide(7)..(81)mat_peptide(82)..(1320) 11gctagc atg ggg gta ctg ctc aca cag agg acg ctg ctc agt ctg gtc 48 Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val -25 -20 -15 ctt gca ctc ctg ttt cca agc atg gcg agc atg ctc gag cag ctc ttc 96Leu Ala Leu Leu Phe Pro Ser Met Ala Ser Met Leu Glu Gln Leu Phe -10 -5 -1 1 5 cac cta cag aag gag ctg gca gaa ctc cga gag tct acc agc cag atg 144His Leu Gln Lys Glu Leu Ala Glu Leu Arg Glu Ser Thr Ser Gln Met 10 15 20 cac aca gca tca tct ttg gag aag caa ata ggc cac ccc agt cca ccc 192His Thr Ala Ser Ser Leu Glu Lys Gln Ile Gly His Pro Ser Pro Pro 25 30 35 cct gaa aaa aag gag ctg agg aaa gtg gcc cat tta aca ggc aag tcc 240Pro Glu Lys Lys Glu Leu Arg Lys Val Ala His Leu Thr Gly Lys Ser 40 45 50 aac tca agg tcc atg cct ctg gaa tgg gaa gac acc tat gga att gtc 288Asn Ser Arg Ser Met Pro Leu Glu Trp Glu Asp Thr Tyr Gly Ile Val 55 60 65 ctg ctt tct gga gtg aag tat aag aag ggt ggc ctt gtg atc aat gaa 336Leu Leu Ser Gly Val Lys Tyr Lys Lys Gly Gly Leu Val Ile Asn Glu 70 75 80 85 act ggg ctg tac ttt gta tat tcc aaa gta tac ttc cgg ggt caa tct 384Thr Gly Leu Tyr Phe Val Tyr Ser Lys Val Tyr Phe Arg Gly Gln Ser 90 95 100 tgc aac aac ctg ccc ctg agc cac aag gtc tac atg agg aac tct aag 432Cys Asn Asn Leu Pro Leu Ser His Lys Val Tyr Met Arg Asn Ser Lys 105 110 115 tat ccc cag gat ctg gtg atg atg gag ggg aag atg atg agc tac tgc 480Tyr Pro Gln Asp Leu Val Met Met Glu Gly Lys Met Met Ser Tyr Cys 120 125 130 act act ggg cag atg tgg gcc cgc agc agc tac ctg ggg gca gtg ttc 528Thr Thr Gly Gln Met Trp Ala Arg Ser Ser Tyr Leu Gly Ala Val Phe 135 140 145 aat ctt acc agt gct gat cat tta tat gtc aac gta tct gag ctc tct 576Asn Leu Thr Ser Ala Asp His Leu Tyr Val Asn Val Ser Glu Leu Ser 150 155 160 165 ctg gtc aat ttt gag gaa tct cag acg ttt ttc ggc tta tat aag ctc 624Leu Val Asn Phe Glu Glu Ser Gln Thr Phe Phe Gly Leu Tyr Lys Leu 170 175 180 gag ccc aaa tct tgt gac aaa act cac aca tgc cca ccg tgc cca gca 672Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 185 190 195 cct gaa ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc 720Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 200 205 210 aag gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg 768Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 215 220 225 gtg gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg 816Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 230 235 240 245 gac ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag 864Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 250 255 260 tac aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag 912Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 265 270 275 gac tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc 960Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 280 285 290 ctc cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc 1008Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 295 300 305 cga gaa cca cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc 1056Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 310 315 320 325 aag aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc 1104Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 330 335 340 gac atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac 1152Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 345 350 355 aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac 1200Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 360 365 370 agc aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc 1248Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 375 380 385 tca tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag 1296Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 390 395 400 405 agc ctc tcc ctg tct ccg ggt aaa tgatctaga 1329Ser Leu Ser Leu Ser Pro Gly Lys 410 12438PRTHomo sapiens 12Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val Leu Ala -25 -20 -15 -10 Leu Leu Phe Pro Ser Met Ala Ser Met Leu Glu Gln Leu Phe His Leu -5 -1 1 5 Gln Lys Glu Leu Ala Glu Leu Arg Glu Ser Thr Ser Gln Met His Thr 10 15 20 Ala Ser Ser Leu Glu Lys Gln Ile Gly His Pro Ser Pro Pro Pro Glu 25 30 35 Lys Lys Glu Leu Arg Lys Val Ala His Leu Thr Gly Lys Ser Asn Ser 40 45 50 55 Arg Ser Met Pro Leu Glu Trp Glu Asp Thr Tyr Gly Ile Val Leu Leu 60 65 70 Ser Gly Val Lys Tyr Lys Lys Gly Gly Leu Val Ile Asn Glu Thr Gly 75 80 85 Leu Tyr Phe Val Tyr Ser Lys Val Tyr Phe Arg Gly Gln Ser Cys Asn 90 95 100 Asn Leu Pro Leu Ser His Lys Val Tyr Met Arg Asn Ser Lys Tyr Pro 105 110 115 Gln Asp Leu Val Met Met Glu Gly Lys Met Met Ser Tyr Cys Thr Thr 120 125 130 135 Gly Gln Met Trp Ala Arg Ser Ser Tyr Leu Gly Ala Val Phe Asn Leu 140 145 150 Thr Ser Ala Asp His Leu Tyr Val Asn Val Ser Glu Leu Ser Leu Val 155 160 165 Asn Phe Glu Glu Ser Gln Thr Phe Phe Gly Leu Tyr Lys Leu Glu Pro 170 175 180 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 185 190 195 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 200 205 210 215 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 220 225 230 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 235 240 245 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 250 255 260 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 265 270 275 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 280 285 290 295 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 300 305 310 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn 315 320 325 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 330 335 340 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 345 350 355 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 360 365 370 375 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 380 385 390 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 395 400 405 Ser Leu Ser Pro Gly Lys 410 131974DNAHomo sapiensCDS(7)..(1965)sig_peptide(7)..(81)sig_peptide(82)..(1965) 13gctagc atg ggg gta ctg ctc aca cag agg acg ctg ctc agt ctg gtc 48 Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val 1 5 10 ctt gca ctc ctg ttt cca agc atg gcg agc atg ctt cat aga agg ttg 96Leu Ala Leu Leu Phe Pro Ser Met Ala Ser Met Leu His Arg Arg Leu 15 20 25 30 gac aag ata gaa gat gaa agg aat ctt cat gaa gat ttt gta ttc atg 144Asp Lys Ile Glu Asp Glu Arg Asn Leu His Glu Asp Phe Val Phe Met 35 40 45 aaa acg ata cag aga tgc aac aca gga gaa aga tcc tta tcc tta ctg 192Lys Thr Ile Gln Arg Cys Asn Thr Gly Glu Arg Ser Leu Ser Leu Leu 50 55 60 aac tgt gag gag att aaa agc cag ttt gaa ggc ttt gtg aag gat ata 240Asn Cys Glu Glu Ile Lys Ser Gln Phe Glu Gly Phe Val Lys Asp Ile 65 70 75 atg tta aac aaa gag gag acg aag aaa gaa aac agc ttt gaa atg caa 288Met Leu Asn Lys Glu Glu Thr Lys Lys Glu Asn Ser Phe Glu Met Gln 80 85 90 aaa ggt gat cag aat cct caa att gcg gca cat gtc ata agt gag gcc 336Lys Gly Asp Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser Glu Ala 95 100 105 110 agc agt aaa aca aca tct gtg tta cag tgg gct gaa aaa gga tac tac 384Ser Ser Lys Thr Thr Ser Val Leu Gln Trp Ala Glu Lys Gly Tyr Tyr 115 120 125 acc atg agc aac aac ttg gta acc ctg gaa aat ggg aaa cag ctg acc 432Thr Met Ser Asn Asn Leu Val Thr Leu Glu Asn Gly Lys Gln Leu Thr 130 135 140 gtt aaa aga caa gga ctc tat tat atc tat gcc caa gtc acc ttc tgt 480Val Lys Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln Val Thr Phe Cys 145 150 155 tcc aat cgg gaa gct tcg agt caa gct cca ttt ata gcc agc ctc tgc 528Ser Asn Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile Ala Ser Leu Cys 160 165 170 cta aag tcc ccc ggt aga ttc gag aga atc tta ctc aga gct gca aat 576Leu Lys Ser Pro Gly Arg Phe Glu Arg Ile Leu Leu Arg Ala Ala Asn 175 180 185 190 acc cac agt tcc gcc aaa cct tgc ggg caa caa tcc att cac ttg gga 624Thr His Ser Ser Ala Lys Pro Cys Gly Gln Gln Ser Ile His Leu Gly 195 200 205 gga gta ttt gaa ttg caa cca ggt gct tcg gtg ttt gtc aat gtg act 672Gly Val Phe Glu Leu Gln Pro Gly Ala Ser Val Phe Val Asn Val Thr 210 215 220 gat cca agc caa gtg agc cat ggc act ggc ttc acg tcc ttt ggc tta 720Asp Pro Ser Gln Val Ser His Gly Thr Gly Phe Thr Ser Phe Gly Leu 225 230 235 ctc aaa ctc gag cag ctc ttc cac cta cag aag gag ctg gca gaa ctc 768Leu Lys Leu Glu Gln Leu Phe His Leu Gln Lys Glu Leu Ala Glu Leu 240 245 250 cga gag tct acc agc cag atg cac aca gca tca tct ttg gag aag caa 816Arg Glu Ser Thr Ser Gln Met His Thr Ala Ser Ser Leu Glu Lys Gln 255 260 265 270 ata ggc cac ccc agt cca ccc cct gaa aaa aag gag ctg agg aaa gtg 864Ile Gly His Pro Ser Pro Pro Pro Glu Lys Lys Glu Leu Arg Lys Val 275 280 285 gcc cat tta aca ggc aag tcc aac tca agg tcc atg cct ctg gaa tgg 912Ala His Leu Thr Gly Lys Ser Asn Ser Arg Ser Met Pro Leu Glu Trp 290 295 300 gaa gac acc tat gga att gtc ctg ctt tct gga gtg aag tat aag aag 960Glu Asp Thr Tyr Gly Ile Val Leu Leu Ser Gly Val Lys Tyr Lys Lys 305 310 315 ggt ggc ctt gtg atc aat gaa act ggg ctg tac ttt gta tat tcc aaa 1008Gly Gly Leu Val Ile Asn Glu Thr Gly Leu Tyr Phe Val Tyr Ser Lys 320 325 330 gta tac ttc cgg ggt caa tct tgc aac aac ctg ccc ctg agc cac aag 1056Val Tyr Phe Arg Gly Gln Ser Cys Asn Asn Leu Pro Leu Ser His Lys 335 340 345 350 gtc tac atg agg aac tct aag tat ccc cag gat ctg gtg atg atg gag 1104Val Tyr Met Arg Asn Ser Lys Tyr Pro Gln Asp Leu Val Met Met Glu 355 360 365 ggg aag atg atg agc tac tgc act act ggg cag atg tgg gcc cgc agc 1152Gly Lys Met Met Ser Tyr Cys Thr Thr Gly Gln Met Trp Ala Arg Ser 370 375 380 agc tac ctg ggg gca gtg ttc aat ctt acc agt gct gat cat tta tat 1200Ser Tyr Leu Gly Ala Val Phe Asn Leu Thr Ser Ala Asp His Leu Tyr 385 390 395 gtc aac gta tct gag ctc tct ctg gtc aat ttt gag gaa tct cag acg 1248Val Asn Val Ser Glu Leu Ser Leu Val Asn Phe Glu Glu Ser Gln Thr 400 405 410 ttt ttc ggc tta tat aag ctc gag ccc aaa tct tgt gac aaa act cac 1296Phe Phe Gly Leu Tyr Lys Leu Glu Pro Lys Ser Cys Asp Lys Thr His 415 420 425 430 aca tgc cca ccg tgc cca gca cct gaa ctc ctg ggg gga ccg tca gtc 1344Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val 435 440 445 ttc ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc 1392Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 450 455 460 cct gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag 1440Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 465 470 475 gtc aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag 1488Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 480 485 490 aca aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc 1536Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 495 500 505 510 gtc ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag 1584Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 515 520 525 tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc 1632Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile

530 535 540 tcc aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc 1680Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 545 550 555 cca tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg 1728Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 560 565 570 gtc aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat 1776Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 575 580 585 590 ggg cag ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc 1824Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 595 600 605 gac ggc tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag agc agg 1872Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 610 615 620 tgg cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg 1920Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 625 630 635 cac aac cac tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa 1965His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 640 645 650 tgatctaga 197414653PRTHomo sapiens 14Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val Leu Ala 1 5 10 15 Leu Leu Phe Pro Ser Met Ala Ser Met Leu His Arg Arg Leu Asp Lys 20 25 30 Ile Glu Asp Glu Arg Asn Leu His Glu Asp Phe Val Phe Met Lys Thr 35 40 45 Ile Gln Arg Cys Asn Thr Gly Glu Arg Ser Leu Ser Leu Leu Asn Cys 50 55 60 Glu Glu Ile Lys Ser Gln Phe Glu Gly Phe Val Lys Asp Ile Met Leu 65 70 75 80 Asn Lys Glu Glu Thr Lys Lys Glu Asn Ser Phe Glu Met Gln Lys Gly 85 90 95 Asp Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser Glu Ala Ser Ser 100 105 110 Lys Thr Thr Ser Val Leu Gln Trp Ala Glu Lys Gly Tyr Tyr Thr Met 115 120 125 Ser Asn Asn Leu Val Thr Leu Glu Asn Gly Lys Gln Leu Thr Val Lys 130 135 140 Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln Val Thr Phe Cys Ser Asn 145 150 155 160 Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile Ala Ser Leu Cys Leu Lys 165 170 175 Ser Pro Gly Arg Phe Glu Arg Ile Leu Leu Arg Ala Ala Asn Thr His 180 185 190 Ser Ser Ala Lys Pro Cys Gly Gln Gln Ser Ile His Leu Gly Gly Val 195 200 205 Phe Glu Leu Gln Pro Gly Ala Ser Val Phe Val Asn Val Thr Asp Pro 210 215 220 Ser Gln Val Ser His Gly Thr Gly Phe Thr Ser Phe Gly Leu Leu Lys 225 230 235 240 Leu Glu Gln Leu Phe His Leu Gln Lys Glu Leu Ala Glu Leu Arg Glu 245 250 255 Ser Thr Ser Gln Met His Thr Ala Ser Ser Leu Glu Lys Gln Ile Gly 260 265 270 His Pro Ser Pro Pro Pro Glu Lys Lys Glu Leu Arg Lys Val Ala His 275 280 285 Leu Thr Gly Lys Ser Asn Ser Arg Ser Met Pro Leu Glu Trp Glu Asp 290 295 300 Thr Tyr Gly Ile Val Leu Leu Ser Gly Val Lys Tyr Lys Lys Gly Gly 305 310 315 320 Leu Val Ile Asn Glu Thr Gly Leu Tyr Phe Val Tyr Ser Lys Val Tyr 325 330 335 Phe Arg Gly Gln Ser Cys Asn Asn Leu Pro Leu Ser His Lys Val Tyr 340 345 350 Met Arg Asn Ser Lys Tyr Pro Gln Asp Leu Val Met Met Glu Gly Lys 355 360 365 Met Met Ser Tyr Cys Thr Thr Gly Gln Met Trp Ala Arg Ser Ser Tyr 370 375 380 Leu Gly Ala Val Phe Asn Leu Thr Ser Ala Asp His Leu Tyr Val Asn 385 390 395 400 Val Ser Glu Leu Ser Leu Val Asn Phe Glu Glu Ser Gln Thr Phe Phe 405 410 415 Gly Leu Tyr Lys Leu Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 420 425 430 Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 435 440 445 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 450 455 460 Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 465 470 475 480 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 485 490 495 Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 500 505 510 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 515 520 525 Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 530 535 540 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 545 550 555 560 Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 565 570 575 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 580 585 590 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 595 600 605 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln 610 615 620 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 625 630 635 640 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 645 650 152807DNAHomo sapiensCDS(148)..(1116)sig_peptide(148)..(195)mat_peptide(196)..(1116) 15aggagcctta ggaggtacgg ggagctcgca aatactcctt ttggtttatt cttaccacct 60tgcttctgtg ttccttggga atgctgctgt gcttatgcat ctggtctctt tttggagcta 120cagtggacag gcatttgtga cagcact atg gga ctg agt aac att ctc ttt gtg 174 Met Gly Leu Ser Asn Ile Leu Phe Val -15 -10 atg gcc ttc ctg ctc tct ggt gct gct cct ctg aag att caa gct tat 222Met Ala Phe Leu Leu Ser Gly Ala Ala Pro Leu Lys Ile Gln Ala Tyr -5 -1 1 5 ttc aat gag act gca gac ctg cca tgc caa ttt gca aac tct caa aac 270Phe Asn Glu Thr Ala Asp Leu Pro Cys Gln Phe Ala Asn Ser Gln Asn 10 15 20 25 caa agc ctg agt gag cta gta gta ttt tgg cag gac cag gaa aac ttg 318Gln Ser Leu Ser Glu Leu Val Val Phe Trp Gln Asp Gln Glu Asn Leu 30 35 40 gtt ctg aat gag gta tac tta ggc aaa gag aaa ttt gac agt gtt cat 366Val Leu Asn Glu Val Tyr Leu Gly Lys Glu Lys Phe Asp Ser Val His 45 50 55 tcc aag tat atg ggc cgc aca agt ttt gat tcg gac agt tgg acc ctg 414Ser Lys Tyr Met Gly Arg Thr Ser Phe Asp Ser Asp Ser Trp Thr Leu 60 65 70 aga ctt cac aat ctt cag atc aag gac aag ggc ttg tat caa tgt atc 462Arg Leu His Asn Leu Gln Ile Lys Asp Lys Gly Leu Tyr Gln Cys Ile 75 80 85 atc cat cac aaa aag ccc aca gga atg att cgc atc cac cag atg aat 510Ile His His Lys Lys Pro Thr Gly Met Ile Arg Ile His Gln Met Asn 90 95 100 105 tct gaa ctg tca gtg ctt gct aac ttc agt caa cct gaa ata gta cca 558Ser Glu Leu Ser Val Leu Ala Asn Phe Ser Gln Pro Glu Ile Val Pro 110 115 120 att tct aat ata aca gaa aat gtg tac ata aat ttg acc tgc tca tct 606Ile Ser Asn Ile Thr Glu Asn Val Tyr Ile Asn Leu Thr Cys Ser Ser 125 130 135 ata cac ggt tac cca gaa cct aag aag atg agt gtt ttg cta aga acc 654Ile His Gly Tyr Pro Glu Pro Lys Lys Met Ser Val Leu Leu Arg Thr 140 145 150 aag aat tca act atc gag tat gat ggt gtt atg cag aaa tct caa gat 702Lys Asn Ser Thr Ile Glu Tyr Asp Gly Val Met Gln Lys Ser Gln Asp 155 160 165 aat gtc aca gaa ctg tac gac gtt tcc atc agc ttg tct gtt tca gac 750Asn Val Thr Glu Leu Tyr Asp Val Ser Ile Ser Leu Ser Val Ser Asp 170 175 180 185 aag acg cgg ctt tta tct tca cct ttc tct ata gag ctt gag ttc cct 798Lys Thr Arg Leu Leu Ser Ser Pro Phe Ser Ile Glu Leu Glu Phe Pro 190 195 200 gat gtt acg agc aat atg acc atc ttc tgt att ctg gaa act gac cct 846Asp Val Thr Ser Asn Met Thr Ile Phe Cys Ile Leu Glu Thr Asp Pro 205 210 215 cag cct ccc cca gac cac att cct tgg att aca gct gta ctt cca aca 894Gln Pro Pro Pro Asp His Ile Pro Trp Ile Thr Ala Val Leu Pro Thr 220 225 230 gtt att ata tgt gtg atg gtt ttc tgt cta att cta tgg aaa tgg aag 942Val Ile Ile Cys Val Met Val Phe Cys Leu Ile Leu Trp Lys Trp Lys 235 240 245 aag aag aag cgg cct cgc aac tct tat aaa tgt gga acc aac aca atg 990Lys Lys Lys Arg Pro Arg Asn Ser Tyr Lys Cys Gly Thr Asn Thr Met 250 255 260 265 gag agg gaa gag agt gaa cag acc aag aaa aga gaa aaa atc cat ata 1038Glu Arg Glu Glu Ser Glu Gln Thr Lys Lys Arg Glu Lys Ile His Ile 270 275 280 cct gaa aga tct gat gaa gcc cag cgt gtt ttt aaa agt tcg aag aca 1086Pro Glu Arg Ser Asp Glu Ala Gln Arg Val Phe Lys Ser Ser Lys Thr 285 290 295 tct tca tgc gac aaa agt gat aca tgt ttt taaataaaga gtaaagccca 1136Ser Ser Cys Asp Lys Ser Asp Thr Cys Phe 300 305 tacaagtatt cattttttct accctttcct ttgtaagttc ctgggcaacc tttttgattt 1196cttccagaag gcaaaaagac attaccatga gtaataaggg ggctccagga ctccctctaa 1256gtggaatagc ctccctgtaa ctccagctct gctccgtatg ccaagaggag actttaattc 1316tcttactgct tcttttcact tcagagcaca cttatgggcc aagcccagct taatggctca 1376tgacctggaa ataaaattta ggaccaatac ctcctccaga tcagattctt ctcttaattt 1436catagattgt gttttttttt taaatagacc tctcaatttc tggaaaactg ccttttatct 1496gcccagaatt ctaagctggt gccccactga attttgtgtg tacctgtgac taaacaacta 1556cctcctcagt ctgggtggga cttatgtatt tatgacctta tagtgttaat atcttgaaac 1616atagagatct atgtactgta atagtgtgat tactatgctc tagagaaaag tctacccctg 1676ctaaggagtt ctcatccctc tgtcagggtc agtaaggaaa acggtggcct agggtacagg 1736caacaatgag cagaccaacc taaatttggg gaaattagga gaggcagaga tagaacctgg 1796agccacttct atctgggctg ttgctaatat tgaggaggct tgccccaccc aacaagccat 1856agtggagaga actgaataaa caggaaaatg ccagagcttg tgaaccctgt ttctcttgaa 1916gaactgacta gtgagatggc ctggggaagc tgtgaaagaa ccaaaagaga tcacaatact 1976caaaagagag agagagagaa aaaagagaga tcttgatcca cagaaataca tgaaatgtct 2036ggtctgtcca ccccatcaac aagtcttgaa acaagcaaca gatggatagt ctgtccaaat 2096ggacataaga cagacagcag tttccctggt ggtcagggag gggttttggt gatacccaag 2156ttattgggat gtcatcttcc tggaagcaga gctggggagg gagagccatc accttgataa 2216tgggatgaat ggaaggaggc ttaggacttt ccactcctgg ctgagagagg aagagctgca 2276acggaattag gaagaccaag acacagatca cccggggctt acttagccta cagatgtcct 2336acgggaacgt gggctggccc agcatagggc tagcaaattt gagttggatg attgtttttg 2396ctcaaggcaa ccagaggaaa cttgcataca gagacagata tactgggaga aatgactttg 2456aaaacctggc tctaaggtgg gatcactaag ggatggggca gtctctgccc aaacataaag 2516agaactctgg ggagcctgag ccacaaaaat gttcctttat tttatgtaaa ccctcaaggg 2576ttatagactg ccatgctaga caagcttgtc catgtaatat tcccatgttt ttaccctgcc 2636cctgccttga ttagactcct agcacctggc tagtttctaa catgttttgt gcagcacagt 2696ttttaataaa tgcttgttac attcaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2756aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa a 280716323PRTHomo sapiens 16Met Gly Leu Ser Asn Ile Leu Phe Val Met Ala Phe Leu Leu Ser Gly -15 -10 -5 -1 Ala Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu 1 5 10 15 Pro Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val 20 25 30 Val Phe Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu 35 40 45 Gly Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Gly Arg Thr 50 55 60 Ser Phe Asp Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile 65 70 75 80 Lys Asp Lys Gly Leu Tyr Gln Cys Ile Ile His His Lys Lys Pro Thr 85 90 95 Gly Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu Ala 100 105 110 Asn Phe Ser Gln Pro Glu Ile Val Pro Ile Ser Asn Ile Thr Glu Asn 115 120 125 Val Tyr Ile Asn Leu Thr Cys Ser Ser Ile His Gly Tyr Pro Glu Pro 130 135 140 Lys Lys Met Ser Val Leu Leu Arg Thr Lys Asn Ser Thr Ile Glu Tyr 145 150 155 160 Asp Gly Val Met Gln Lys Ser Gln Asp Asn Val Thr Glu Leu Tyr Asp 165 170 175 Val Ser Ile Ser Leu Ser Val Ser Asp Lys Thr Arg Leu Leu Ser Ser 180 185 190 Pro Phe Ser Ile Glu Leu Glu Phe Pro Asp Val Thr Ser Asn Met Thr 195 200 205 Ile Phe Cys Ile Leu Glu Thr Asp Pro Gln Pro Pro Pro Asp His Ile 210 215 220 Pro Trp Ile Thr Ala Val Leu Pro Thr Val Ile Ile Cys Val Met Val 225 230 235 240 Phe Cys Leu Ile Leu Trp Lys Trp Lys Lys Lys Lys Arg Pro Arg Asn 245 250 255 Ser Tyr Lys Cys Gly Thr Asn Thr Met Glu Arg Glu Glu Ser Glu Gln 260 265 270 Thr Lys Lys Arg Glu Lys Ile His Ile Pro Glu Arg Ser Asp Glu Ala 275 280 285 Gln Arg Val Phe Lys Ser Ser Lys Thr Ser Ser Cys Asp Lys Ser Asp 290 295 300 Thr Cys Phe 305 172019DNAHomo sapiensCDS(7)..(2010)sig_peptide(7)..(81)mat_peptide(82)..(2010) 17gctagc atg ggg gta ctg ctc aca cag agg acg ctg ctc agt ctg gtc 48 Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val -25 -20 -15 ctt gca ctc ctg ttt cca agc atg gcg agc atg gaa ttc acg cgt gct 96Leu Ala Leu Leu Phe Pro Ser Met Ala Ser Met Glu Phe Thr Arg Ala -10 -5 -1 1 5 cct ctg aag att caa gct tat ttc aat gag act gca gac ctg cca tgc 144Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro Cys 10 15 20 caa ttt gca aac tct caa aac caa agc ctg agt gag cta gta gta ttt 192Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val Phe 25 30 35 tgg cag gac cag gaa aac ttg gtt ctg aat gag gta tac tta ggc aaa 240Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly Lys 40 45 50 gag aaa ttt gac agt gtt cat tcc aag tat atg ggc cgc aca agt ttt 288Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Gly Arg Thr Ser Phe 55 60 65 gat tcg gac agt tgg acc ctg aga ctt cac aat ctt cag atc aag gac 336Asp Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys Asp 70 75 80 85 aag ggc ttg tat caa tgt atc atc cat cac aaa aag ccc aca gga atg 384Lys Gly Leu Tyr Gln Cys Ile Ile His His Lys Lys Pro Thr Gly Met 90 95 100 att cgc atc cac cag atg aat tct gaa ctg tca gtg ctt gct aac ttc 432Ile Arg Ile His Gln Met Asn Ser

Glu Leu Ser Val Leu Ala Asn Phe 105 110 115 agt caa cct gaa ata gta cca att tct aat ata aca gaa aat gtg tac 480Ser Gln Pro Glu Ile Val Pro Ile Ser Asn Ile Thr Glu Asn Val Tyr 120 125 130 ata aat ttg acc tgc tca tct ata cac ggt tac cca gaa cct aag aag 528Ile Asn Leu Thr Cys Ser Ser Ile His Gly Tyr Pro Glu Pro Lys Lys 135 140 145 atg agt gtt ttg cta aga acc aag aat tca act atc gag tat gat ggt 576Met Ser Val Leu Leu Arg Thr Lys Asn Ser Thr Ile Glu Tyr Asp Gly 150 155 160 165 gtt atg cag aaa tct caa gat aat gtc aca gaa ctg tac gac gtt tcc 624Val Met Gln Lys Ser Gln Asp Asn Val Thr Glu Leu Tyr Asp Val Ser 170 175 180 atc agc ttg tct gtt tca ttc cct gat gtt acg agc aat atg acc atc 672Ile Ser Leu Ser Val Ser Phe Pro Asp Val Thr Ser Asn Met Thr Ile 185 190 195 ttc tgt att ctg gaa act gac aag acg cgg ctt tta tct tca cct ttc 720Phe Cys Ile Leu Glu Thr Asp Lys Thr Arg Leu Leu Ser Ser Pro Phe 200 205 210 tct ata gag ctt gag gac cct cag cct ccc cca gac cac att cct acg 768Ser Ile Glu Leu Glu Asp Pro Gln Pro Pro Pro Asp His Ile Pro Thr 215 220 225 cgt ggt acc cag ctc ttc cac cta cag aag gag ctg gca gaa ctc cga 816Arg Gly Thr Gln Leu Phe His Leu Gln Lys Glu Leu Ala Glu Leu Arg 230 235 240 245 gag tct acc agc cag atg cac aca gca tca tct ttg gag aag caa ata 864Glu Ser Thr Ser Gln Met His Thr Ala Ser Ser Leu Glu Lys Gln Ile 250 255 260 ggc cac ccc agt cca ccc cct gaa aaa aag gag ctg agg aaa gtg gcc 912Gly His Pro Ser Pro Pro Pro Glu Lys Lys Glu Leu Arg Lys Val Ala 265 270 275 cat tta aca ggc aag tcc aac tca agg tcc atg cct ctg gaa tgg gaa 960His Leu Thr Gly Lys Ser Asn Ser Arg Ser Met Pro Leu Glu Trp Glu 280 285 290 gac acc tat gga att gtc ctg ctt tct gga gtg aag tat aag aag ggt 1008Asp Thr Tyr Gly Ile Val Leu Leu Ser Gly Val Lys Tyr Lys Lys Gly 295 300 305 ggc ctt gtg atc aat gaa act ggg ctg tac ttt gta tat tcc aaa gta 1056Gly Leu Val Ile Asn Glu Thr Gly Leu Tyr Phe Val Tyr Ser Lys Val 310 315 320 325 tac ttc cgg ggt caa tct tgc aac aac ctg ccc ctg agc cac aag gtc 1104Tyr Phe Arg Gly Gln Ser Cys Asn Asn Leu Pro Leu Ser His Lys Val 330 335 340 tac atg agg aac tct aag tat ccc cag gat ctg gtg atg atg gag ggg 1152Tyr Met Arg Asn Ser Lys Tyr Pro Gln Asp Leu Val Met Met Glu Gly 345 350 355 aag atg atg agc tac tgc act act ggg cag atg tgg gcc cgc agc agc 1200Lys Met Met Ser Tyr Cys Thr Thr Gly Gln Met Trp Ala Arg Ser Ser 360 365 370 tac ctg ggg gca gtg ttc aat ctt acc agt gct gat cat tta tat gtc 1248Tyr Leu Gly Ala Val Phe Asn Leu Thr Ser Ala Asp His Leu Tyr Val 375 380 385 aac gta tct gag ctc tct ctg gtc aat ttt gag gaa tct cag acg ttt 1296Asn Val Ser Glu Leu Ser Leu Val Asn Phe Glu Glu Ser Gln Thr Phe 390 395 400 405 ttc ggc tta tat aag ctc gag ccc aaa tct tgt gac aaa act cac aca 1344Phe Gly Leu Tyr Lys Leu Glu Pro Lys Ser Cys Asp Lys Thr His Thr 410 415 420 tgc cca ccg tgc cca gca cct gaa ctc ctg ggg gga ccg tca gtc ttc 1392Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe 425 430 435 ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct 1440Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 440 445 450 gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc 1488Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val 455 460 465 aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca 1536Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr 470 475 480 485 aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc 1584Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val 490 495 500 ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc 1632Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 505 510 515 aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc 1680Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser 520 525 530 aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca 1728Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro 535 540 545 tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc 1776Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val 550 555 560 565 aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg 1824Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly 570 575 580 cag ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac 1872Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 585 590 595 ggc tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg 1920Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp 600 605 610 cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac 1968Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His 615 620 625 aac cac tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa tgatctaga 2019Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 630 635 640 18668PRTHomo sapiens 18Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val Leu Ala -25 -20 -15 -10 Leu Leu Phe Pro Ser Met Ala Ser Met Glu Phe Thr Arg Ala Pro Leu -5 -1 1 5 Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro Cys Gln Phe 10 15 20 Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val Phe Trp Gln 25 30 35 Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly Lys Glu Lys 40 45 50 55 Phe Asp Ser Val His Ser Lys Tyr Met Gly Arg Thr Ser Phe Asp Ser 60 65 70 Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys Asp Lys Gly 75 80 85 Leu Tyr Gln Cys Ile Ile His His Lys Lys Pro Thr Gly Met Ile Arg 90 95 100 Ile His Gln Met Asn Ser Glu Leu Ser Val Leu Ala Asn Phe Ser Gln 105 110 115 Pro Glu Ile Val Pro Ile Ser Asn Ile Thr Glu Asn Val Tyr Ile Asn 120 125 130 135 Leu Thr Cys Ser Ser Ile His Gly Tyr Pro Glu Pro Lys Lys Met Ser 140 145 150 Val Leu Leu Arg Thr Lys Asn Ser Thr Ile Glu Tyr Asp Gly Val Met 155 160 165 Gln Lys Ser Gln Asp Asn Val Thr Glu Leu Tyr Asp Val Ser Ile Ser 170 175 180 Leu Ser Val Ser Phe Pro Asp Val Thr Ser Asn Met Thr Ile Phe Cys 185 190 195 Ile Leu Glu Thr Asp Lys Thr Arg Leu Leu Ser Ser Pro Phe Ser Ile 200 205 210 215 Glu Leu Glu Asp Pro Gln Pro Pro Pro Asp His Ile Pro Thr Arg Gly 220 225 230 Thr Gln Leu Phe His Leu Gln Lys Glu Leu Ala Glu Leu Arg Glu Ser 235 240 245 Thr Ser Gln Met His Thr Ala Ser Ser Leu Glu Lys Gln Ile Gly His 250 255 260 Pro Ser Pro Pro Pro Glu Lys Lys Glu Leu Arg Lys Val Ala His Leu 265 270 275 Thr Gly Lys Ser Asn Ser Arg Ser Met Pro Leu Glu Trp Glu Asp Thr 280 285 290 295 Tyr Gly Ile Val Leu Leu Ser Gly Val Lys Tyr Lys Lys Gly Gly Leu 300 305 310 Val Ile Asn Glu Thr Gly Leu Tyr Phe Val Tyr Ser Lys Val Tyr Phe 315 320 325 Arg Gly Gln Ser Cys Asn Asn Leu Pro Leu Ser His Lys Val Tyr Met 330 335 340 Arg Asn Ser Lys Tyr Pro Gln Asp Leu Val Met Met Glu Gly Lys Met 345 350 355 Met Ser Tyr Cys Thr Thr Gly Gln Met Trp Ala Arg Ser Ser Tyr Leu 360 365 370 375 Gly Ala Val Phe Asn Leu Thr Ser Ala Asp His Leu Tyr Val Asn Val 380 385 390 Ser Glu Leu Ser Leu Val Asn Phe Glu Glu Ser Gln Thr Phe Phe Gly 395 400 405 Leu Tyr Lys Leu Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro 410 415 420 Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe 425 430 435 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 440 445 450 455 Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe 460 465 470 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 475 480 485 Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 490 495 500 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 505 510 515 Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala 520 525 530 535 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg 540 545 550 Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 555 560 565 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 570 575 580 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 585 590 595 Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln 600 605 610 615 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 620 625 630 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 635 640 191469DNAHomo sapiensCDS(7)..(1458)sig_peptide(7)..(81)mat_peptide(82)..(1458) 19gctagc atg ggg gta ctg ctc aca cag agg acg ctg ctc agt ctg gtc 48 Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val -25 -20 -15 ctt gca ctc ctg ttt cca agc atg gcg agc atg ctc gag gct cct ctg 96Leu Ala Leu Leu Phe Pro Ser Met Ala Ser Met Leu Glu Ala Pro Leu -10 -5 -1 1 5 aag att caa gct tat ttc aat gag act gca gac ctg cca tgc caa ttt 144Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro Cys Gln Phe 10 15 20 gca aac tct caa aac caa agc ctg agt gag cta gta gta ttt tgg cag 192Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val Phe Trp Gln 25 30 35 gac cag gaa aac ttg gtt ctg aat gag gta tac tta ggc aaa gag aaa 240Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly Lys Glu Lys 40 45 50 ttt gac agt gtt cat tcc aag tat atg ggc cgc aca agt ttt gat tcg 288Phe Asp Ser Val His Ser Lys Tyr Met Gly Arg Thr Ser Phe Asp Ser 55 60 65 gac agt tgg acc ctg aga ctt cgc aat ctt cag atc aag gac aag ggc 336Asp Ser Trp Thr Leu Arg Leu Arg Asn Leu Gln Ile Lys Asp Lys Gly 70 75 80 85 ttg tat caa tgt atc atc cat cac aaa aag ccc aca gga atg att cgc 384Leu Tyr Gln Cys Ile Ile His His Lys Lys Pro Thr Gly Met Ile Arg 90 95 100 atc cac cag atg aat tct gaa ctg tca gtg ctt gct aac ttc agt caa 432Ile His Gln Met Asn Ser Glu Leu Ser Val Leu Ala Asn Phe Ser Gln 105 110 115 cct gaa ata gta cca att tct aat ata aca gaa aat gtg tac ata aat 480Pro Glu Ile Val Pro Ile Ser Asn Ile Thr Glu Asn Val Tyr Ile Asn 120 125 130 ttg acc tgc tca tct ata cac ggt tac cca gaa cct aag aag atg agt 528Leu Thr Cys Ser Ser Ile His Gly Tyr Pro Glu Pro Lys Lys Met Ser 135 140 145 gtt ttg cta aga acc aag aat tca act atc gag tat gat ggt gtt atg 576Val Leu Leu Arg Thr Lys Asn Ser Thr Ile Glu Tyr Asp Gly Val Met 150 155 160 165 cag aaa tct caa gat aat gtc aca gaa ctg tac gac gtt tcc atc agc 624Gln Lys Ser Gln Asp Asn Val Thr Glu Leu Tyr Asp Val Ser Ile Ser 170 175 180 ttg tct gtt tca ttc cct gat gtt acg agc aat atg acc atc ttc tgt 672Leu Ser Val Ser Phe Pro Asp Val Thr Ser Asn Met Thr Ile Phe Cys 185 190 195 att ctg gaa act gac aag acg cgg ctt tta tct tca cct ttc tct ata 720Ile Leu Glu Thr Asp Lys Thr Arg Leu Leu Ser Ser Pro Phe Ser Ile 200 205 210 gag ctt gag gac cct cag cct ccc cca gac cac att cct tct aga ccc 768Glu Leu Glu Asp Pro Gln Pro Pro Pro Asp His Ile Pro Ser Arg Pro 215 220 225 aaa tct tgt gac aaa act cac aca tgc cca ccg tgc cca gca cct gaa 816Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 230 235 240 245 ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac 864Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 250 255 260 acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac 912Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 265 270 275 gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc 960Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 280 285 290 gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac 1008Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 295 300 305 agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg 1056Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 310 315 320 325 ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca 1104Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 330 335 340 gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa 1152Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 345 350 355 cca cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac 1200Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn 360 365 370 cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc 1248Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile

375 380 385 gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc 1296Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 390 395 400 405 acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag 1344Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 410 415 420 ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc 1392Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 425 430 435 tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc 1440Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 440 445 450 tcc ctg tct ccg ggt aaa tgagcggccg c 1469Ser Leu Ser Pro Gly Lys 455 20484PRTHomo sapiens 20Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val Leu Ala -25 -20 -15 -10 Leu Leu Phe Pro Ser Met Ala Ser Met Leu Glu Ala Pro Leu Lys Ile -5 -1 1 5 Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro Cys Gln Phe Ala Asn 10 15 20 Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val Phe Trp Gln Asp Gln 25 30 35 Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly Lys Glu Lys Phe Asp 40 45 50 55 Ser Val His Ser Lys Tyr Met Gly Arg Thr Ser Phe Asp Ser Asp Ser 60 65 70 Trp Thr Leu Arg Leu Arg Asn Leu Gln Ile Lys Asp Lys Gly Leu Tyr 75 80 85 Gln Cys Ile Ile His His Lys Lys Pro Thr Gly Met Ile Arg Ile His 90 95 100 Gln Met Asn Ser Glu Leu Ser Val Leu Ala Asn Phe Ser Gln Pro Glu 105 110 115 Ile Val Pro Ile Ser Asn Ile Thr Glu Asn Val Tyr Ile Asn Leu Thr 120 125 130 135 Cys Ser Ser Ile His Gly Tyr Pro Glu Pro Lys Lys Met Ser Val Leu 140 145 150 Leu Arg Thr Lys Asn Ser Thr Ile Glu Tyr Asp Gly Val Met Gln Lys 155 160 165 Ser Gln Asp Asn Val Thr Glu Leu Tyr Asp Val Ser Ile Ser Leu Ser 170 175 180 Val Ser Phe Pro Asp Val Thr Ser Asn Met Thr Ile Phe Cys Ile Leu 185 190 195 Glu Thr Asp Lys Thr Arg Leu Leu Ser Ser Pro Phe Ser Ile Glu Leu 200 205 210 215 Glu Asp Pro Gln Pro Pro Pro Asp His Ile Pro Ser Arg Pro Lys Ser 220 225 230 Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 235 240 245 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 250 255 260 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 265 270 275 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 280 285 290 295 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 300 305 310 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 315 320 325 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 330 335 340 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 345 350 355 Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val 360 365 370 375 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 380 385 390 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 395 400 405 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 410 415 420 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 425 430 435 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 440 445 450 455 Ser Pro Gly Lys 213362DNAHomo sapiensCDS(37)..(585) 21ccatatcttc atcttccctc tacccagatt gtgaag atg gaa agg gtc caa ccc 54 Met Glu Arg Val Gln Pro 1 5 ctg gaa gag aat gtg gga aat gca gcc agg cca aga ttc gag agg aac 102Leu Glu Glu Asn Val Gly Asn Ala Ala Arg Pro Arg Phe Glu Arg Asn 10 15 20 aag cta ttg ctg gtg gcc tct gta att cag gga ctg ggg ctg ctc ctg 150Lys Leu Leu Leu Val Ala Ser Val Ile Gln Gly Leu Gly Leu Leu Leu 25 30 35 tgc ttc acc tac atc tgc ctg cac ttc tct gct ctt cag gta tca cat 198Cys Phe Thr Tyr Ile Cys Leu His Phe Ser Ala Leu Gln Val Ser His 40 45 50 cgg tat cct cga att caa agt atc aaa gta caa ttt acc gaa tat aag 246Arg Tyr Pro Arg Ile Gln Ser Ile Lys Val Gln Phe Thr Glu Tyr Lys 55 60 65 70 aag gag aaa ggt ttc atc ctc act tcc caa aag gag gat gaa atc atg 294Lys Glu Lys Gly Phe Ile Leu Thr Ser Gln Lys Glu Asp Glu Ile Met 75 80 85 aag gtg cag aac aac tca gtc atc atc aac tgt gat ggg ttt tat ctc 342Lys Val Gln Asn Asn Ser Val Ile Ile Asn Cys Asp Gly Phe Tyr Leu 90 95 100 atc tcc ctg aag ggc tac ttc tcc cag gaa gtc aac att agc ctt cat 390Ile Ser Leu Lys Gly Tyr Phe Ser Gln Glu Val Asn Ile Ser Leu His 105 110 115 tac cag aag gat gag gag ccc ctc ttc caa ctg aag aag gtc agg tct 438Tyr Gln Lys Asp Glu Glu Pro Leu Phe Gln Leu Lys Lys Val Arg Ser 120 125 130 gtc aac tcc ttg atg gtg gcc tct ctg act tac aaa gac aaa gtc tac 486Val Asn Ser Leu Met Val Ala Ser Leu Thr Tyr Lys Asp Lys Val Tyr 135 140 145 150 ttg aat gtg acc act gac aat acc tcc ctg gat gac ttc cat gtg aat 534Leu Asn Val Thr Thr Asp Asn Thr Ser Leu Asp Asp Phe His Val Asn 155 160 165 ggc gga gaa ctg att ctt atc cat caa aat cct ggt gaa ttc tgt gtc 582Gly Gly Glu Leu Ile Leu Ile His Gln Asn Pro Gly Glu Phe Cys Val 170 175 180 ctt tgaggggctg atggcaatat ctaaaaccag gcaccagcat gaacaccaag 635Leu ctgggggtgg acagggcatg gattcttcat tgcaagtgaa ggagcctccc agctcagcca 695cgtgggatgt gacaagaagc agatcctggc cctcccgccc ccacccctca gggatattta 755aaacttattt tatataccag ttaatcttat ttatccttat attttctaaa ttgcctagcc 815gtcacacccc aagattgcct tgagcctact aggcaccttt gtgagaaaga aaaaatagat 875gcctcttctt caagatgcat tgtttctatt ggtcaggcaa ttgtcataat aaacttatgt 935cattgaaaac ggtacctgac taccatttgc tggaaatttg acatgtgtgt ggcattatca 995aaatgaagag gagcaaggag tgaaggagtg gggttatgaa tctgccaaag gtggtatgaa 1055ccaacccctg gaagccaaag cggcctctcc aaggttaaat tgattgcagt ttgcatattg 1115cctaaattta aactttctca tttggtgggg gttcaaaaga agaatcagct tgtgaaaaat 1175caggacttga agagagccgt ctaagaaata ccacgtgctt tttttcttta ccattttgct 1235ttcccagcct ccaaacatag ttaatagaaa tttcccttca aagaactgtc tggggatgtg 1295atgctttgaa aaatctaatc agtgacttaa gagagatttt cttgtataca gggagagtga 1355gataacttat tgtgaagggt tagctttact gtacaggata gcagggaact ggacatctca 1415gggtaaaagt cagtacggat tttaatagcc tggggaggaa aacacattct ttgccacaga 1475caggcaaagc aacacatgct catcctcctg cctatgctga gatacgcact cagctccatg 1535tcttgtacac acagaaacat tgctggtttc aagaaatgag gtgatcctat tatcaaattc 1595aatctgatgt caaatagcac taagaagtta ttgtgcctta tgaaaaataa tgatctctgt 1655ctagaaatac catagaccat atatagtctc acattgataa ttgaaactag aagggtctat 1715atcagcctat gccagggctt caatggaata gtatcccctt atgtttagtt gaaatgtccc 1775cttaacttga tataatgtgt tatgcttatg gcgctgtgac aatctgattt ttcatgtcaa 1835cttccagatg atttgtaact tctctgtgcc aaacctttta taaacataaa tttttgagat 1895atgtatttta aaattgtagc acatgtttcc ctgacatttt caatagagga tacaacatca 1955cagaatcttt ctggatgatt ctgtgttatc aaggaattgt actgtgctac aattatctct 2015agaatctcca gaaaggtgga gggctgttcg cccttacact aaatggtctc agttggattt 2075ttttttcctg ttttctattt cctcttaagt acaccttcaa ctatattccc atccctctat 2135tttaatctgt tatgaaggaa ggtaaataaa aatgctaaat agaagaaatt gtaggtaagg 2195taagaggaat caagttctga gtggctgcca aggcactcac agaatcataa tcatggctaa 2255atatttatgg agggcctact gtggaccagg cactggctaa atacttacat ttacaagaat 2315cattctgaga cagatattca atgatatctg gcttcactac tcagaagatt gtgtgtgtgt 2375ttgtgtgtgt gtgtgtgtgt gtatttcact ttttgttatt gaccatgttc tgcaaaattg 2435cagttactca gtgagtgata tccgaaaaag taaacgttta tgactatagg taatatttaa 2495gaaaatgcat ggttcatttt taagtttgga atttttatct atatttctca cagatgtgca 2555gtgcacatgc aggcctaagt atatgttgtg tgtgtttgtc tttgacgtca tggtcccctc 2615tcttaggtgc tcactcgctt tgggtgcacc tggcctgctc ttcccatgtt ggcctctgca 2675accacacagg gatatttctg ctatgcacca gcctcactcc accttccttc catcaaaaat 2735atgtgtgtgt gtctcagtcc ctgtaagtca tgtccttcac agggagaatt aacccttcga 2795tatacatggc agagttttgt gggaaaagaa ttgaatgaaa agtcaggaga tcagaatttt 2855aaatttgact tagccactaa ctagccatgt aaccttggga aagtcatttc ccatttctgg 2915gtcttgcttt tctttctgtt aaatgagagg aatgttaaat atctaacagt ttagaatctt 2975atgcttacag tgttatctgt gaatgcacat attaaatgtc tatgttcttg ttgctatgag 3035tcaaggagtg tacacttctc ctttactatg ttgaatgtat ttttttctgg acaagcttac 3095atcttcctca gccatctttg tgagtccttc aagagcagtt atcaattgtt agttagatat 3155tttctattta gagaatgctt aagggattcc aatcccgatc caaatcataa tttgttctta 3215agtatactgg gcaggtcccc tattttaagt cataattttg tatttagtgc tttcctggct 3275ctcagagagt attaatattg atattaataa tatagttaat agtaatattg ctatttacat 3335ggaaacaaat aaaagatctc agaattc 336222183PRTHomo sapiens 22Met Glu Arg Val Gln Pro Leu Glu Glu Asn Val Gly Asn Ala Ala Arg 1 5 10 15 Pro Arg Phe Glu Arg Asn Lys Leu Leu Leu Val Ala Ser Val Ile Gln 20 25 30 Gly Leu Gly Leu Leu Leu Cys Phe Thr Tyr Ile Cys Leu His Phe Ser 35 40 45 Ala Leu Gln Val Ser His Arg Tyr Pro Arg Ile Gln Ser Ile Lys Val 50 55 60 Gln Phe Thr Glu Tyr Lys Lys Glu Lys Gly Phe Ile Leu Thr Ser Gln 65 70 75 80 Lys Glu Asp Glu Ile Met Lys Val Gln Asn Asn Ser Val Ile Ile Asn 85 90 95 Cys Asp Gly Phe Tyr Leu Ile Ser Leu Lys Gly Tyr Phe Ser Gln Glu 100 105 110 Val Asn Ile Ser Leu His Tyr Gln Lys Asp Glu Glu Pro Leu Phe Gln 115 120 125 Leu Lys Lys Val Arg Ser Val Asn Ser Leu Met Val Ala Ser Leu Thr 130 135 140 Tyr Lys Asp Lys Val Tyr Leu Asn Val Thr Thr Asp Asn Thr Ser Leu 145 150 155 160 Asp Asp Phe His Val Asn Gly Gly Glu Leu Ile Leu Ile His Gln Asn 165 170 175 Pro Gly Glu Phe Cys Val Leu 180 231680DNAHomo sapiensCDS(39)..(800) 23aaaaagcggc gcgctgtgtc ttcccgcagt ctctcgtc atg gaa tac gcc tct gac 56 Met Glu Tyr Ala Ser Asp 1 5 gct tca ctg gac ccc gaa gcc ccg tgg cct ccc gcg ccc cgc gct cgc 104Ala Ser Leu Asp Pro Glu Ala Pro Trp Pro Pro Ala Pro Arg Ala Arg 10 15 20 gcc tgc cgc gta ctg cct tgg gcc ctg gtc gcg ggg ctg ctg ctg ctg 152Ala Cys Arg Val Leu Pro Trp Ala Leu Val Ala Gly Leu Leu Leu Leu 25 30 35 ctg ctg ctc gct gcc gcc tgc gcc gtc ttc ctc gcc tgc ccc tgg gcc 200Leu Leu Leu Ala Ala Ala Cys Ala Val Phe Leu Ala Cys Pro Trp Ala 40 45 50 gtg tcc ggg gct cgc gcc tcg ccc ggc tcc gcg gcc agc ccg aga ctc 248Val Ser Gly Ala Arg Ala Ser Pro Gly Ser Ala Ala Ser Pro Arg Leu 55 60 65 70 cgc gag ggt ccc gag ctt tcg ccc gac gat ccc gcc ggc ctc ttg gac 296Arg Glu Gly Pro Glu Leu Ser Pro Asp Asp Pro Ala Gly Leu Leu Asp 75 80 85 ctg cgg cag ggc atg ttt gcg cag ctg gtg gcc caa aat gtt ctg ctg 344Leu Arg Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val Leu Leu 90 95 100 atc gat ggg ccc ctg agc tgg tac agt gac cca ggc ctg gca ggc gtg 392Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala Gly Val 105 110 115 tcc ctg acg ggg ggc ctg agc tac aaa gag gac acg aag gag ctg gtg 440Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu Leu Val 120 125 130 gtg gcc aag gct gga gtc tac tat gtc ttc ttt caa cta gag ctg cgg 488Val Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu Leu Arg 135 140 145 150 cgc gtg gtg gcc ggc gag ggc tca ggc tcc gtt tca ctt gcg ctg cac 536Arg Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala Leu His 155 160 165 ctg cag cca ctg cgc tct gct gct ggg gcc gcc gcc ctg gct ttg acc 584Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Ala Leu Thr 170 175 180 gtg gac ctg cca ccc gcc tcc tcc gag gct cgg aac tcg gcc ttc ggt 632Val Asp Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala Phe Gly 185 190 195 ttc cag ggc cgc ttg ctg cac ctg agt gcc ggc cag cgc ctg ggc gtc 680Phe Gln Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu Gly Val 200 205 210 cat ctt cac act gag gcc agg gca cgc cat gcc tgg cag ctt acc cag 728His Leu His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu Thr Gln 215 220 225 230 ggc gcc aca gtc ttg gga ctc ttc cgg gtg acc ccc gaa atc cca gcc 776Gly Ala Thr Val Leu Gly Leu Phe Arg Val Thr Pro Glu Ile Pro Ala 235 240 245 gga ctc cct tca ccg agg tcg gaa taacgtccag cctgggtgca gcccacctgg 830Gly Leu Pro Ser Pro Arg Ser Glu 250 acagagtccg aatcctactc catccttcat ggagacccct ggtgctgggt ccctgctgct 890ttctctacct caaggggctt ggcaggggtc cctgctgctg acctcccctt gaggaccctc 950ctcacccact ccttccccaa gttggacctt gatatttatt ctgagcctga gctcagataa 1010tatattatat atattatata tatatatata tttctattta aagaggatcc tgagtttgtg 1070aatggacttt tttagaggag ttgttttggg gggggggggg tcttcgacat tgccgaggct 1130ggtcttgaac tcctggactt agacgatcct cctgcctcag cctcccaagc aactgggatt 1190catcctttct attaattcat tgtacttatt tgcttatttg tgtgtattga gcatctgtaa 1250tgtgccagca ttgtgcccag gctagggggc tatagaaaca tctagaaata gactgaaaga 1310aaatctgagt tatggtaata cgtgaggaat ttaaagactc atccccagcc tccacctcct 1370gtgtgatact tgggggctag cttttttctt tctttctttt ttttgagatg gtcttgttct 1430gtcaaccagg ctagaatgca gcggtgcaat catgagtcaa tgcagcctcc agcctcgacc 1490tcccgaggct caggtgatcc tcccatctca gcctctcgag tagctgggac cacagttgtg 1550tgccaccaca cttggctaac tttttaattt ttttgcggag acggtattgc tatgttgcca 1610aggttgttta catgccagta caatttataa taaacactca tttttcctcc ctctgaaaaa 1670aaaaaaaaaa 168024254PRTHomo sapiens 24Met Glu Tyr Ala Ser Asp Ala Ser Leu Asp Pro Glu Ala Pro Trp Pro 1 5 10 15 Pro Ala Pro Arg Ala Arg Ala Cys Arg Val Leu Pro Trp Ala Leu Val 20 25 30 Ala Gly Leu Leu Leu Leu Leu Leu Leu Ala Ala Ala Cys Ala Val Phe 35 40 45 Leu Ala Cys Pro Trp Ala Val Ser Gly Ala Arg Ala Ser Pro Gly Ser 50 55 60 Ala Ala Ser Pro Arg Leu Arg Glu Gly Pro Glu Leu Ser Pro Asp Asp 65 70 75 80 Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val 85 90 95 Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp

100 105 110 Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu 115 120 125 Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe 130 135 140 Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser 145 150 155 160 Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala 165 170 175 Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala 180 185 190 Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala 195 200 205 Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His 210 215 220 Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val 225 230 235 240 Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu 245 250 251821DNAHomo sapiensCDS(7)..(1812)sig_peptide(7)..(81)mat_peptide(82)..(1812) 25gctagc atg ggg gta ctg ctc aca cag agg acg ctg ctc agt ctg gtc 48 Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val -25 -20 -15 ctt gca ctc ctg ttt cca agc atg gcg agc atg ctc gag cag gta tca 96Leu Ala Leu Leu Phe Pro Ser Met Ala Ser Met Leu Glu Gln Val Ser -10 -5 -1 1 5 cat cgg tat cct cga att caa agt atc aaa gta caa ttt acc gaa tat 144His Arg Tyr Pro Arg Ile Gln Ser Ile Lys Val Gln Phe Thr Glu Tyr 10 15 20 aag aag gag aaa ggt ttc atc ctc act tcc caa aag gag gat gaa atc 192Lys Lys Glu Lys Gly Phe Ile Leu Thr Ser Gln Lys Glu Asp Glu Ile 25 30 35 atg aag gtg cag aac aac tca gtc atc atc aac tgt gat ggg ttt tat 240Met Lys Val Gln Asn Asn Ser Val Ile Ile Asn Cys Asp Gly Phe Tyr 40 45 50 ctc atc tcc ctg aag ggc tac ttc tcc cag gaa gtc aac att agc ctt 288Leu Ile Ser Leu Lys Gly Tyr Phe Ser Gln Glu Val Asn Ile Ser Leu 55 60 65 cat tac cag aag gat gag gag ccc ctc ttc caa ctg aag aag gtc agg 336His Tyr Gln Lys Asp Glu Glu Pro Leu Phe Gln Leu Lys Lys Val Arg 70 75 80 85 tct gtc aac tcc ttg atg gtg gcc tct ctg act tac aaa gac aaa gtc 384Ser Val Asn Ser Leu Met Val Ala Ser Leu Thr Tyr Lys Asp Lys Val 90 95 100 tac ttg aat gtg acc act gac aat acc tcc ctg gat gac ttc cat gtg 432Tyr Leu Asn Val Thr Thr Asp Asn Thr Ser Leu Asp Asp Phe His Val 105 110 115 aat ggc gga gaa ctg att ctt atc cat caa aat cct ggt gaa ttc tgt 480Asn Gly Gly Glu Leu Ile Leu Ile His Gln Asn Pro Gly Glu Phe Cys 120 125 130 gtc ctt acg cgt gcc tgc ccc tgg gcc gtg tcc ggg gct cgc gcc tcg 528Val Leu Thr Arg Ala Cys Pro Trp Ala Val Ser Gly Ala Arg Ala Ser 135 140 145 ccc ggc tcc gcg gcc agc ccg aga ctc cgc gag ggt ccc gag ctt tcg 576Pro Gly Ser Ala Ala Ser Pro Arg Leu Arg Glu Gly Pro Glu Leu Ser 150 155 160 165 ccc gac gat ccc gcc ggc ctc ttg gac ctg cgg cag ggc atg ttt gcg 624Pro Asp Asp Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala 170 175 180 cag ctg gtg gcc caa aat gtt ctg ctg atc gat ggg ccc ctg agc tgg 672Gln Leu Val Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp 185 190 195 tac agt gac cca ggc ctg gca ggc gtg tcc ctg acg ggg ggc ctg agc 720Tyr Ser Asp Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser 200 205 210 tac aaa gag gac acg aag gag ctg gtg gtg gcc aag gct gga gtc tac 768Tyr Lys Glu Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr 215 220 225 tat gtc ttc ttt caa cta gag ctg cgg cgc gtg gtg gcc ggc gag ggc 816Tyr Val Phe Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly 230 235 240 245 tca ggc tcc gtt tca ctt gcg ctg cac ctg cag cca ctg cgc tct gct 864Ser Gly Ser Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala 250 255 260 gct ggg gcc gcc gcc ctg gct ttg acc gtg gac ctg cca ccc gcc tcc 912Ala Gly Ala Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser 265 270 275 tcc gag gct cgg aac tcg gcc ttc ggt ttc cag ggc cgc ttg ctg cac 960Ser Glu Ala Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His 280 285 290 ctg agt gcc ggc cag cgc ctg ggc gtc cat ctt cac act gag gcc agg 1008Leu Ser Ala Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg 295 300 305 gca cgc cat gcc tgg cag ctt acc cag ggc gcc aca gtc ttg gga ctc 1056Ala Arg His Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu 310 315 320 325 ttc cgg gtg acc ccc gaa atc cca gcc gga ctc cct tca ccg agg tcg 1104Phe Arg Val Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser 330 335 340 gaa ggt acc tct aga ccc aaa tct tgt gac aaa act cac aca tgc cca 1152Glu Gly Thr Ser Arg Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro 345 350 355 ccg tgc cca gca cct gaa ctc ctg ggg gga ccg tca gtc ttc ctc ttc 1200Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe 360 365 370 ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct gag gtc 1248Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 375 380 385 aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc aag ttc 1296Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe 390 395 400 405 aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca aag ccg 1344Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 410 415 420 cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc ctc acc 1392Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 425 430 435 gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc aag gtc 1440Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 440 445 450 tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc aaa gcc 1488Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala 455 460 465 aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc cgg 1536Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg 470 475 480 485 gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa ggc 1584Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 490 495 500 ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg cag ccg 1632Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 505 510 515 gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc 1680Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 520 525 530 ttc ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg cag cag 1728Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln 535 540 545 ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac 1776Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 550 555 560 565 tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa tgatctaga 1821Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 570 575 26602PRTHomo sapiens 26Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val Leu Ala -25 -20 -15 -10 Leu Leu Phe Pro Ser Met Ala Ser Met Leu Glu Gln Val Ser His Arg -5 -1 1 5 Tyr Pro Arg Ile Gln Ser Ile Lys Val Gln Phe Thr Glu Tyr Lys Lys 10 15 20 Glu Lys Gly Phe Ile Leu Thr Ser Gln Lys Glu Asp Glu Ile Met Lys 25 30 35 Val Gln Asn Asn Ser Val Ile Ile Asn Cys Asp Gly Phe Tyr Leu Ile 40 45 50 55 Ser Leu Lys Gly Tyr Phe Ser Gln Glu Val Asn Ile Ser Leu His Tyr 60 65 70 Gln Lys Asp Glu Glu Pro Leu Phe Gln Leu Lys Lys Val Arg Ser Val 75 80 85 Asn Ser Leu Met Val Ala Ser Leu Thr Tyr Lys Asp Lys Val Tyr Leu 90 95 100 Asn Val Thr Thr Asp Asn Thr Ser Leu Asp Asp Phe His Val Asn Gly 105 110 115 Gly Glu Leu Ile Leu Ile His Gln Asn Pro Gly Glu Phe Cys Val Leu 120 125 130 135 Thr Arg Ala Cys Pro Trp Ala Val Ser Gly Ala Arg Ala Ser Pro Gly 140 145 150 Ser Ala Ala Ser Pro Arg Leu Arg Glu Gly Pro Glu Leu Ser Pro Asp 155 160 165 Asp Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu 170 175 180 Val Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser 185 190 195 Asp Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys 200 205 210 215 Glu Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val 220 225 230 Phe Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly 235 240 245 Ser Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly 250 255 260 Ala Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu 265 270 275 Ala Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser 280 285 290 295 Ala Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg 300 305 310 His Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg 315 320 325 Val Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu Gly 330 335 340 Thr Ser Arg Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 345 350 355 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 360 365 370 375 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 380 385 390 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 395 400 405 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 410 415 420 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 425 430 435 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 440 445 450 455 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 460 465 470 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu 475 480 485 Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 490 495 500 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 505 510 515 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 520 525 530 535 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 540 545 550 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 555 560 565 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 570 575 271206DNAHomo sapiensCDS(7)..(1197)sig_peptide(7)..(81)mat_peptide(82)..(1197) 27gctagc atg ggg gta ctg ctc aca cag agg acg ctg ctc agt ctg gtc 48 Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val -25 -20 -15 ctt gca ctc ctg ttt cca agc atg gcg agc atg ctc gag cag gta tca 96Leu Ala Leu Leu Phe Pro Ser Met Ala Ser Met Leu Glu Gln Val Ser -10 -5 -1 1 5 cat cgg tat cct cga att caa agt atc aaa gta caa ttt acc gaa tat 144His Arg Tyr Pro Arg Ile Gln Ser Ile Lys Val Gln Phe Thr Glu Tyr 10 15 20 aag aag gag aaa ggt ttc atc ctc act tcc caa aag gag gat gaa atc 192Lys Lys Glu Lys Gly Phe Ile Leu Thr Ser Gln Lys Glu Asp Glu Ile 25 30 35 atg aag gtg cag aac aac tca gtc atc atc aac tgt gat ggg ttt tat 240Met Lys Val Gln Asn Asn Ser Val Ile Ile Asn Cys Asp Gly Phe Tyr 40 45 50 ctc atc tcc ctg aag ggc tac ttc tcc cag gaa gtc aac att agc ctt 288Leu Ile Ser Leu Lys Gly Tyr Phe Ser Gln Glu Val Asn Ile Ser Leu 55 60 65 cat tac cag aag gat gag gag ccc ctc ttc caa ctg aag aag gtc agg 336His Tyr Gln Lys Asp Glu Glu Pro Leu Phe Gln Leu Lys Lys Val Arg 70 75 80 85 tct gtc aac tcc ttg atg gtg gcc tct ctg act tac aaa gac aaa gtc 384Ser Val Asn Ser Leu Met Val Ala Ser Leu Thr Tyr Lys Asp Lys Val 90 95 100 tac ttg aat gtg acc act gac aat acc tcc ctg gat gac ttc cat gtg 432Tyr Leu Asn Val Thr Thr Asp Asn Thr Ser Leu Asp Asp Phe His Val 105 110 115 aat ggc gga gaa ctg att ctt atc cat caa aat cct ggt gaa ttc tgt 480Asn Gly Gly Glu Leu Ile Leu Ile His Gln Asn Pro Gly Glu Phe Cys 120 125 130 gtc ctt acg cgt ggt acc tct aga ccc aaa tct tgt gac aaa act cac 528Val Leu Thr Arg Gly Thr Ser Arg Pro Lys Ser Cys Asp Lys Thr His 135 140 145 aca tgc cca ccg tgc cca gca cct gaa ctc ctg ggg gga ccg tca gtc 576Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val 150 155 160 165 ttc ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc 624Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 170 175 180 cct gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag 672Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 185 190 195 gtc aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag 720Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 200 205 210 aca aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc 768Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 215 220 225 gtc ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag 816Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 230 235 240 245 tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc 864Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 250 255

260 tcc aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc 912Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 265 270 275 cca tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg 960Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 280 285 290 gtc aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat 1008Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 295 300 305 ggg cag ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc 1056Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 310 315 320 325 gac ggc tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag agc agg 1104Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 330 335 340 tgg cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg 1152Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 345 350 355 cac aac cac tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa 1197His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 360 365 370 tgatctaga 120628397PRTHomo sapiens 28Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val Leu Ala -25 -20 -15 -10 Leu Leu Phe Pro Ser Met Ala Ser Met Leu Glu Gln Val Ser His Arg -5 -1 1 5 Tyr Pro Arg Ile Gln Ser Ile Lys Val Gln Phe Thr Glu Tyr Lys Lys 10 15 20 Glu Lys Gly Phe Ile Leu Thr Ser Gln Lys Glu Asp Glu Ile Met Lys 25 30 35 Val Gln Asn Asn Ser Val Ile Ile Asn Cys Asp Gly Phe Tyr Leu Ile 40 45 50 55 Ser Leu Lys Gly Tyr Phe Ser Gln Glu Val Asn Ile Ser Leu His Tyr 60 65 70 Gln Lys Asp Glu Glu Pro Leu Phe Gln Leu Lys Lys Val Arg Ser Val 75 80 85 Asn Ser Leu Met Val Ala Ser Leu Thr Tyr Lys Asp Lys Val Tyr Leu 90 95 100 Asn Val Thr Thr Asp Asn Thr Ser Leu Asp Asp Phe His Val Asn Gly 105 110 115 Gly Glu Leu Ile Leu Ile His Gln Asn Pro Gly Glu Phe Cys Val Leu 120 125 130 135 Thr Arg Gly Thr Ser Arg Pro Lys Ser Cys Asp Lys Thr His Thr Cys 140 145 150 Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 155 160 165 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 170 175 180 Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 185 190 195 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 200 205 210 215 Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 220 225 230 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 235 240 245 Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 250 255 260 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 265 270 275 Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 280 285 290 295 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 300 305 310 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 315 320 325 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln 330 335 340 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 345 350 355 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 360 365 370 291422DNAHomo sapiensCDS(7)..(1413)sig_peptide(7)..(81)mat_peptide(82)..(1413) 29gctagc atg ggg gta ctg ctc aca cag agg acg ctg ctc agt ctg gtc 48 Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val -25 -20 -15 ctt gca ctc ctg ttt cca agc atg gcg agc atg ctc gag gcc tgc ccc 96Leu Ala Leu Leu Phe Pro Ser Met Ala Ser Met Leu Glu Ala Cys Pro -10 -5 -1 1 5 tgg gcc gtg tcc ggg gct cgc gcc tcg ccc ggc tcc gcg gcc agc ccg 144Trp Ala Val Ser Gly Ala Arg Ala Ser Pro Gly Ser Ala Ala Ser Pro 10 15 20 aga ctc cgc gag ggt ccc gag ctt tcg ccc gac gat ccc gcc ggc ctc 192Arg Leu Arg Glu Gly Pro Glu Leu Ser Pro Asp Asp Pro Ala Gly Leu 25 30 35 ttg gac ctg cgg cag ggc atg ttt gcg cag ctg gtg gcc caa aat gtt 240Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val 40 45 50 ctg ctg atc gat ggg ccc ctg agc tgg tac agt gac cca ggc ctg gca 288Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala 55 60 65 ggc gtg tcc ctg acg ggg ggc ctg agc tac aaa gag gac acg aag gag 336Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu 70 75 80 85 ctg gtg gtg gcc aag gct gga gtc tac tat gtc ttc ttt caa cta gag 384Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu 90 95 100 ctg cgg cgc gtg gtg gcc ggc gag ggc tca ggc tcc gtt tca ctt gcg 432Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala 105 110 115 ctg cac ctg cag cca ctg cgc tct gct gct ggg gcc gcc gcc ctg gct 480Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Ala 120 125 130 ttg acc gtg gac ctg cca ccc gcc tcc tcc gag gct cgg aac tcg gcc 528Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala 135 140 145 ttc ggt ttc cag ggc cgc ttg ctg cac ctg agt gcc ggc cag cgc ctg 576Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu 150 155 160 165 ggc gtc cat ctt cac act gag gcc agg gca cgc cat gcc tgg cag ctt 624Gly Val His Leu His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu 170 175 180 acc cag ggc gcc aca gtc ttg gga ctc ttc cgg gtg acc ccc gaa atc 672Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val Thr Pro Glu Ile 185 190 195 cca gcc gga ctc cct tca ccg agg tcg gaa acg cgt ggt acc tct aga 720Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu Thr Arg Gly Thr Ser Arg 200 205 210 ccc aaa tct tgt gac aaa act cac aca tgc cca ccg tgc cca gca cct 768Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 215 220 225 gaa ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag 816Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 230 235 240 245 gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg 864Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 250 255 260 gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac 912Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 265 270 275 ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac 960Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 280 285 290 aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac 1008Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 295 300 305 tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc 1056Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 310 315 320 325 cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga 1104Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 330 335 340 gaa cca cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag 1152Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys 345 350 355 aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac 1200Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 360 365 370 atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag 1248Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 375 380 385 acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc 1296Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 390 395 400 405 aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca 1344Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 410 415 420 tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc 1392Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 425 430 435 ctc tcc ctg tct ccg ggt aaa tgatctaga 1422Leu Ser Leu Ser Pro Gly Lys 440 30469PRTHomo sapiens 30Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val Leu Ala -25 -20 -15 -10 Leu Leu Phe Pro Ser Met Ala Ser Met Leu Glu Ala Cys Pro Trp Ala -5 -1 1 5 Val Ser Gly Ala Arg Ala Ser Pro Gly Ser Ala Ala Ser Pro Arg Leu 10 15 20 Arg Glu Gly Pro Glu Leu Ser Pro Asp Asp Pro Ala Gly Leu Leu Asp 25 30 35 Leu Arg Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val Leu Leu 40 45 50 55 Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala Gly Val 60 65 70 Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu Leu Val 75 80 85 Val Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu Leu Arg 90 95 100 Arg Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala Leu His 105 110 115 Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Ala Leu Thr 120 125 130 135 Val Asp Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala Phe Gly 140 145 150 Phe Gln Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu Gly Val 155 160 165 His Leu His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu Thr Gln 170 175 180 Gly Ala Thr Val Leu Gly Leu Phe Arg Val Thr Pro Glu Ile Pro Ala 185 190 195 Gly Leu Pro Ser Pro Arg Ser Glu Thr Arg Gly Thr Ser Arg Pro Lys 200 205 210 215 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 220 225 230 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 235 240 245 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 250 255 260 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 265 270 275 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 280 285 290 295 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 300 305 310 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 315 320 325 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 330 335 340 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 345 350 355 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 360 365 370 375 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 380 385 390 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 395 400 405 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 410 415 420 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 425 430 435 Leu Ser Pro Gly Lys 440 312620DNAHomo sapiensCDS(36)..(632)sig_peptide(36)..(95)mat_peptide(96)..(632) 31ctgaacgcga ggactgttaa ctgtttctgg caaac atg aag tca ggc ctc tgg 53 Met Lys Ser Gly Leu Trp -20 -15 tat ttc ttt ctc ttc tgc ttg cgc att aaa gtt tta aca gga gaa atc 101Tyr Phe Phe Leu Phe Cys Leu Arg Ile Lys Val Leu Thr Gly Glu Ile -10 -5 -1 1 aat ggt tct gcc aat tat gag atg ttt ata ttt cac aac gga ggt gta 149Asn Gly Ser Ala Asn Tyr Glu Met Phe Ile Phe His Asn Gly Gly Val 5 10 15 caa att tta tgc aaa tat cct gac att gtc cag caa ttt aaa atg cag 197Gln Ile Leu Cys Lys Tyr Pro Asp Ile Val Gln Gln Phe Lys Met Gln 20 25 30 ttg ctg aaa ggg ggg caa ata ctc tgc gat ctc act aag aca aaa gga 245Leu Leu Lys Gly Gly Gln Ile Leu Cys Asp Leu Thr Lys Thr Lys Gly 35 40 45 50 agt gga aac aca gtg tcc att aag agt ctg aaa ttc tgc cat tct cag 293Ser Gly Asn Thr Val Ser Ile Lys Ser Leu Lys Phe Cys His Ser Gln 55 60 65 tta tcc aac aac agt gtc tct ttt ttt cta tac aac ttg gac cat tct 341Leu Ser Asn Asn Ser Val Ser Phe Phe Leu Tyr Asn Leu Asp His Ser 70 75 80 cat gcc aac tat tac ttc tgc aac cta tca att ttt gat cct cct cct 389His Ala Asn Tyr Tyr Phe Cys Asn Leu Ser Ile Phe Asp Pro Pro Pro 85 90 95 ttt aaa gta act ctt aca gga gga tat ttg cat att tat gaa tca caa 437Phe Lys Val Thr Leu Thr Gly Gly Tyr Leu His Ile Tyr Glu Ser Gln 100 105 110 ctt tgt tgc cag ctg aag ttc tgg tta ccc ata gga tgt gca gcc ttt 485Leu Cys Cys Gln Leu Lys Phe Trp Leu Pro Ile Gly Cys Ala Ala Phe 115 120 125 130 gtt gta gtc tgc att ttg gga tgc ata ctt att tgt tgg ctt aca aaa 533Val Val Val Cys Ile Leu Gly Cys Ile Leu Ile Cys Trp Leu Thr Lys 135 140 145 aag aag tat tca tcc agt gtg cac gac cct aac ggt gaa tac atg ttc 581Lys Lys Tyr Ser Ser Ser Val His Asp Pro Asn Gly Glu Tyr Met Phe 150 155 160 atg aga gca gtg aac aca gcc aaa aaa tct aga ctc aca gat gtg acc 629Met Arg Ala Val Asn Thr Ala Lys Lys Ser Arg Leu Thr Asp Val Thr 165 170 175 cta taatatggaa ctctggcacc caggcatgaa gcacgttggc cagttttcct 682Leu caacttgaag tgcaagattc tcttatttcc gggaccacgg agagtctgac ttaactacat

742acatcttctg ctggtgtttt gttcaatctg gaagaatgac tgtatcagtc aatggggatt 802ttaacagact gccttggtac tgccgagtcc tctcaaaaca aacaccctct tgcaaccagc 862tttggagaaa gcccagctcc tgtgtgctca ctgggagtgg aatccctgtc tccacatctg 922ctcctagcag tgcatcagcc agtaaaacaa acacatttac aagaaaaatg ttttaaagat 982gccaggggta ctgaatctgc aaagcaaatg agcagccaag gaccagcatc tgtccgcatt 1042tcactatcat actacctctt ctttctgtag ggatgagaat tcctctttta atcagtcaag 1102ggagatgctt caaagctgga gctattttat ttctgagatg ttgatgtgaa ctgtacatta 1162gtacatactc agtactctcc ttcaattgct gaaccccagt tgaccatttt accaagactt 1222tagatgcttt cttgtgccct caattttctt tttaaaaata cttctacatg actgcttgac 1282agcccaacag ccactctcaa tagagagcta tgtcttacat tctttcctct gctgctcaat 1342agttttatat atctatgcat acatatatac acacatatgt atataaaatt cataatgaat 1402atatttgcct atattctccc tacaagaata tttttgctcc agaaagacat gttcttttct 1462caaattcagt taaaatggtt tactttgttc aagttagtgg taggaaacat tgcccggaat 1522tgaaagcaaa tttattttat tatcctattt tctaccatta tctatgtttt catggtgcta 1582ttaattacaa gtttagttct ttttgtagat catattaaaa ttgcaaacaa aatcatcttt 1642aatgggccag cattctcatg gggtagagca gaatattcat ttagcctgaa agctgcagtt 1702actataggtt gctgtcagac tatacccatg gtgcctctgg gcttgacagg tcaaaatggt 1762ccccatcagc ctggagcagc cctccagacc tgggtggaat tccagggttg agagactccc 1822ctgagccaga ggccactagg tattcttgct cccagaggct gaagtcaccc tgggaatcac 1882agtggtctac ctgcattcat aattccagga tctgtgaaga gcacatatgt gtcagggcac 1942aattccctct cataaaaacc acacagcctg gaaattggcc ctggcccttc aagatagcct 2002tctttagaat atgatttggc tagaaagatt cttaaatatg tggaatatga ttattcttag 2062ctggaatatt ttctctactt cctgtctgca tgcccaaggc ttctgaagca gccaatgtcg 2122atgcaacaac atttgtaact ttaggtaaac tgggattatg ttgtagttta acattttgta 2182actgtgtgct tatagtttac aagtgagacc cgatatgtca ttatgcatac ttatattatc 2242ttaagcatgt gtaatgctgg atgtgtacag tacagtactg aacttgtaat ttgaatctag 2302tatggtgttc tgttttcagc tgacttggac aacctgactg gctttgcaca ggtgttccct 2362gagttgtttg caggtttctg tgtgtggggt ggggtatggg gaggagaacc ttcatggtgg 2422cccacctggc ctggttgtcc aagctgtgcc tcgacacatc ctcatcccca gcatgggaca 2482cctcaagatg aataataatt cacaaaattt ctgtgaaatc aaatccagtt ttaagaggag 2542ccacttatca aagagatttt aacagtagta agaaggcaaa gaataaacat ttgatattca 2602gcaactgaaa aaaaaaaa 262032199PRTHomo sapiens 32Met Lys Ser Gly Leu Trp Tyr Phe Phe Leu Phe Cys Leu Arg Ile Lys -20 -15 -10 -5 Val Leu Thr Gly Glu Ile Asn Gly Ser Ala Asn Tyr Glu Met Phe Ile -1 1 5 10 Phe His Asn Gly Gly Val Gln Ile Leu Cys Lys Tyr Pro Asp Ile Val 15 20 25 Gln Gln Phe Lys Met Gln Leu Leu Lys Gly Gly Gln Ile Leu Cys Asp 30 35 40 Leu Thr Lys Thr Lys Gly Ser Gly Asn Thr Val Ser Ile Lys Ser Leu 45 50 55 60 Lys Phe Cys His Ser Gln Leu Ser Asn Asn Ser Val Ser Phe Phe Leu 65 70 75 Tyr Asn Leu Asp His Ser His Ala Asn Tyr Tyr Phe Cys Asn Leu Ser 80 85 90 Ile Phe Asp Pro Pro Pro Phe Lys Val Thr Leu Thr Gly Gly Tyr Leu 95 100 105 His Ile Tyr Glu Ser Gln Leu Cys Cys Gln Leu Lys Phe Trp Leu Pro 110 115 120 Ile Gly Cys Ala Ala Phe Val Val Val Cys Ile Leu Gly Cys Ile Leu 125 130 135 140 Ile Cys Trp Leu Thr Lys Lys Lys Tyr Ser Ser Ser Val His Asp Pro 145 150 155 Asn Gly Glu Tyr Met Phe Met Arg Ala Val Asn Thr Ala Lys Lys Ser 160 165 170 Arg Leu Thr Asp Val Thr Leu 175 331806DNAHomo sapiensCDS(7)..(1797)sig_peptide(7)..(81)mat_peptide(82)..(1797) 33gctagc atg ggg gta ctg ctc aca cag agg acg ctg ctc agt ctg gtc 48 Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val -25 -20 -15 ctt gca ctc ctg ttt cca agc atg gcg agc atg ctt cat aga agg ttg 96Leu Ala Leu Leu Phe Pro Ser Met Ala Ser Met Leu His Arg Arg Leu -10 -5 -1 1 5 gac aag ata gaa gat gaa agg aat ctt cat gaa gat ttt gta ttc atg 144Asp Lys Ile Glu Asp Glu Arg Asn Leu His Glu Asp Phe Val Phe Met 10 15 20 aaa acg ata cag aga tgc aac aca gga gaa aga tcc tta tcc tta ctg 192Lys Thr Ile Gln Arg Cys Asn Thr Gly Glu Arg Ser Leu Ser Leu Leu 25 30 35 aac tgt gag gag att aaa agc cag ttt gaa ggc ttt gtg aag gat ata 240Asn Cys Glu Glu Ile Lys Ser Gln Phe Glu Gly Phe Val Lys Asp Ile 40 45 50 atg tta aac aaa gag gag acg aag aaa gaa aac agc ttt gaa atg caa 288Met Leu Asn Lys Glu Glu Thr Lys Lys Glu Asn Ser Phe Glu Met Gln 55 60 65 aaa ggt gat cag aat cct caa att gcg gca cat gtc ata agt gag gcc 336Lys Gly Asp Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser Glu Ala 70 75 80 85 agc agt aaa aca aca tct gtg tta cag tgg gct gaa aaa gga tac tac 384Ser Ser Lys Thr Thr Ser Val Leu Gln Trp Ala Glu Lys Gly Tyr Tyr 90 95 100 acc atg agc aac aac ttg gta acc ctg gaa aat ggg aaa cag ctg acc 432Thr Met Ser Asn Asn Leu Val Thr Leu Glu Asn Gly Lys Gln Leu Thr 105 110 115 gtt aaa aga caa gga ctc tat tat atc tat gcc caa gtc acc ttc tgt 480Val Lys Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln Val Thr Phe Cys 120 125 130 tcc aat cgg gaa gct tcg agt caa gct cca ttt ata gcc agc ctc tgc 528Ser Asn Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile Ala Ser Leu Cys 135 140 145 cta aag tcc ccc ggt aga ttc gag aga atc tta ctc aga gct gca aat 576Leu Lys Ser Pro Gly Arg Phe Glu Arg Ile Leu Leu Arg Ala Ala Asn 150 155 160 165 acc cac agt tcc gcc aaa cct tgc ggg caa caa tcc att cac ttg gga 624Thr His Ser Ser Ala Lys Pro Cys Gly Gln Gln Ser Ile His Leu Gly 170 175 180 gga gta ttt gaa ttg caa cca ggt gct tcg gtg ttt gtc aat gtg act 672Gly Val Phe Glu Leu Gln Pro Gly Ala Ser Val Phe Val Asn Val Thr 185 190 195 gat cca agc caa gtg agc cat ggc act ggc ttc acg tcc ttt ggc tta 720Asp Pro Ser Gln Val Ser His Gly Thr Gly Phe Thr Ser Phe Gly Leu 200 205 210 ctc aaa ctc gag gga gaa atc aat ggt tct gcc aat tat gag atg ttt 768Leu Lys Leu Glu Gly Glu Ile Asn Gly Ser Ala Asn Tyr Glu Met Phe 215 220 225 ata ttt cac aac gga ggt gta caa att tta tgc aaa tat cct gac att 816Ile Phe His Asn Gly Gly Val Gln Ile Leu Cys Lys Tyr Pro Asp Ile 230 235 240 245 gtc cag caa ttt aaa atg cag ttg ctg aaa ggg ggg caa ata ctc tgc 864Val Gln Gln Phe Lys Met Gln Leu Leu Lys Gly Gly Gln Ile Leu Cys 250 255 260 gat ctc act aag aca aaa gga agt gga aac aca gtg tcc att aag agt 912Asp Leu Thr Lys Thr Lys Gly Ser Gly Asn Thr Val Ser Ile Lys Ser 265 270 275 ctg aaa ttc tgc cat tct cag tta tcc aac aac agt gtc tcc ttt ttt 960Leu Lys Phe Cys His Ser Gln Leu Ser Asn Asn Ser Val Ser Phe Phe 280 285 290 cta tac aac ttg gac cat tct cat gcc aac tat tac ttc tgt aac cta 1008Leu Tyr Asn Leu Asp His Ser His Ala Asn Tyr Tyr Phe Cys Asn Leu 295 300 305 tca att ttt gat cct cct cct ttt aaa gta act ctt aca gga gga tat 1056Ser Ile Phe Asp Pro Pro Pro Phe Lys Val Thr Leu Thr Gly Gly Tyr 310 315 320 325 ttg cat att tat gaa tca caa ctt tgt tgc cag ctg aag ttc ctc gag 1104Leu His Ile Tyr Glu Ser Gln Leu Cys Cys Gln Leu Lys Phe Leu Glu 330 335 340 ccc aaa tct tgt gac aaa act cac aca tgc cca ccg tgc cca gca cct 1152Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 345 350 355 gaa ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag 1200Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 360 365 370 gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg 1248Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 375 380 385 gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac 1296Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 390 395 400 405 ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac 1344Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 410 415 420 aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac 1392Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 425 430 435 tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc 1440Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 440 445 450 cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga 1488Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 455 460 465 gaa cca cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag 1536Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys 470 475 480 485 aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac 1584Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 490 495 500 atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag 1632Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 505 510 515 acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc 1680Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 520 525 530 aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca 1728Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 535 540 545 tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc 1776Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 550 555 560 565 ctc tcc ctg tct ccg ggt aaa tgatctaga 1806Leu Ser Leu Ser Pro Gly Lys 570 34597PRTHomo sapiens 34Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val Leu Ala -25 -20 -15 -10 Leu Leu Phe Pro Ser Met Ala Ser Met Leu His Arg Arg Leu Asp Lys -5 -1 1 5 Ile Glu Asp Glu Arg Asn Leu His Glu Asp Phe Val Phe Met Lys Thr 10 15 20 Ile Gln Arg Cys Asn Thr Gly Glu Arg Ser Leu Ser Leu Leu Asn Cys 25 30 35 Glu Glu Ile Lys Ser Gln Phe Glu Gly Phe Val Lys Asp Ile Met Leu 40 45 50 55 Asn Lys Glu Glu Thr Lys Lys Glu Asn Ser Phe Glu Met Gln Lys Gly 60 65 70 Asp Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser Glu Ala Ser Ser 75 80 85 Lys Thr Thr Ser Val Leu Gln Trp Ala Glu Lys Gly Tyr Tyr Thr Met 90 95 100 Ser Asn Asn Leu Val Thr Leu Glu Asn Gly Lys Gln Leu Thr Val Lys 105 110 115 Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln Val Thr Phe Cys Ser Asn 120 125 130 135 Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile Ala Ser Leu Cys Leu Lys 140 145 150 Ser Pro Gly Arg Phe Glu Arg Ile Leu Leu Arg Ala Ala Asn Thr His 155 160 165 Ser Ser Ala Lys Pro Cys Gly Gln Gln Ser Ile His Leu Gly Gly Val 170 175 180 Phe Glu Leu Gln Pro Gly Ala Ser Val Phe Val Asn Val Thr Asp Pro 185 190 195 Ser Gln Val Ser His Gly Thr Gly Phe Thr Ser Phe Gly Leu Leu Lys 200 205 210 215 Leu Glu Gly Glu Ile Asn Gly Ser Ala Asn Tyr Glu Met Phe Ile Phe 220 225 230 His Asn Gly Gly Val Gln Ile Leu Cys Lys Tyr Pro Asp Ile Val Gln 235 240 245 Gln Phe Lys Met Gln Leu Leu Lys Gly Gly Gln Ile Leu Cys Asp Leu 250 255 260 Thr Lys Thr Lys Gly Ser Gly Asn Thr Val Ser Ile Lys Ser Leu Lys 265 270 275 Phe Cys His Ser Gln Leu Ser Asn Asn Ser Val Ser Phe Phe Leu Tyr 280 285 290 295 Asn Leu Asp His Ser His Ala Asn Tyr Tyr Phe Cys Asn Leu Ser Ile 300 305 310 Phe Asp Pro Pro Pro Phe Lys Val Thr Leu Thr Gly Gly Tyr Leu His 315 320 325 Ile Tyr Glu Ser Gln Leu Cys Cys Gln Leu Lys Phe Leu Glu Pro Lys 330 335 340 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 345 350 355 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 360 365 370 375 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 380 385 390 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 395 400 405 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 410 415 420 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 425 430 435 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 440 445 450 455 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 460 465 470 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 475 480 485 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 490 495 500 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 505 510 515 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 520 525 530 535 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 540 545 550 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 555 560 565 Leu Ser Pro Gly Lys 570 351052DNAHomo sapiensCDS(170)..(892)sig_peptide(170)..(220)mat_peptide(221)..(892) 35agagagcgct gggagccgga ggggagcgca gcgagttttg gccagtggtc gtgcagtcca 60aggggctgga tggcatgctg gacccaagct cagctcagcg tccggaccca ataacagttt 120taccaaggga gcagctttct atcctggcca cactgaggtg catagcgta atg tcc atg 178 Met Ser Met -15 ttg ttc tac act ctg atc aca gct ttt ctg atc ggc ata cag gcg gaa 226Leu Phe Tyr Thr Leu Ile Thr Ala Phe Leu Ile Gly Ile Gln Ala Glu -10 -5 -1 1 cca cac tca gag agc aat gtc cct gca gga cac acc atc ccc caa gcc 274Pro His Ser Glu Ser Asn Val Pro Ala Gly His Thr Ile Pro Gln Ala 5 10 15 cac tgg act aaa ctt cag cat tcc ctt gac act gcc ctt cgc aga gcc 322His Trp Thr Lys Leu Gln His Ser Leu Asp Thr Ala Leu Arg Arg Ala 20 25 30 cgc agc gcc ccg gca gcg gcg ata gct gca cgc gtg gcg ggg cag acc

370Arg Ser Ala Pro Ala Ala Ala Ile Ala Ala Arg Val Ala Gly Gln Thr 35 40 45 50 cgc aac att act gtg gac ccc agg ctg ttt aaa aag cgg cga ctc cgt 418Arg Asn Ile Thr Val Asp Pro Arg Leu Phe Lys Lys Arg Arg Leu Arg 55 60 65 tca ccc cgt gtg ctg ttt agc acc cag cct ccc cgt gaa gct gca gac 466Ser Pro Arg Val Leu Phe Ser Thr Gln Pro Pro Arg Glu Ala Ala Asp 70 75 80 act cag gat ctg gac ttc gag gtc ggt ggt gct gcc ccc ttc aac agg 514Thr Gln Asp Leu Asp Phe Glu Val Gly Gly Ala Ala Pro Phe Asn Arg 85 90 95 act cac agg agc aag cgg tca tca tcc cat ccc atc ttc cac agg ggc 562Thr His Arg Ser Lys Arg Ser Ser Ser His Pro Ile Phe His Arg Gly 100 105 110 gaa ttc tcg gtg tgt gac agt gtc agc gtg tgg gtt ggg gat aag acc 610Glu Phe Ser Val Cys Asp Ser Val Ser Val Trp Val Gly Asp Lys Thr 115 120 125 130 acc gcc aca gac atc aag ggc aag gag gtg atg gtg ttg gga gag gtg 658Thr Ala Thr Asp Ile Lys Gly Lys Glu Val Met Val Leu Gly Glu Val 135 140 145 aac att aac aac agt gta ttc aaa cag tac ttt ttt gag acc aag tgc 706Asn Ile Asn Asn Ser Val Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys 150 155 160 cgg gac cca aat ccc gtt gac agc ggg tgc cgg ggc att gac tca aag 754Arg Asp Pro Asn Pro Val Asp Ser Gly Cys Arg Gly Ile Asp Ser Lys 165 170 175 cac tgg aac tca tat tgt acc acg act cac acc ttt gtc aag gcg ctg 802His Trp Asn Ser Tyr Cys Thr Thr Thr His Thr Phe Val Lys Ala Leu 180 185 190 acc atg gat ggc aag cag gct gcc tgg cgg ttt atc cgg ata gat acg 850Thr Met Asp Gly Lys Gln Ala Ala Trp Arg Phe Ile Arg Ile Asp Thr 195 200 205 210 gcc tgt gtg tgt gtg ctc agc agg aag gct gtg aga aga gcc 892Ala Cys Val Cys Val Leu Ser Arg Lys Ala Val Arg Arg Ala 215 220 tgacctgccg acacgctccc tccccctgcc ccttctacac tctcctgggc ccctccctac 952ctcaacctgt aaattatttt aaattataag gactgcatgg taatttatag tttatacagt 1012tttaaagaat cattatttat taaatttttg gaagcataaa 105236241PRTHomo sapiens 36Met Ser Met Leu Phe Tyr Thr Leu Ile Thr Ala Phe Leu Ile Gly Ile -15 -10 -5 Gln Ala Glu Pro His Ser Glu Ser Asn Val Pro Ala Gly His Thr Ile -1 1 5 10 15 Pro Gln Ala His Trp Thr Lys Leu Gln His Ser Leu Asp Thr Ala Leu 20 25 30 Arg Arg Ala Arg Ser Ala Pro Ala Ala Ala Ile Ala Ala Arg Val Ala 35 40 45 Gly Gln Thr Arg Asn Ile Thr Val Asp Pro Arg Leu Phe Lys Lys Arg 50 55 60 Arg Leu Arg Ser Pro Arg Val Leu Phe Ser Thr Gln Pro Pro Arg Glu 65 70 75 Ala Ala Asp Thr Gln Asp Leu Asp Phe Glu Val Gly Gly Ala Ala Pro 80 85 90 95 Phe Asn Arg Thr His Arg Ser Lys Arg Ser Ser Ser His Pro Ile Phe 100 105 110 His Arg Gly Glu Phe Ser Val Cys Asp Ser Val Ser Val Trp Val Gly 115 120 125 Asp Lys Thr Thr Ala Thr Asp Ile Lys Gly Lys Glu Val Met Val Leu 130 135 140 Gly Glu Val Asn Ile Asn Asn Ser Val Phe Lys Gln Tyr Phe Phe Glu 145 150 155 Thr Lys Cys Arg Asp Pro Asn Pro Val Asp Ser Gly Cys Arg Gly Ile 160 165 170 175 Asp Ser Lys His Trp Asn Ser Tyr Cys Thr Thr Thr His Thr Phe Val 180 185 190 Lys Ala Leu Thr Met Asp Gly Lys Gln Ala Ala Trp Arg Phe Ile Arg 195 200 205 Ile Asp Thr Ala Cys Val Cys Val Leu Ser Arg Lys Ala Val Arg Arg 210 215 220 Ala 371697DNAHomo sapiensCDS(7)..(1686)sig_peptide(7)..(81)mat_peptide(82)..(1686) 37gctagc atg ggg gta ctg ctc aca cag agg acg ctg ctc agt ctg gtc 48 Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val -25 -20 -15 ctt gca ctc ctg ttt cca agc atg gcg agc atg ctc gag tca tca tcc 96Leu Ala Leu Leu Phe Pro Ser Met Ala Ser Met Leu Glu Ser Ser Ser -10 -5 -1 1 5 cat ccc atc ttc cac agg ggc gaa ttc tcg gtg tgt gac agt gtc agc 144His Pro Ile Phe His Arg Gly Glu Phe Ser Val Cys Asp Ser Val Ser 10 15 20 gtg tgg gtt ggg gat aag acc acc gcc aca gac atc aag ggc aag gag 192Val Trp Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Lys Gly Lys Glu 25 30 35 gtg atg gtg ttg gga gag gtg agc att aac aac agt gta ttc aaa cag 240Val Met Val Leu Gly Glu Val Ser Ile Asn Asn Ser Val Phe Lys Gln 40 45 50 tac ttt ttt gag acc aag tgc cgg gac cca aat ccc gtt gac agc ggg 288Tyr Phe Phe Glu Thr Lys Cys Arg Asp Pro Asn Pro Val Asp Ser Gly 55 60 65 tgc cgg ggc att gac tca aag cac tgg aac tca tat tgt acc acg act 336Cys Arg Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys Thr Thr Thr 70 75 80 85 cac acc ttt gtc aag gcg ctg acc atg gat ggc aag cag gct gcc tgg 384His Thr Phe Val Lys Ala Leu Thr Met Asp Gly Lys Gln Ala Ala Trp 90 95 100 cgg ttt atc cgg ata gat acg gcc tgt atg tgt gtg ctc agc agg aag 432Arg Phe Ile Arg Ile Asp Thr Ala Cys Met Cys Val Leu Ser Arg Lys 105 110 115 gct gtg aga aga gcc ctc gag cag ctc ttc cac cta cag aag gag ctg 480Ala Val Arg Arg Ala Leu Glu Gln Leu Phe His Leu Gln Lys Glu Leu 120 125 130 gca gaa ctc cga gag tct acc agc cag atg cac aca gca tca tct ttg 528Ala Glu Leu Arg Glu Ser Thr Ser Gln Met His Thr Ala Ser Ser Leu 135 140 145 gag aag caa ata ggc cac ccc agt cca ccc cct gaa aaa aag gag ctg 576Glu Lys Gln Ile Gly His Pro Ser Pro Pro Pro Glu Lys Lys Glu Leu 150 155 160 165 agg aaa gtg gcc cat tta aca ggc aag tcc aac tca agg tcc atg cct 624Arg Lys Val Ala His Leu Thr Gly Lys Ser Asn Ser Arg Ser Met Pro 170 175 180 ctg gaa tgg gaa gac acc tat gga att gtc ctg ctt tct gga gtg aag 672Leu Glu Trp Glu Asp Thr Tyr Gly Ile Val Leu Leu Ser Gly Val Lys 185 190 195 tat aag aag ggt ggc ctt gtg atc aat gaa act ggg ctg tac ttt gta 720Tyr Lys Lys Gly Gly Leu Val Ile Asn Glu Thr Gly Leu Tyr Phe Val 200 205 210 tat tcc aaa gta tac ttc cgg ggt caa tct tgc aac aac ctg ccc ctg 768Tyr Ser Lys Val Tyr Phe Arg Gly Gln Ser Cys Asn Asn Leu Pro Leu 215 220 225 agc cac aag gtc tac atg agg aac tct aag tat ccc cag gat ctg gtg 816Ser His Lys Val Tyr Met Arg Asn Ser Lys Tyr Pro Gln Asp Leu Val 230 235 240 245 atg atg gag ggg aag atg atg agc tac tgc act act ggg cag atg tgg 864Met Met Glu Gly Lys Met Met Ser Tyr Cys Thr Thr Gly Gln Met Trp 250 255 260 gcc cgc agc agc tac ctg ggg gca gtg ttc aat ctt acc agt gct gat 912Ala Arg Ser Ser Tyr Leu Gly Ala Val Phe Asn Leu Thr Ser Ala Asp 265 270 275 cat tta tat gtc aac gta tct gag ctc tct ctg gtc aat ttt gag gaa 960His Leu Tyr Val Asn Val Ser Glu Leu Ser Leu Val Asn Phe Glu Glu 280 285 290 tct cag acg ttt ttc ggc tta tat aag tct gag ccc aaa tct tgt gac 1008Ser Gln Thr Phe Phe Gly Leu Tyr Lys Ser Glu Pro Lys Ser Cys Asp 295 300 305 aaa act cac aca tgc cca ccg tgc cca gca cct gaa ctc ctg ggg gga 1056Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 310 315 320 325 ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc 1104Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 330 335 340 tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa 1152Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 345 350 355 gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat 1200Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 360 365 370 aat gcc aag aca aag ccg cgg gag gag cag tac aac agc acg tac cgt 1248Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 375 380 385 gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag 1296Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 390 395 400 405 gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag 1344Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 410 415 420 aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac 1392Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 425 430 435 acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag gtc agc ctg 1440Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu 440 445 450 acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg 1488Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 455 460 465 gag agc aat ggg cag ccg gag aac aac tac aag acc acg cct ccc gtg 1536Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 470 475 480 485 ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc acc gtg gac 1584Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 490 495 500 aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat 1632Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 505 510 515 gag gct ctg cac aac cac tac acg cag aag agc ctc tcc ctg tct ccg 1680Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 520 525 530 ggt aaa tgagcggccg c 1697Gly Lys 535 38560PRTHomo sapiens 38Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val Leu Ala -25 -20 -15 -10 Leu Leu Phe Pro Ser Met Ala Ser Met Leu Glu Ser Ser Ser His Pro -5 -1 1 5 Ile Phe His Arg Gly Glu Phe Ser Val Cys Asp Ser Val Ser Val Trp 10 15 20 Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Lys Gly Lys Glu Val Met 25 30 35 Val Leu Gly Glu Val Ser Ile Asn Asn Ser Val Phe Lys Gln Tyr Phe 40 45 50 55 Phe Glu Thr Lys Cys Arg Asp Pro Asn Pro Val Asp Ser Gly Cys Arg 60 65 70 Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys Thr Thr Thr His Thr 75 80 85 Phe Val Lys Ala Leu Thr Met Asp Gly Lys Gln Ala Ala Trp Arg Phe 90 95 100 Ile Arg Ile Asp Thr Ala Cys Met Cys Val Leu Ser Arg Lys Ala Val 105 110 115 Arg Arg Ala Leu Glu Gln Leu Phe His Leu Gln Lys Glu Leu Ala Glu 120 125 130 135 Leu Arg Glu Ser Thr Ser Gln Met His Thr Ala Ser Ser Leu Glu Lys 140 145 150 Gln Ile Gly His Pro Ser Pro Pro Pro Glu Lys Lys Glu Leu Arg Lys 155 160 165 Val Ala His Leu Thr Gly Lys Ser Asn Ser Arg Ser Met Pro Leu Glu 170 175 180 Trp Glu Asp Thr Tyr Gly Ile Val Leu Leu Ser Gly Val Lys Tyr Lys 185 190 195 Lys Gly Gly Leu Val Ile Asn Glu Thr Gly Leu Tyr Phe Val Tyr Ser 200 205 210 215 Lys Val Tyr Phe Arg Gly Gln Ser Cys Asn Asn Leu Pro Leu Ser His 220 225 230 Lys Val Tyr Met Arg Asn Ser Lys Tyr Pro Gln Asp Leu Val Met Met 235 240 245 Glu Gly Lys Met Met Ser Tyr Cys Thr Thr Gly Gln Met Trp Ala Arg 250 255 260 Ser Ser Tyr Leu Gly Ala Val Phe Asn Leu Thr Ser Ala Asp His Leu 265 270 275 Tyr Val Asn Val Ser Glu Leu Ser Leu Val Asn Phe Glu Glu Ser Gln 280 285 290 295 Thr Phe Phe Gly Leu Tyr Lys Ser Glu Pro Lys Ser Cys Asp Lys Thr 300 305 310 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 315 320 325 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 330 335 340 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 345 350 355 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 360 365 370 375 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 380 385 390 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 395 400 405 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 410 415 420 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 425 430 435 Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys 440 445 450 455 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 460 465 470 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 475 480 485 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 490 495 500 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 505 510 515 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 520 525 530 535 39822DNAHomo sapiensCDS(56)..(514) 39agttccctat cactctcttt aatcactact cacagtaacc tcaactcctg ccaca atg 58 Met 1 tac agg atg caa ctc ctg tct tgc att gca cta agt ctt gca ctt gtc 106Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val 5 10 15 aca aac agt gca cct act tca agt tct aca aag aaa aca cag cta caa 154Thr Asn Ser Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln 20 25 30 ctg gag cat tta ctg ctg gat tta cag atg att ttg aat gga att aat 202Leu Glu His Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn 35 40 45 aat tac aag aat ccc aaa ctc acc agg atg ctc aca ttt aag ttt tac 250Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr 50 55 60 65 atg ccc aag aag gcc aca gaa ctg aaa cat ctt cag tgt cta gaa gaa 298Met Pro Lys Lys Ala Thr Glu Leu Lys His

Leu Gln Cys Leu Glu Glu 70 75 80 gaa ctc aaa cct ctg gag gaa gtg cta aat tta gct caa agc aaa aac 346Glu Leu Lys Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn 85 90 95 ttt cac tta aga ccc agg gac tta atc agc aat atc aac gta ata gtt 394Phe His Leu Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val 100 105 110 ctg gaa cta aag gga tct gaa aca aca ttc atg tgt gaa tat gct gat 442Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp 115 120 125 gag aca gca acc att gta gaa ttt ctg aac aga tgg att acc ttt tgt 490Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys 130 135 140 145 caa agc atc atc tca aca ctg act tgataattaa gtgcttccca cttaaaacat 544Gln Ser Ile Ile Ser Thr Leu Thr 150 atcaggcctt ctatttattt aaatatttaa attttatatt tattgttgaa tgtatggttt 604gctacctatt gtaactatta ttcttaatct taaaactata aatatggatc ttttatgatt 664ctttttgtaa gccctagggg ctctaaaatg gtttcactta tttatcccaa aatatttatt 724attatgttga atgttaaata tagtatctat gtagattggt tagtaaaact atttaataaa 784tttgataaat ataaaaaaaa aaaaaaaaaa aaaaaaaa 82240153PRTHomo sapiens 40Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu 1 5 10 15 Val Thr Asn Ser Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu 20 25 30 Gln Leu Glu His Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile 35 40 45 Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe 50 55 60 Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu 65 70 75 80 Glu Glu Leu Lys Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys 85 90 95 Asn Phe His Leu Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile 100 105 110 Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala 115 120 125 Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe 130 135 140 Cys Gln Ser Ile Ile Ser Thr Leu Thr 145 150 411743DNAHomo sapiensCDS(7)..(1734)sig_peptide(7)..(81)mat_peptide(82)..(1734) 41gctagc atg ggg gta ctg ctc aca cag agg acg ctg ctc agt ctg gtc 48 Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val -25 -20 -15 ctt gca ctc ctg ttt cca agc atg gcg agc atg gaa ttc gca cct act 96Leu Ala Leu Leu Phe Pro Ser Met Ala Ser Met Glu Phe Ala Pro Thr -10 -5 -1 1 5 tca agt tct aca aag aaa aca cag cta caa ctg gag cat tta ctg ctg 144Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His Leu Leu Leu 10 15 20 gat tta cag atg att ttg aat gga att aat aat tac aag aat ccc aaa 192Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys 25 30 35 ctc acc agg atg ctc aca ttt aag ttt tac atg ccc aag aag gcc aca 240Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys Lys Ala Thr 40 45 50 gaa ctg aaa cat ctt cag tgt cta gaa gaa gaa gaa ctc aaa cct ctg 288Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Glu Leu Lys Pro Leu 55 60 65 gag gaa gtg cta aat tta gct caa agc aaa aac ttt cac tta aga ccc 336Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu Arg Pro 70 75 80 85 agg gac tta atc agc aat atc aac gta ata gtt ctg gaa cta aag gga 384Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu Lys Gly 90 95 100 tct gaa aca aca ttc atg tgt gaa tat gct gat gag aca gca acc att 432Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala Thr Ile 105 110 115 gta gaa ttt ctg aac aga tgg att acc ttt tgt caa agc atc atc tca 480Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile Ile Ser 120 125 130 aca ctg act acg cgt ggt acc cag ctc ttc cac cta cag aag gag ctg 528Thr Leu Thr Thr Arg Gly Thr Gln Leu Phe His Leu Gln Lys Glu Leu 135 140 145 gca gaa ctc cga gag tct acc agc cag atg cac aca gca tca tct ttg 576Ala Glu Leu Arg Glu Ser Thr Ser Gln Met His Thr Ala Ser Ser Leu 150 155 160 165 gag aag caa ata ggc cac ccc agt cca ccc cct gaa aaa aag gag ctg 624Glu Lys Gln Ile Gly His Pro Ser Pro Pro Pro Glu Lys Lys Glu Leu 170 175 180 agg aaa gtg gcc cat tta aca ggc aag tcc aac tca agg tcc atg cct 672Arg Lys Val Ala His Leu Thr Gly Lys Ser Asn Ser Arg Ser Met Pro 185 190 195 ctg gaa tgg gaa gac acc tat gga att gtc ctg ctt tct gga gtg aag 720Leu Glu Trp Glu Asp Thr Tyr Gly Ile Val Leu Leu Ser Gly Val Lys 200 205 210 tat aag aag ggt ggc ctt gtg atc aat gaa act ggg ctg tac ttt gta 768Tyr Lys Lys Gly Gly Leu Val Ile Asn Glu Thr Gly Leu Tyr Phe Val 215 220 225 tat tcc aaa gta tac ttc cgg ggt caa tct tgc aac aac ctg ccc ctg 816Tyr Ser Lys Val Tyr Phe Arg Gly Gln Ser Cys Asn Asn Leu Pro Leu 230 235 240 245 agc cac aag gtc tac atg agg aac tct aag tat ccc cag gat ctg gtg 864Ser His Lys Val Tyr Met Arg Asn Ser Lys Tyr Pro Gln Asp Leu Val 250 255 260 atg atg gag ggg aag atg atg agc tac tgc act act ggg cag atg tgg 912Met Met Glu Gly Lys Met Met Ser Tyr Cys Thr Thr Gly Gln Met Trp 265 270 275 gcc cgc agc agc tac ctg ggg gca gtg ttc aat ctt acc agt gct gat 960Ala Arg Ser Ser Tyr Leu Gly Ala Val Phe Asn Leu Thr Ser Ala Asp 280 285 290 cat tta tat gtc aac gta tct gag ctc tct ctg gtc aat ttt gag gaa 1008His Leu Tyr Val Asn Val Ser Glu Leu Ser Leu Val Asn Phe Glu Glu 295 300 305 tct cag acg ttt ttc ggc tta tat aag ctc gag ccc aaa tct tgt gac 1056Ser Gln Thr Phe Phe Gly Leu Tyr Lys Leu Glu Pro Lys Ser Cys Asp 310 315 320 325 aaa act cac aca tgc cca ccg tgc cca gca cct gaa ctc ctg ggg gga 1104Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 330 335 340 ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc 1152Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 345 350 355 tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa 1200Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 360 365 370 gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat 1248Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 375 380 385 aat gcc aag aca aag ccg cgg gag gag cag tac aac agc acg tac cgt 1296Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 390 395 400 405 gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag 1344Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 410 415 420 gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag 1392Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 425 430 435 aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac 1440Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 440 445 450 acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag gtc agc ctg 1488Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu 455 460 465 acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg 1536Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 470 475 480 485 gag agc aat ggg cag ccg gag aac aac tac aag acc acg cct ccc gtg 1584Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 490 495 500 ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc acc gtg gac 1632Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 505 510 515 aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat 1680Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 520 525 530 gag gct ctg cac aac cac tac acg cag aag agc ctc tcc ctg tct ccg 1728Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 535 540 545 ggt aaa tgatctaga 1743Gly Lys 550 42576PRTHomo sapiens 42Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val Leu Ala -25 -20 -15 -10 Leu Leu Phe Pro Ser Met Ala Ser Met Glu Phe Ala Pro Thr Ser Ser -5 -1 1 5 Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His Leu Leu Leu Asp Leu 10 15 20 Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys Leu Thr 25 30 35 Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys Lys Ala Thr Glu Leu 40 45 50 55 Lys His Leu Gln Cys Leu Glu Glu Glu Glu Leu Lys Pro Leu Glu Glu 60 65 70 Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu Arg Pro Arg Asp 75 80 85 Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu Lys Gly Ser Glu 90 95 100 Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala Thr Ile Val Glu 105 110 115 Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile Ile Ser Thr Leu 120 125 130 135 Thr Thr Arg Gly Thr Gln Leu Phe His Leu Gln Lys Glu Leu Ala Glu 140 145 150 Leu Arg Glu Ser Thr Ser Gln Met His Thr Ala Ser Ser Leu Glu Lys 155 160 165 Gln Ile Gly His Pro Ser Pro Pro Pro Glu Lys Lys Glu Leu Arg Lys 170 175 180 Val Ala His Leu Thr Gly Lys Ser Asn Ser Arg Ser Met Pro Leu Glu 185 190 195 Trp Glu Asp Thr Tyr Gly Ile Val Leu Leu Ser Gly Val Lys Tyr Lys 200 205 210 215 Lys Gly Gly Leu Val Ile Asn Glu Thr Gly Leu Tyr Phe Val Tyr Ser 220 225 230 Lys Val Tyr Phe Arg Gly Gln Ser Cys Asn Asn Leu Pro Leu Ser His 235 240 245 Lys Val Tyr Met Arg Asn Ser Lys Tyr Pro Gln Asp Leu Val Met Met 250 255 260 Glu Gly Lys Met Met Ser Tyr Cys Thr Thr Gly Gln Met Trp Ala Arg 265 270 275 Ser Ser Tyr Leu Gly Ala Val Phe Asn Leu Thr Ser Ala Asp His Leu 280 285 290 295 Tyr Val Asn Val Ser Glu Leu Ser Leu Val Asn Phe Glu Glu Ser Gln 300 305 310 Thr Phe Phe Gly Leu Tyr Lys Leu Glu Pro Lys Ser Cys Asp Lys Thr 315 320 325 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 330 335 340 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 345 350 355 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 360 365 370 375 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 380 385 390 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 395 400 405 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 410 415 420 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 425 430 435 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 440 445 450 455 Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys 460 465 470 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 475 480 485 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 490 495 500 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 505 510 515 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 520 525 530 535 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 540 545 550 4324DNAHomo sapiens 43cttcatagaa ggttggacaa gata 244424DNAHomo sapiens 44gagtttgagt aagccaaagg acgt 244524DNAHomo sapiens 45atgggggtac tgctcacaca gagg 244624DNAHomo sapiens 46catgctcgcc atgcttggaa acag 244744DNAHomo sapiens 47aaactcgaga aatcttgtga caaaactcac acatgcccac cgtg 444832DNAHomo sapiens 48cgtctagatc atttacccgg agacagggag ag 324927DNAHomo sapiens 49ccgctcgagc agctcttcca cctacag 275031DNAHomo sapiens 50ggcctcgagc ttatataagc cgaaaaacgt c 315129DNAHomo sapiens 51ggactcgagg ctcctctgaa gattcaagc 295229DNAHomo sapiens 52aatctcgaga ggaatgtggt ctgggggag 295329DNAHomo sapiens 53ggactcgagc aggtatcaca tcggtatcc 295429DNAHomo sapiens 54ggaacgcgta aggacacaga attcaccag 295529DNAHomo sapiens 55ggaacgcgtg cctgccctgg ccgtgtccg 295629DNAHomo sapiens 56aatctcgagt tccgacctcg gtgaaggga 295729DNAHomo sapiens 57ggactcgagg gagaaatcaa tggttctgc 295829DNAHomo sapiens 58aatctcgagg aacttcagct ggcaacaaa 295929DNAHomo sapiens 59ggactcgagt catcatccca tcccatctt 296029DNAHomo sapiens 60aatctcgagg gctcttctca cagccttcc 296129DNAHomo sapiens 61ggagaattcg cacctacttc aagttctac 296230DNAHomo sapiens 62aatacgcgta gtcagtgttg agatgctgct 30

Claims

1. An immunostimulatory fusion polypeptide comprising in N-terminal to C-terminal direction a polypeptide comprising the receptor binding domain of Interleukin-2, a polypeptide comprising the receptor binding domain of Fas ligand, and a polypeptide comprising the human immunoglobulin Fc domain.

2. A recombinant nucleic acid (cDNA) comprising a polynucleotide sequence that encodes the fusion polypeptide of claim 1.

3. A cDNA expression vector containing a fusion polynucleotide sequence according to claim 2.

4. A cDNA expression vector of claim 3, which is selected from a plasmid, recombinant virus, and episomal vector.

5. A cell line that comprises the cDNA expression vector of claim 3.

6. The immunostimulatory fusion polypeptide of claim 1, which is substantially pure.